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 ABSTRACT 
 
Through the production of milk, the mammary gland provides nutritional and 
immunological protection for newborns.  However, lactation is required for only short 
periods of time in the adult animal, which allows the mammary gland to develop through 
a series of distinct stages.  During embryogenesis and puberty, the gland establishes an 
extensive network of epithelial ducts, which then undergo widespread branching and 
differentiation during pregnancy to maximize milk production.  Throughout this process, 
the mammary gland relies on coordination of major cellular processes, including 
proliferation, invasion, and differentiation.  As many of these pathways become 
aberrantly regulated during breast cancer, understanding mechanisms that regulate 
mammary gland development has important disease implications.   
Although previous studies have characterized several systemic hormones and 
local factors central to mammary development, little is known about the downstream 
mediators of these pathways.  To identify new factors, we established a three-dimensional 
model of mammary branching morphogenesis using primary mammary epithelial cells 
(MECs) stimulated with fibroblast growth factor-2 (FGF2).  We performed a forward 
chemical genetic screen to identify compounds that modulate FGF2-induced branching 
and discovered a novel bis-aryloxadiazole, called 1023, which completely blocks 
branching through activation of the aryl hydrocarbon receptor (AHR). 
  
iv 
Using 1023 as a molecular probe, we found AHR activation blocks mammary 
branching through upregulation of desmosomal adhesion.  These results identified 
desmosomes as a novel target of AHR signaling and suggested desmosomes are 
downregulated to facilitate mammary branching.  Supporting this hypothesis, we found 
desmosomes absent in the mammary glands of pregnant mice in a cell-type specific 
manner.  These results suggest desmosomes control initiation of mammary branching, 
and may also be targeted during breast cancer to promote cellular invasion. 
We also investigated mechanisms of AHR activation and the impact of AHR on 
mammary differentiation.  We performed a structure activity relationship study of 1023 
and defined moieties of the molecule critical for AHR stimulation.  Moreover, we 
investigated the effect of AHR on mammary differentiation and elucidated a 
transcriptional mechanism through which the AHR pathway directly blocks lactation in 
MECs.  Since several environmental pollutants stimulate AHR, these studies provide 






































“The more we see, the more we are capable of seeing.”  
Maria Mitchell 
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Mammary Gland Biology 
The origin and function of the mammary gland   
As a defining feature of mammals, the mammary gland has long been recognized 
as a unique organ.  In 1758, Carolus Linnaeus used the mammary gland as the basis for 
classifying and naming the Mammalia class of the animal kingdom (1).  Meaning “of the 
breast,” Mammalia describes a diverse group of species that, among other definitive 
features, utilize the mammary gland for milk production to support the perinatal growth 
of offspring. 
Through the production of milk, the mammary gland provides nutritional and 
immunological protection for newborns.  Although lactation fulfills this duel role, 
increasing evidence suggests the gland first evolved to carry out a protective function (2-
5).  Initially, the ancestral mammary structure is thought to have secreted antimicrobial 
molecules, including lysozyme (5) and xanthine oxidoreductase (XOR) (2).  These 
enzymes later evolved additional roles to augment the nutritional content of secretions.  
For example, lysozyme evolved to synthesize and secrete milk sugars (i.e., lactose) (5) 
while XOR obtained the ability to promote milk fat droplet secretion (2).   
 
Mammary gland composition 
To successfully produce and deliver milk for newborn animals, the mammary 
gland establishes an elaborate network of epithelial ducts.  Initially, a rudimentary ductal 
tree is formed during embryogenesis, which then undergoes significant growth and 
branching during puberty to create a mature ductal network.  During pregnancy, this 
framework of epithelial ducts supports further branching and formation of alveoli, which 
! 3!
functionally differentiate to produce milk.  As a highly complex process, development of 
the mammary gland relies on coordination between its two cellular compartments: the 
epithelium and the surrounding stroma.   
The epithelium is derived embryonically from ectoderm and gives rise to 
mammary ducts, which are composed of luminal epithelial and myoepithelial cells 
(Figure 1.1) (6).  Luminal epithelial cells form the inner layer of ducts and give rise to 
milk-producing alveoli during pregnancy.  In contrast, myoepithelial cells form the outer 
layer of mammary ducts and lie adjacent to the basement membrane.  These more 
specialized cells contract in response to hormonal cues during lactation to move milk 
along the ductal network.  While still controversial, recent studies suggest each of these 
cell types is maintained by a small stem cell population, which allows for expansion of 
the gland during puberty and pregnancy (7).   
The mammary epithelium is supported by the surrounding stroma, or mammary 
fat pad (Figure 1.1).  The stromal compartment is derived embryonically from mesoderm 
and includes a condensed layer of cells and extracellular matrix (ECM) near the ducts in 
addition to more distal adipocytes, vascular endothelial cells, fibroblasts, and immune 
cells (8).  The importance of the stromal compartment during mammary gland 
development has been elegantly demonstrated by transplantation studies.  Recombination 
of mammary epithelium and salivary mesenchyme gives rise to a structure with salivary 
morphology (9).  In contrast, transplantation of skin epithelium and mammary 
mesenchyme results in mammary structures capable of lactogenic differentiation (10).  
These studies demonstrate mesenchyme-derived signals significantly impact mammary 
morphogenesis and cell fate.  
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Figure 1.1.  Schematic representation of mammary gland architecture.  (Left)  The 
mammary gland contains two cellular compartments, the epithelium and the stroma, 
which function together to produce and deliver milk for newborn animals.  (Right)  
Within the mammary epithelium, luminal epithelial cells line the inside of mammary 




Stages of mammary gland development  
Together, the mammary epithelium and stromal compartment function to promote 
growth and expansion of the mammary gland at each stage of development.  During 
embryogenesis, puberty, and pregnancy, the gland undergoes extensive branching 
morphogenesis to increase its surface area and thereby maximize the capacity for milk 
production.  However, each stage of development is governed by unique branching 
mechanisms and regulatory signals. 
Embryogenesis.  The earliest stage of morphogenesis in the mammary gland 
begins at embryonic day 10.5 (E10.5) in mice (11).  Initially, bilateral ridges of epidermal 
cells, called milk lines, are specified ventrally from forelimb to hindlimb.  Ectodermal 
cells within each milk line migrate into clusters by E11.5 (12,13), forming 5 pairs of 
placodes at the site of each future nipple.  Although these initial events in the mouse 








humans during the first trimester and only gives rise to one pair of placodes (14).  
However, in both humans and mice, crosstalk between the epithelial and mesenchymal 
layers coordinates these early events.  
Somite-derived fibroblast growth factors (FGFs) and Wnt signaling in the 
ectoderm are among the critical factors for early mammary development.  FGF signaling, 
which acts through receptors in the ectoderm, stimulates TBX3 expression in the 
underlying mesenchyme (15).  This is one of the first observable regulatory events and 
occurs at E10.25 (16).  TBX3 then activates Wnt signaling in the ectoderm, particularly 
Wnt10b, to ultimately specify the mammary line.  The importance of these major 
signaling pathways has been demonstrated by loss-of-function approaches.  Mice 
deficient in FGFR2b only develop one pair of placodes (17) and Tbx3-/- mice fail to 
activate Wnt signaling or form placodes (18).  Furthermore, overexpression of the 
diffusible Wnt inhibitor, DKK1, in the ectoderm completely blocks placode formation 
(19).  Together, these studies suggest local FGFs, TBX3 and Wnt ligands collectively 
regulate mammary line specification and placode development.          
Following formation, each placode grows into the underlying mesenchyme to 
form a primary anlage, or bulb-shaped mammary rudiment.  As growth continues, the 
mammary bud invades the preadipocyte layer beneath the mesenchyme, which represents 
the future mammary fat pad.  Here, between E15.5 and E16.5, the mammary bud sprouts 
into a rudimentary ductal tree.  This structure is the culmination of embryonic mammary 
development and is composed of a primary duct with 15-20 secondary branches (11).  
However, in humans, multiple independent ductal trees develop and join together at each 
nipple. 
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This first phase of mammary development occurs independent of hormonal 
stimulation, since mice deficient in the estrogen receptor (20,21), progesterone receptor 
(22), or prolactin receptor (23) display normal embryonic mammary gland development.  
Rather, parathyroid hormone-related protein (PTHLH), which is produced in the 
mammary epithelium and signals through its receptor in the mammary mesenchyme (24), 
is one of the key regulators of embryonic mammary branching.  Pthlh-/- mice display 
normal mammary bud development, but fail to form a ductal tree, suggesting PTHLH is 
required for fetal mammary branching (25).  These studies demonstrate the critical role of 
localized factors in early morphogenesis, as compared to the dual role of local and 
systemic signals that function during later stages (Figure 1.2). 
 
Figure 1.2.  Summary of mammary gland development during embryogenesis.  (Left) A 
rudimentary ductal network is established in the mammary gland during embryogenesis. 
(Right) Initially, bilateral ridges of epidermal cells (milk lines) are specified, which then 
migrate to form placodes.  Each placode grows into the underlying mesenchyme to form 
a mammary bud that sprouts into a small ductal tree.  Rather than hormonal cues, this 




















Puberty.  Following embryogenesis, the mammary gland enters an isometric 
growth phase in which the rudimentary ductal tree grows proportional to the body.  
Growth continues in this manner until puberty, when hormone-dependent branching 
transforms the mammary gland into an elaborate ductal network (26) (Figure 1.3).  
During puberty, branching occurs through two main mechanisms: bifurcation of terminal 
end buds (TEBs) and sprouting of side branches.   
TEBs are club-shaped structures that form at the tips of elongating ducts and 
contain a multilayered inner core of body cells surrounded by an outer layer of 
undifferentiated cap cells (26).  Through proliferation and invasion of the fat tissue, TEBs 
drive elongation of immature ducts and undergo bifurcation to create new primary 
branches.  TEBs are heavily regulated by rates of mitosis, as ectopic overexpression of 
transforming growth factor beta1 (TGFB1), which inhibits epithelial proliferation,  
 
 
Figure 1.3.  Summary of mammary gland development during puberty.  (Left) An 
elaborate ductal network is established in the mammary gland during puberty.  
Representative whole mount analysis from a mature, female FVB/n mouse. The 
mammary gland was collected at 8 weeks of age and stained with carmine alum.  LN: 
lymph node.  (Right) During puberty, branching occurs through two mechanisms: side 
branching and terminal end bud formation.  These processes are controlled by several 
hormonal and local factors.  Scale bars: 0.25mm. 
Puberty
LN











significantly restricts ductal elongation and bifurcation (27,28).  Additionally, the 
surrounding stroma has a significant influence on growth and branching of TEBs, 
particularly components of the ECM and infiltrating macrophages (reviewed in (26)).   
Concurrent with TEBs, side branches emerge laterally from the trailing portion of 
primary ducts.  C/EBPβ is one factor required in the mammary epithelium for this 
process, as evidenced by the dramatic decrease in secondary branches observed after 
targeted deletion in the mouse (29).  C/EBPβ is a transcription factor induced through 
paracrine signaling by epimorphin, which is expressed by neighboring fibroblasts and 
subsequently released by matrix metalloproteinases (MMPs) (30).  In addition to 
C/EBPβ, epimorphin also promotes side branching through upregulation of MMPs.  
Inhibition of MMP activity in mammary organoid cultures blocks branching, suggesting 
these factors are also required for normal mammary branching morphogenesis (31).  
These mechanisms of lateral branching, together with elongation and bifurcation of 
TEBs, create a ductal network that fills approximately 60% of the mammary fat pad area 
by the end of puberty (32), leaving space for alveoli formation during pregnancy. 
 In addition to localized signaling pathways that control specific branching 
mechanisms, systemic hormones globally regulate mammary development during 
puberty.  Removal of either the ovaries (ovariectomy) or pituitary gland 
(hypophysectomy) results in failed mammary morphogenesis during puberty (33), 
implicating a critical role for both ovarian and pituitary hormones.  In particular, 
estrogens produced in the ovaries and growth hormone (GH) and insulin-like growth 
factor (IGF-1) from the pituitary are critical factors required for morphogenesis.   
! 9!
A central role for estrogen signaling during adolescent development has been 
demonstrated by gain-of-function and loss-of-function studies.  In initial experiments, 
estrogen was delivered in Elvax pellets to the mammary glands of ovariectomized mice 
and was found to stimulate ductal growth.  In contrast, loss of estrogen receptor-alpha 
(ERα) (21,34) or loss of enzymes critical for estrogen biosynthesis (35), resulted in 
formation of a rudimentary ductal tree that failed to elongate and grow during puberty.  
These studies defined a central role for estrogen in puberty-associated growth of the 
mammary gland.  Similar approaches were also used to define critical roles for GH and 
IGF-1 during puberty.  Specifically, mice lacking GH receptor (36) or IGF-1 (37) display 
a significant reduction in ductal development.  Moreover, estrogens are capable of 
rescuing ductal development in hypophysectomized animals only if GH or IGF-1 is also 
provided (37), suggesting estrogen cooperates with pituitary hormones to promote 
mammary development. 
Although these early experiments demonstrated the importance of estrogen 
signaling during mammary ductal morphogenesis, it wasn’t until later that transplantation 
studies showed estrogen acts through stromal-derived growth factors, rather than directly 
on mammary ducts.  In these seminal experiments, recombination of estrogen receptor 
knockout mammary epithelium and wild type mammary stroma in the subrenal capsule of 
nude mice displayed normal epithelial proliferation (38).  These results demonstrated that 
hormonal regulation of epithelial growth was mediated by estrogen-induced stromal 
factors, which were later shown to include epidermal growth factor (EGF) (39,40).    
This link between ER and EGF is based on observations that EGF receptor 
(EGFR) activation rescues ductal development in ovariectomized (39) and ER-α-
! 10!
deficient mice (40).  EGFR is a receptor tyrosine kinase that can be activated by a variety 
of ligands to promote cell proliferation and survival.  Amphiregulin (AREG) is the only 
EGFR ligand known to be required for normal ductal development (41).  Mechanistically, 
AREG is induced in mammary epithelial cells in response to estrogen and IGF-1 
signaling, and is proteolytically released from epithelial cells by ADAM metallopeptidase 
domain 17 (ADAM17).  AREG then activates EGFR on stromal cells to induce release of 
stromal factors that promote epithelial growth.  These EGFR-stimulated factors are 
essential for mammary development, as EGFR-null stroma is unable to support growth of 
wild type epithelium in cotransplantation studies (42).       
 Although still ongoing, a number of studies suggest FGF signaling is the critical 
downstream pathway stimulated by EGFR activation.  FGFs are upregulated in the 
stroma during puberty (43) and growth of EGFR-null mammary organoids in culture can 
be rescued by FGF2 and FGF7 (41).  However, FGF signaling during adolescent 
mammary development was initially difficult to study, as deletion of FGF receptor-2b 
(FGFR2b) resulted in the failure of most embryonic placodes to form (17).  Later 
conditional deletion of FGFR2 during puberty in the mammary epithelium caused 
impaired ductal development (44).  Moreover, mosaic inactivation of FGFR2, due to 
inefficiency of the MMTV-Cre transgene, found FGFR2-null epithelial cells were 
outcompeted by their wild type counterparts, particularly within TEBs.  Taken together, 
these results strongly support FGF as the key downstream mediator of EGFR activation 
during ductal morphogenesis. 
Overall, hormonal and local signals function during puberty to create an extensive 
ductal network.  Estrogen produced in the ovary and GH and IGF-1 from the pituitary 
! 11!
gland, act in concert to stimulate the production and release of EGFR ligands from the 
mammary epithelium.  These factors activate stromal EGFR signaling and subsequent 
production of FGF ligands, which act on mammary epithelial cells to promote ductal 
morphogenesis.  These major hormonal and local factors critical during mammary 
development have been largely studied through recombination experiments and 
genetically engineered mice.  Although powerful, the cellular complexity of these 
systems limits our understanding of the direct cellular targets of these signals, particularly 
the downstream mediators of FGFR activation.  Through the use of new techniques that 
allow more precise manipulation of specific factors within certain cell types, we will be 
able to study these pathways in greater detail and further elucidate mechanisms of 
cellular proliferation and invasion during ductal morphogenesis.  
Pregnancy.  In preparation for lactation, rapid expansion of the mammary gland 
occurs during pregnancy (Figure 1.4).  The network of ducts established during puberty 
undergoes extensive secondary and tertiary branching.  Moreover, epithelial proliferation 
results in formation of alveolar buds, which differentiate into mature alveoli primed for 
milk production.  Overall, alveolar morphogenesis increases epithelial surface area to 
maximize the capacity of milk production in the mammary gland.  Similar to pubertal 
development, both local and systemic signals are key mediators of this developmental 
phase.  
 Progesterone and prolactin are the primary hormonal regulators of mammary 
development during pregnancy.  Produced in the ovary, progesterone acts on mammary 
epithelial cells to elicit branching and alveolar differentiation.  The requirement of 
progesterone signaling during mammary development has been demonstrated in  
! 12!
Figure 1.4.  Summary of mammary gland development during pregnancy.  (Left) High 
levels of secondary and tertiary branching occur in the mammary gland during 
pregnancy.  Representative whole mount analysis from a pregnant, female FVB/n mouse.  
The mammary gland was collected at day 10 of pregnancy and stained with carmine 
alum.  LN: lymph node.  (Right) Lobuloalveolar branching occurs during pregnancy to 
form alveoli, which are primed for milk production.  This developmental stage is 




progesterone receptor (Pgr) knockout mice.  Specifically, loss of Pgr in the mammary 
epithelium limits mammary development to a small ductal network that fails to expand 
and differentiate during pregnancy (45).  
Synergistic with progesterone, prolactin (PRL) is also critical for mammary 
development during pregnancy.  PRL is produced in both the pituitary and the mammary 
epithelium, which parallels its dual role as a systemic and local regulator of mammary 
development.  Systemically, PRL is required to stimulate progesterone production in the 
ovaries.  This role was elucidated from Prl knockout mice, which show impaired alveolar 
development (46) that is rescued when Prl-/- mammary tissue is transplanted into wild 
type recipient mice (47) or when progesterone levels are exogenously restored in Prl-/- 
mice (48).  In addition to the impact of PRL on the ovaries, it also directly targets 













impairs alveolar development (23).  These studies demonstrate a key role for prolactin in 
both systemic and local control of mammary development.   
Progesterone and prolactin cooperate to promote mammary development and 
differentiation during pregnancy.  As a result, many of their proposed downstream 
pathways overlap.  For example, PGR (49) and PRLR (50) both regulate Wnt4, which is 
required for paracrine activation of tertiary branching (49).  However, Wnt4 only appears 
to be required during early pregnancy, suggesting involvement of other parallel or 
compensatory pathways.  For instance, receptor activator of NFKB1 ligand (RANKL) 
and its receptor, RANK, are thought to play a critical role downstream of PGR and 
PRLR.  RANKL is induced by prolactin (50) and also by progesterone (51) in epithelial 
cells expressing PGR (52).  Moreover, loss of RANK or RANKL phenocopies Pgr-/- 
glands (53) and ectopic expression of RANKL rescues alveolar development in Pgr null 
glands (54).  As a common mediator of PGR and PRLR signaling, RANK activation is 
thought to drive high levels of epithelial proliferation required during formation of 
alveolar structures. 
In addition to shared pathways, progesterone and PRL also maintain unique 
targets.  In particular, PRLR activates JAK/STAT (Janus kinase/ Signal transducer and 
activator of transcription) signaling through phosphorylation of JAK2 and subsequent 
activation of STAT5.  As a key transcription factor, STAT5 mediates expression of genes 
important for alveolar development and differentiation, including milk proteins (reviewed 
in (55)).  Overall, progesterone and prolactin act through a number of downstream 
pathways to precisely control mammary differentiation and lactation. 
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Involution.  The final phase of mammary morphogenesis, called involution, 
occurs after weaning to restore the gland to a virgin-like state.  In this process, milk-
producing epithelial cells are destroyed in two distinct phases.  The first period of 
involution lasts for 48 hours after weaning and is characterized by detachment of 
epithelial cells from the extracellular matrix, which induces cell death and shedding (56).  
As no major architectural changes occur, this process is reversible if suckling is 
reinitiated.  Teat-sealing experiments, in which individual glands are physically closed 
off, have demonstrated this phase is regulated by local factors (57,58).  Although several 
signaling pathways influence early involution, a switch in STAT signaling is thought to 
have a critical role (59).  Specifically, the accumulation of milk within ducts, called milk 
stasis, leads to decreased Stat5 phosphorylation and increased Stat3 phosphorylation, 
which has a significant impact on both cell survival and apoptosis (60).  
 After the initial wave, a more aggressive and irreversible period of involution 
begins.  Collapse of alveoli, breakdown of the extracellular matrix (ECM), and 
widespread apoptosis removes nearly all of the secretory cells from the mammary gland 
within 6 days (61).  Unlike the first phase, this later portion of involution is regulated by 
systemic hormones and can be suppressed with glucocorticoid (62,63).  Moreover, serine 
proteases and matrix metalloproteinases (MMPs) expressed by stromal cells have a 
critical role (64).  As the surrounding matrix is remodeled, epithelial cells lose cellular 
contacts and undergo apoptosis.  To compensate for the loss in epithelial tissue, MMPs 




In vitro models of mammary development 
The mouse mammary gland has been the primary model system used to study 
mammary gland biology.  Compared to the human breast, the mouse mammary gland is 
composed of the same epithelial cell types, similarly responds to hormonal cues including 
estrogen and progesterone, and progresses through a remarkably similar series of 
developmental stages.  Moreover, the mouse mammary gland is amenable to a wide 
range of elegant in vivo manipulations, including tissue recombination, transplantation, 
and genetic engineering (65).  These techniques have been widely used to study both 
normal mammary gland development and breast cancer biology.  However, these 
approaches are not well suited for study of the human mammary gland and are both cost 
and time intensive. 
To complement studies in the mouse, several in vitro models of the mammary 
gland have been developed.  Specifically, three-dimensional (3D) models have been 
highly successful in recapitulating the in vivo physiology and differentiation of the 
mammary gland (66,67).  These models can be performed with both mouse and human 
cells and are highly amenable to genetic and pharmacological manipulations, which has 
allowed for in depth analysis of signaling pathways and has facilitated the development 
of novel breast cancer therapeutics.   
The first 3D model of the mammary gland was created over 30 years ago, when 
mouse mammary epithelial cells were cultured on floating collagen gels (68).  In contrast 
to the more rigid matrices of plastic, glass, and fixed collagen, flexible collagen gels 
allowed mammary epithelial cells to functionally differentiate and produce milk proteins 
in the presence of lactogenic hormones (69,70).  Since these early experiments, a large 
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number of studies have been performed to understand the role of the extracellular matrix 
(ECM) in mammary gland development and function (reviewed in (71)).  Much more 
than a scaffold, the ECM and its specific composition are now known to significantly 
impact cellular response, growth, and differentiation. 
In the mammary gland, the epithelial compartment is surrounded by basement 
membrane, which contains large amounts of collagen IV and laminin (72).  Given these 
observations, it is not surprising that 3D models of mammary morphology have 
significantly evolved over time to more closely mimic the endogenous setting.  In 
particular, Matrigel is now widely used, which is a laminin-rich extracellular matrix 
derived from Engelbreth-Holm-Swarm tumors (73). 
When embedded in Matrigel, mammary cells from both mice (74) and humans 
(75) reorganize to form polarized, spherical structures.  Moreover, human MCF-10A 
mammary epithelial cells grown in Matrigel form polarized acini-like spheres (76).  
These phenotypes more closely resemble in vivo mammary morphology compared to 
cultures with collagen I gels, which induce purified luminal epithelial cells to form 
structures with inverse polarity (77).  In addition to the appropriate cellular morphology, 
Matrigel promotes differentiation of mouse mammary epithelial cells in response to 
lactogenic hormones (74).  Furthermore, malignant human breast cells form disorganized 
cellular structures in Matrigel (75), highlighting the ability of this system to also mimic 
the disease state. 
 The establishment of 3D models has significantly advanced our ability to study 
the mammary gland in vitro.  These techniques allow for the rapid ex vivo culture of 
mammary cells and are highly accessible to experimental manipulations.  Moreover, 3D 
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models are particularly well suited for the study of signaling pathways, as both mono- 
and co-culture, consisting of combinations of epithelium and stroma, can be performed.  
For example, individual mammary cell types can be grown alone or in combination to 
study cell autonomous signaling as well as crosstalk between neighboring cells.  These 
studies demonstrate the wide range of experimental questions that can be addressed using 
3D culture systems.  
 
Perspectives on mammary gland biology 
Through a series of distinct developmental stages, the mammary gland undergoes 
a unique pattern of growth and differentiation.  Early developmental phases give rise to a 
framework of ducts, which temporarily undergo functional differentiation and milk 
production to support the growth of offspring.  This segmented growth pattern precisely 
links the differentiation state of the gland with the birth of offspring, thus limiting the 
high-energy expenditure of lactation to the short timeframe necessary to nurse newborns.   
In order to precisely coordinate this process, the gland relies on tight regulation of 
key signaling pathways that underlie mammary development.  Through in vivo and in 
vitro approaches, many of the major hormonal and local cues have been identified.  
Estrogen, progesterone, prolactin, growth hormone, and insulin-like growth factor are 
among the dominant hormonal signals, while EGF and FGF remain a few of the major 
local factors.  These signaling pathways facilitate communication between the epithelial 
and stromal compartments of the mammary gland and control critical morphological and 
functional changes. 
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 To build upon this initial framework, one of the critical next steps in mammary 
gland biology is to identify and understand the downstream mediators of the major 
signaling pathways.  The molecular connection between primary signaling molecules and 
actual cellular changes, such as proliferation, invasion, and differentiation, remain 
elusive.  Specifically, the targets of FGF signaling that drive ductal elongation and lateral 
branching are unknown.  To address this question, we developed a novel in vitro model 
of mammary branching morphogenesis using primary mammary epithelial cells 
stimulated with FGF2.  We then used a small molecule-based approach to rapidly identify 
novel targets important for mammary branching (Chapter 2) and have begun to validate 
our initial studies in vivo (Chapter 5).  Since the normal cellular processes governing 
mammary morphogenesis also underlie the mechanisms of breast cancer, our study of 
mammary gland development has significant implications for both normal and cancer 
biology.   
 
Aryl Hydrocarbon Receptor Signaling 
Discovery of the aryl hydrocarbon receptor 
 The aryl hydrocarbon receptor (AHR) was first described by Alan Poland’s 
laboratory in 1976 (78).  However, a number of key experiments dating back to the 1950s 
set the stage for this important discovery.  Early on, it was known that aminoazo dyes, 
such as 3’-methyl-4-dimethylaminoazobenzene, caused liver cancer in rats (79).  Yet the 
carcinogenic effect of these compounds could be abrogated by simultaneous injection of 
3-methylcholanthrene (3-MC) (80).  As a polyaromatic hydrocarbon (PAH), 3-MC was 
hypothesized to protect animals from carcinogenesis by altering metabolism of the 
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aminoazo dye.  Through a series of studies on 3-MC and related chemicals, PAHs were 
shown to selectively induce metabolism of certain drugs (81,82), suggestive of a specific 
signaling pathway protective against chemical exposures.  Furthermore, the induction of 
metabolic enzymes by PAHs varied across mouse strains (83,84) and segregated in what 
appeared to be an autosomal dominant fashion (85-87).  These studies defined a new 
genetic locus, named the Ah locus, based on aromatic hydrocarbon sensitivity.  C57BL/6 
mice, who displayed a strong metabolic response to PAHs, were characterized by the 
“responsive” Ahb allele, while DBA2 mice were associated with the “nonresponsive” Ahd 
allele (88).       
Just as the Ah locus emerged as an important mediator of toxin metabolism, Alan 
Poland began studying factory-produced toxins that caused skin ailments in workers.  
Poland focused on 2,4,5-trichlorophenol (2,4,5-T) and its active contaminant, 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), which was thought to be responsible for chemically 
induced acne (chloracne) and skin blistering (porphyria cutanea tarda).  Over the course 
of many studies, TCDD was found to induce the same metabolic enzymes as 3-MC, but 
was 30,000 times more toxic (89).  Taking advantage of TCDD’s potency and genetic 
differences between mouse strains, Poland was ultimately able to show the Ah locus 
produced a soluble protein, now referred to as the aryl hydrocarbon receptor (AHR), that 
specifically bound radiolabeled TCDD (78).  Furthermore, mutation in the Ah locus of 
“nonresponsive” mice was shown to produce a receptor with decreased affinity for PAHs 




Classical AHR-mediated signaling 
After his landmark discovery, Poland hypothesized AHR activation by PAHs 
mimicked that of steroid hormone receptors (78).  More specifically, Poland predicted 
activated AHR localized to the nucleus to alter specific metabolic target genes.  However, 
later cloning and sequencing of AHR (92,93) found little in common with steroid 
hormone receptors.  Rather, AHR contained a basic helix-loop-helix (bHLH) domain and 
a PER/ARNT/SIM (PAS) domain, classifying it as a member of the bHLH/PAS family of 
transcriptional regulators.   
Although not structurally related to steroid hormone receptors, AHR does 
function as a ligand-activated transcription factor, as Poland predicted (Figure 1.5).  In 
the absence of ligands, AHR interacts with a multiprotein chaperone complex to remain 
inactive in the cytoplasm (94).  Among the members of this complex, p23 and two 
molecules of heat shock protein 90 (Hsp90) interact with AHR to prevent degradation 
and premature dimerization, and to promote a conformation of AHR capable of ligand 
binding (95,96).  Additionally, hepatitis B virus X-associated protein 2 (XAP2) increases 
the stability of AHR and promotes cytoplasmic retention of the receptor (97,98).  
Together, the protein complex associated with the inactive form of AHR regulates its 
stability, ligand binding ability, and subcellular trafficking.  
Ligand binding induces a conformational change in the AHR complex, which 
exposes a nuclear localization sequence (NLS) on AHR to promote its nuclear 
translocation (98).  Once nuclear, AHR dissociates from its chaperone proteins, which 
allows interaction with other binding partners.   In particular, AHR forms a heterodimer 

















Figure 1.5.  Model of classical AHR signaling.  In the absence of ligands, AHR remains 
inactive in the cytoplasm, bound to a chaperone complex.  Upon ligand activation, AHR 
translocates to the nucleus and dissociates from its chaperone proteins.  This allows AHR 
to interact with ARNT and form transcriptional activating complexes.  As a heterodimer, 
AHR/ARNT binds specific response elements located upstream of AHR-regulated genes 
to promote their transcription.  Abbreviations: AHR, aryl hydrocarbon receptor; ARNT, 


























DNA and specifically interact with the core nucleotide sequence 5’-TNGCGTG-3’ in the 
5’ flanking region of gene targets (100,101).  Referred to as the AHR-responsive element 
(AHRE), this consensus sequence is found near AHR-regulated genes.  Some of the most 
well characterized AHR response genes include metabolic enzymes such as CYP1A1, 
CYP1A2, CYP1B1, NAD(P)H:quinone oxidoreductase (NQO1), aldehyde 
dehydrogenase (ALDH) 3A1, UDP-glucuronosyltransferase (UGT) 1A1, and 
glutathione-S-transferase (GST) A1 (102).  These enzymes catalyze critical reactions, 
such as oxidation, reduction, and hydrolysis, to increase clearance of toxic substrates.  In 
the case of aminoazo dyes, the protective effect of 3-MC against liver cancer is attributed 
to 3-MC activation of AHR and subsequent metabolism of the dye through these 
enzymatic reactions.  
 
Negative regulation of AHR 
 Once activated, AHR signaling is downregulated by multiple mechanisms, 
suggesting the importance of precise pathway control and prevention of overstimulation.  
Proteasome-mediated degradation was the first mechanism found to attenuate AHR 
activity (103-105).  This pathway has primarily been studied in cultured cells treated with 
TCDD.  In this system, AHR is ubiquitinated (104) and steadily declines in a time-
dependent manner (106).  Proteasome inhibitors block receptor turnover (103-105), 
increase nuclear AHR/ARNT complexes (105), and amplify target gene expression (104).  
Moreover, proteasome-mediated degradation of AHR depends on transcriptional 
activation (104) and subsequent nuclear export (103,105), as inhibition of either process 
blocks turnover.  
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 In addition to degradation by the proteasome, AHR activity is also dampened by a 
negative feedback loop driven by the aryl hydrocarbon receptor repressor (AHRR).  
AHRR is a bHLH/PAS family member that is constitutively expressed at very low levels 
in many tissues (107,108).  However, AHRR contains 3 copies of the AHRE in its 
promoter region, which results in high AHR-mediated induction (109).  A portion of 
AHRR is highly similar to the N-terminal region of AHR (107), and facilitates ARNT 
interaction and DNA binding.  As a result, AHRR is able to form competitive ARNT 
heterodimers that bind and transcriptionally repress AHR response genes (110).  
Mechanistically, AHRR is SUMOylated at three specific residues following dimerization 
(111).  Modification of these sites is required for interaction between AHRR and a 
corepressor complex, containing ankyrin repeat family A protein 2 (ANKRA2), histone 
deacetylase (HDAC) 4, and HDAC 5 (112).  This complex blocks transcription of AHR 
target genes.  The ability of AHRR to negatively regulate AHR signaling helps prevent 
sustained activation of the pathway.  
 
AHR ligands 
Historically, AHR was defined based on its ability to respond to toxic chemicals, 
including 3-MC and TCDD.  Although these compounds are among the most well 
characterized and high-affinity ligands, AHR is able to bind structurally diverse 
molecules.  This is largely attributed to the promiscuous nature of the AHR ligand 
binding domain (LBD), which is both necessary and sufficient for ligand-mediated 
activation.   
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The LBD of AHR is located within a structural repeat of the PAS domain, called 
PAS B.  Since this region also interacts with Hsp90, deletion of PAS B disrupts 
cytoplasmic retention of the receptor by its chaperone complex and results in ligand-
independent, constitutive AHR activation (113).  Conversely, expression of PAS B alone 
binds TCDD with a comparable affinity to wild type AHR (114).  Structural information 
about the AHR binding pocket is limited, as no X-ray or NMR structures of AHR have 
been solved.  However, homology models of the AHR LBD have been built based on 
crystal structures of homologous proteins in the PAS family (115,116).  These models 
have further defined residues of the AHR LBD important for binding and revealed a wide 
range of compound characteristics able to confer activity.   
The diverse range of known AHR ligands is broadly classified into two groups: 
synthetic and naturally occurring (117,118).  Synthetic AHR ligands are typified by 
halogenated aromatic hydrocarbons (HAHs) derived from industrial sources, which 
include polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls, and polycyclic 
aromatic hydrocarbons (PAHs), including 3-MC and benzo[a]pyrene, released by the 
process of combustion (118).  In addition to synthetic ligands, numerous naturally 
occurring compounds activate AHR (117).  These include indigo (119), indirubin (119), 
dietary flavonoids (120), and metabolites of both arachidonic acid (121) and heme (122).  
Although these compounds show AHR-specific activity, many are present at very low 
levels in vertebrate tissues and display varying degrees of receptor activation.    
Despite the large number of exogenous activators, no known endogenous ligands 
of AHR have been identified.  While AHR may function only to protect against harmful 
toxins, it is also possible that AHR has a role in normal physiology and thus, an 
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endogenous ligand.  In fact, the role for AHR in normal developmental processes is 
argued to predate its role in toxicity.  This idea is supported by the presence of AHR 
homologs in most major groups of animals, including many of the earliest bilateral 
metazoans that evolved more than 500 million years ago (123).  Although the ancestral 
AHR was a transcriptional activator, it was unable to bind PAHs (124), suggesting AHR 
originally functioned as a regulatory gene during development.  The ability of AHR to 
bind PAHs did not emerge until jawed vertebrates.  In particular, AHR regulation of 
Cyp1A1 was first evidenced in bony fishes (123), which is thought to be in response to 
the emergence of natural halogenated products in marine species (125).  In addition to 
phylogenetic evidence, AHR knockout mice also support an important physiological 
function for AHR.  Specifically, AHR-null mice (126,127) display vascular, immune, and 
skin defects, among others.  Together, these studies are consistent with a role for AHR 
beyond toxicity and support the continued effort to identify an endogenous ligand.     
 
AHR in the mammary gland 
 Mammary gland development is among the physiological pathways proposed to 
be regulated by AHR signaling.  This idea is supported by expression analysis, which has 
found key AHR pathway components expressed at different stages of mammary growth 
and differentiation.  AHR, which is present in both the epithelial and stromal 
compartment, is highly expressed during puberty and into pregnancy and declines 
dramatically at lactation and involution (128).  Similarly, ARNT is expressed throughout 
the gland and is highest in the virgin and pregnant state (129).  ARNT remains highly 
expressed during lactation and decreases significantly at involution.  In addition to AHR 
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and ARNT proteins, readouts of pathway activation are also seen in the developing gland.  
Specifically, mammary glands from C57Bl/6 mice show nuclear AHR localization in 
~15% of ductal and lobular epithelial cells (128).  Moreover, AHR targets, including 
Cyp1A1 and Cyp1B1, are increased in these animals, as well as in organ explants 
stimulated with hormone treatment.  Together, these studies show the AHR pathway is 
expressed and activated in the mammary gland. 
 In addition to expression studies, knockout animals also support a potential role 
for AHR signaling during mammary development.  AHR null animals show a 50% 
reduction in TEBs (128), which are structures highly active during puberty-associated 
branching, when AHR is also highly expressed.  Moreover, loss of AHR results in severe 
reproductive phenotypes, as evidenced by difficulty maintaining pregnancies and high 
mortality of null mothers during pregnancy (130).  Of those that survive, less than half of 
dams are able to support their pups until weaning.  In addition to AHR, loss of ARNT 
impacts mammary development and function.  Complete loss of ARNT is lethal, but 
conditional ARNT inactivation has been performed in the mammary gland.  Loss of 
ARNT at puberty using MMTV-Cre, which is expressed in luminal epithelial cells, 
impairs subsequent alveolar development and results in more than half of mothers that 
are unable to nutritionally support their offspring (129).  However, transplantation of 
these glands into normal recipient mice rescues alveolar development and milk 
production, suggesting the stromal compartment mediates the observed defect in ARNT 
loss.  Furthermore, inactivation of ARNT during pregnancy using WAP-Cre, with is 
active in luminal epithelial cells during pregnancy, does not appear to decrease mammary 
function.  This approach does not inactivate ARNT until the onset of pregnancy and only 
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reduces ARNT levels by 80%, leaving residual protein expression.  As a result, further in 
vivo analysis is needed to interpret these conflicting results. 
 While loss of function studies remain unclear about the role of the AHR pathway 
in the mammary gland, activation of AHR undoubtedly disrupts mammary development 
and function.  Rats exposed to TCDD during gestation (131) or at 4-5 weeks of age (132) 
display decreased branching and TEB formation during puberty, resulting in immature, 
small mammary glands.  Furthermore, numerous studies show adverse effects of AHR 
activation during pregnancy.  For example, C57Bl/6 mice exposed to TCDD during 
pregnancy display branching defects, particularly within alveolar structures (133).  
Consequently, expression of milk proteins is reduced and dams are unable to support 
their litter.  Reciprocal transplant studies with AHR knockout mice suggest TCDD 
exposure blocks mammary differentiation through multiple mechanisms (134).  In these 
experiments, both wild type mammary epithelial cells (MECs) transplanted into AHR 
knockout recipients and AHR knockout MECs transplanted into wild type recipients 
showed mammary defects after TCDD treatment during pregnancy.  However, mutant 
mice that express an AHR protein lacking the DNA binding domain show normal 
alveolar development in the presence of TCDD.  These results suggest AHR:DNA 
interactions mediate the toxic effects of TCDD and strongly implicate a direct 
consequence of AHR stimulation on mammary epithelial cells.  Despite these studies, the 





Crosstalk between AHR and ER 
 Beyond its classical signaling axis, AHR converges with several other important 
physiological pathways.  In particular, AHR activation antagonizes the estrogen receptor 
(ER) (reviewed in (135)), which likely contributes to the reproductive phenotypes 
observed in TCDD-treated animals.  This relationship between AHR and ER has been 
observed in humans and rodent models through both in vitro and in vivo approaches.  
Specifically, TCDD inhibits estrogen-dependent growth of human breast cancer cells 
(136) and significantly reduces the incidence of mammary and uterine tumors in 
chronically exposed rats (137).  Similar results have also been observed in women from 
Seveso, Italy who were exposed to TCDD during a 1976 industrial explosion.  Compared 
to control individuals, women who experienced TCDD exposure have a lower incidence 
of breast cancer (138).  These data suggest antagonism of ER signaling by AHR 
activation reduces ER-dependent breast cancer, although the precise connection between 
breast cancer subtype specificity and the AHR pathway requires further investigation. 
The mechanism of interaction between AHR and ER appears to be multifaceted 
and may be tissue- or cell-type dependent.  AHR complexes have been shown to bind 
regulatory regions within ER target genes and sterically hinder transcription (139).  In 
addition, AHR and ER compete for similar coactivators (140), which limits the activation 
capacity of each pathway.  Finally, activated AHR increases proteasome-mediated 
degradation of ER (141) as well as metabolism of circulating estrogens (142).  Given the 
importance of estrogen signaling during mammary gland development, this complex 
relationship between AHR and ER likely plays a role in TCDD-mediated toxicity.    
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Perspectives on the AHR pathway 
 Since Alan Poland’s initial discovery, the field of AHR research has rapidly 
expanded.  AHR was originally defined based on its central role mediating toxicity.   
However, more than 6,000 studies on AHR have been published to date and researchers 
now appreciate a dual role for AHR in both toxicology and normal physiology.   
In terms of toxicity, it is clear that many hazardous chemicals elicit their harmful 
effects through AHR.  Furthermore, the AHR binding pocket is promiscuous in nature 
and different types of ligands seemingly display different binding requirements.  As a 
result, structure activity relationship (SAR) studies for different classes of agonists are 
needed to more definitively define mechanisms of AHR activation.  We identified 1,2,4-
bis-aryloxadiazole as a potent AHR agonist and performed a SAR study to determine 
which moieties of the molecule are critical for AHR activation (Chapter 3).  Insight from 
these studies will not only help detect other harmful chemicals that bind AHR, but will 
also aid in identifying and validating potential endogenous ligands.  
 In addition to toxicology, the involvement of AHR in normal biological processes 
is still a highly active area of investigation.  In the mammary gland, exposure to AHR 
agonists notably disrupts mammary development and function.  However, these effects 
likely stem from both systemic hormone changes and local AHR signaling within the 
epithelial compartment.  To uncouple these effects, we used an epithelial-based model of 
mammary lactation to recapitulate lactogenesis in the presence of AHR agonists.  We 
found AHR activation directly blocked milk production in mammary epithelial cells, and 
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Background: Mammary gland branching morphogenesis is a highly regulated developmental process often disrupted in
breast cancer.
Results: A chemical genetic screen in primary three-dimensional culture revealed that activation of the aryl hydrocarbon
receptor promotes desmosomes to block branching.
Conclusion: Down-regulation of desmosomes is required for proper mammary branching morphogenesis.
Significance:Desmosomes are a novel mechanism through which exposure to environmental pollutants may affect mammary
development.
During the process of branching morphogenesis, the mam-
mary gland undergoes distinct phases of remodeling to form an
elaborate ductal network that ultimately produces and delivers
milk to newborn animals. These developmental events rely on
tight regulation of critical cellular pathways, many of which are
probably disrupted during initiation and progression of breast
cancer. Transgenic mouse and in vitro organoid models previ-
ously identified growth factor signaling as a key regulator of
mammary branching, but the functional downstream targets of
these pathways remain unclear. Here, we used purified primary
mammary epithelial cells stimulated with fibroblast growth fac-
tor-2 (FGF2) to model mammary branching morphogenesis in
vitro. We employed a forward chemical genetic approach to
identify modulators of this process and describe a potent com-
pound, 1023, that blocks FGF2-induced branching. In primary
mammary epithelial cells, we used lentivirus-mediated knock-
down of the aryl hydrocarbon receptor (AHR) to demonstrate
that 1023 acts throughAHR to block branching. Using 1023 as a
tool, we identified desmosomal adhesion as a novel target of
AHR signaling and show that desmosomes are critical for AHR
agonists to block branching. Our findings support a functional
role for desmosomes during mammarymorphogenesis and also
in blocking FGF-induced invasion.
Branching morphogenesis is a developmental process that
maximizes surface area in order to enhance gas, nutrient, and
waste exchange by tissue (1). Consequently, branching mor-
phogenesis occurs during development of a variety of organs,
including Drosophila trachea, mammalian lungs, kidneys, and
salivary and mammary glands (2). Because this developmental
event relies on coordination ofmajor cellular processes, includ-
ing proliferation, invasion, differentiation, and apoptosis (1),
understanding the pathways that drive branching morphogen-
esis may lead to discoveries of mechanisms involved in human
diseases, such as cancer, where these fundamental cellular
pathways are aberrantly regulated.
In contrast to other organs, the mammary gland undergoes
key stages of development postnatally. Due to its delayed devel-
opment and capacity to branch in organotypic systems in vitro,
the mammary gland is a uniquely accessible model organ of
branching morphogenesis (3). At birth, the mammary gland
consists of a small ductal network embedded in adipose tissue.
Hormonal cues stimulate its development during puberty,
which results in elongation of ducts that eventually fill the fat
pad (4). Importantly, mammary ducts are composed of an epi-
thelial bilayer, with a basal layer consisting of myoepithelial
cells and inner layer of luminal cells. Each layer contains pro-
genitor and differentiated cell populations that are poised to
respond to developmental and hormonal changes. During
pregnancy, alveolar buds branch from ducts and develop into
lobuloalveolar acini, where functionally differentiated luminal
cells produce milk during lactation. In addition, differentiated
myoepithelial cells contract in response to oxytocin to facilitate
milk delivery (5). Cumulatively, mammary branching morpho-
genesis functions to establish an extensive tubular gland capa-
ble of producing and delivering milk to newborn animals.
Studies using genetically modified mice and three-dimen-
sional organotypic culture of mammary tissue have identified
several molecular pathways important for mammary gland
development. Among these pathways, epidermal growth factor
(EGF) receptor and fibroblast growth factor (FGF) receptor
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have been shown to be critical drivers of proliferation and inva-
sion, respectively (5). Although these studies support a pivotal
role for EGF and FGF signaling in mammary development, the
downstream cellular targets of these cascades remain unclear.
We sought to develop an in vitromodel of mammary devel-
opment well suited to define intracellular pathways targeted by
growth factor signaling. In previously established organotypic
models of mammary morphogenesis, fragments of murine
mammary epithelium, called organoids, were embedded in
extracellularmatrix and stimulatedwith specific growth factors
to induce branching (6–9). However, organoids are complex
tissue structures consisting of both epithelial and stromal cells.
As a result, one limitation of these studies is the inability to
distinguish the effects of growth factor signaling directly on
epithelial cells from the indirect effects exerted through stro-
mal cells. We developed an in vitro three-dimensional branch-
ing model consisting of enriched, primary mammary epithelial
cells (MECs)4 and employed a forward chemical genetic screen
to identify modulators of branching morphogenesis. We
describe a compound, 1023, which effectively blocks FGF2-in-
duced branching while maintaining cells as normal mammary
cysts. We demonstrate that 1023 acts through the aryl hydro-
carbon receptor (AHR) to functionally inhibit branching by
regulating desmosome adhesion complexes in mammary
epithelium.
EXPERIMENTAL PROCEDURES
Isolation of Primary MECs—Organoids from the fourth
inguinal mammary glands were isolated from 8–12-week-old
female FVB/nmice as described previously (10). Protocol mod-
ifications and dissociation of organoids into single cells are
described in the supplemental material.
Aggregation and Culture of PrimaryMECs inMatrigel—Fro-
zen primary MECs were thawed, washed, and pelleted three
times with 5 ml of DMEM/F-12 (HyClone) (150! g, 3 min) to
remove DMSO. To form aggregates, 2 ! 106 primary MECs
were resuspended in 1 ml of primary MEC growth medium
(DMEM/F-12 supplemented with 5 !g/ml ITS-X (Invitrogen),
1 !g/ml hydrocortisone, 10 ng/ml murine EGF (BD Biosci-
ences), 10% FBS (HyClone), and 1! penicillin/streptomycin/
glutamine (Invitrogen)) and incubated overnight at 37 °C with
5% CO2 in a 24-well ultra-low attachment tissue culture plate
(Costar). After 16 h, stromal contaminants were removed by
differential centrifugation as described previously (6). To create
a base layer, 20 !l of growth factor-reduced Matrigel (BD Bio-
sciences) was plated in the center of each well of a 24-well glass
SensoPlate (Greiner Bio-One) and allowed to solidify at 37 °C.
Aggregates (250 per well) were plated on top of the hardened
base layer in 40 !l of Matrigel per well and incubated at 37 °C
with 5% CO2 to solidify Matrigel. Embedded aggregates were
cultured in DMEM/F-12 supplemented with 5 !g/ml ITS-X,
1! penicillin/streptomycin/glutamine, and either murine EGF
or human FGF2 (Invitrogen) (2.5 nM unless otherwise indi-
cated). 1023, 1023-CF3, and 2,3,7,8-tetrachlorodibenzodioxin
(TCDD) were added as indicated. Cells were incubated at 37 °C
with 5% CO2 with medium changes every 48 h. When single
cells were cultured inMatrigel, 2,500 single trypsinized primary
MECs were embedded in 40!l of Matrigel per well of a 24-well
plate. For peptide experiments, aggregateswere plated on top of
Matrigel as described previously (11). Briefly, 50 !l of Matrigel
was plated in each well of a 96-well plate and incubated at 37 °C
to harden. Aggregates (250 per well) were resuspended in 100
!l of medium containing 2% Matrigel and plated on top of the
base layer. We used this overlay technique to ensure that the
peptides could access aggregates. To calculate the percentage of
branching in all assays, samples were fixed in 4% paraformalde-
hyde and imaged with bright field microscopy at low magnifi-
cation (!4). At least 100 aggregates/well were scored, with
branching counted as three ducts or more, as established pre-
viously in organoid culture models (6). At least 3 independent
samples/condition were averaged for each experiment.
Small Molecule Library Screen—Compound stocks were
obtained from theUniversity of UtahDepartment of Chemistry
Collection and diluted to 10 !M in serum-free medium
(DMEM/F-12 supplemented with 5 !g/ml ITS-X, 1! penicil-
lin/streptomycin/glutamine, and 2.5 nM human FGF2). Aggre-
gates were embedded as described above in 48-well tissue cul-
ture plates (BD Biosciences) with a 5-!l Matrigel base layer and
200 aggregates suspended in 10 !l of Matrigel on top. Medium
was replaced with fresh compound-containing medium after
72 h in culture. After 144 h total, cells were fixed in 4% parafor-
maldehyde, and an Olympus CKX41 inverted microscope was
used to score each compound based on the phenotype observed
in greater than 50% of aggregates in each well.
Homology Modeling—Sequence alignment, homology mod-
eling, and molecular docking of 1023 with human AHR is
described in detail in the supplemental material.
Construction of shRNALentiviral Plasmids—RNA sequences
(supplemental Table S2) for shRNAAhr orArnt (aryl hydrocar-
bon receptor nuclear translocator) knockdown were designed
using the Dharmacon siDESIGN Center (available on the
Thermo Scientific Web site). Oligonucleotides were annealed
and ligated into HpaI and XhoI sites in pLentiLox5.0-GFP (12)
following themolecular cloning protocol detailed in the supple-
mental material.
Virus Production and Transduction of Primary MECs—Len-
tivirus was produced and titrated as previously described (10,
13). High efficiency lentiviral transduction of primary MECs
was conducted as described previously (14) with modifications
detailed in the supplemental material.
Statistical Analysis—All values are shown asmeans" S.E. or
S.D., as indicated. p values were determined using Student’s t
test with two-tailed distribution and unequal variance.
Additional Experimental Procedures—Additionalmethodol-
ogy is provided in the supplementary material.
RESULTS
Development of in Vitro Three-dimensional Branching Assay
Using PrimaryMECs—To study the direct effect of growth fac-
tor signaling on epithelial cells, we developed a three-dimen-
sional branching assay using isolated primary MECs devoid of
4 The abbreviations used are: MEC, mammary epithelial cell; AHR, aryl hydro-
carbon receptor; K8, keratin-8; K14, keratin-14; TCDD, 2,3,7,8-tetrachlorod-
ibenzodioxin; ARNT, aryl hydrocarbon receptor nuclear translocator; DIC,
differential interference contrast.
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stromal components. Primary MECs were prepared as single
cells from the fourth inguinal mammary glands of 8–12-week-
old FVB/n mice. Dissociated primary MECs were cultured in
suspension to allow aggregation of epithelial cells, and after
16 h, the cell clusters were enriched from stromal cells by dif-
ferential centrifugation as described previously (6). The MEC
aggregates were embedded inMatrigel and grown in culture for
144 h in serum-free medium supplemented with either EGF or
FGF2. In this assay, aggregates cultured with either growth fac-
tor underwent considerable reorganization, motility, and pro-
liferation (Fig. 1, A and B). However, EGF and FGF2 induced
distinct differences in morphology. Unlike in vitro organoid
cultures (7), aggregated primary MECs in our assay did not
branch efficiently in the presence of EGF and predominately
formed hollow cysts with a fluid-filled lumen (Fig. 1A). The
significantly reduced branching observed with EGF further
supports its role as an indirectmediator of branching (8, 15) and
is in agreement with the lack of stromal cells in our aggregate
culture model (10) compared with the organoid model (16). In
contrast to EGF, FGF2 stimulated extensive branching ofMECs
(Fig. 1B), which is consistent with the robust branching pheno-
type elicited by activation of the FGF receptor in mammary
epithelial cells in vivo (17). To determine the optimal concen-
tration of FGF2 required to stimulate branching in the aggre-
gate model, we performed a dose-response analysis and found
the half-maximal effective concentration (EC50) for FGF2-in-
duced branching to be 0.41! 0.053 nM (Fig. 1C). Based on these
results, we used 2.5 nM growth factor for all subsequent assays,
which was the minimum concentration required to achieve
maximal branching. At this concentration, 56.4% of primary
MECs branched in the presence of FGF2 compared with only
8.9% with EGF (Fig. 1D).
We next used immunofluorescence to assess the cellular
architecture of cyst and branched structures. Both EGF and
FGF2 induced a cellular organization similar to that observed in
vivo. Immunofluorescence staining showed that like in vivo
mammary ducts (Fig. 1E), EGF-induced cysts were composed
of an epithelial bilayer (Fig. 1F), with keratin-8 (K8)-positive
luminal epithelial cells surrounded by keratin-14 (K14)-posi-
tive myoepithelial cells. In branched structures induced by
FGF2, we found K8-positive luminal epithelial cells invading
into theMatrigel at branch points andK14-positivemyoepithe-
FIGURE1.PrimaryMECsbranch in thepresenceofFGF2.A, aggregatedprimaryMECsgrown inMatrigelwith2.5nMEGFunderwentextensive reorganization
to form a fluid-filled cyst between 72 and 96 h in culture. Continued growth was observed through 144 h. B, 2.5 nM FGF2 stimulated robust branching.
Aggregates initially reorganized to form a cyst, which collapsed near 72 h in culture. Extensive branching and increased growth was observed through 144 h
in culture. Representative time course DIC images are shown. C, dose-response analysis for EGF- and FGF2-induced branching over 144 h.D, quantification of
percentage of branching in primaryMECs grown for 144 hwith 2.5 nM EGF or 2.5 nM FGF2. Statistical analysis was performed using Student’s t test. Results are
shown asmean! S.D. (error bars); n" 3; ****, p# 0.0001. E, mammary ducts are composed of an epithelial bilayer, as shown by immunofluorescence staining
of a cross-sectionof aduct fromavirgin FVB/nmousewith a luminal epithelialmarker, K8 (green), andamyoepithelialmarker, K14 (red). F, immunofluorescence
staining for K8 and K14 in our three-dimensional primary MEC culture model with 2.5 nM EGF. G, immunofluorescence staining for K8 and K14 in our
three-dimensional primary MEC culture model with 2.5 nM FGF2. E–G, interactions between luminal epithelial and myoepithelial cells were similar to those
observed in vivo. Nuclei were stained with DAPI (in blue). The dashed white line defines the lumen. A, B, and E–G, scale bar, 40 !m.
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lial cells retained at points of constriction at the base of
branches (Fig. 1G), which is consistent with previous studies
showing that branch points arise at breaks in the myoepithelial
layer (16). Thus, our aggregate-based model recapitulated key
aspects of in vivo mammary branching morphogenesis and
allowed us to uncouple epithelial inducedmorphogenesis from
stromal mediated events.
Chemical Genetic Screen to IdentifyModulators of Branching
Morphogenesis—With our three-dimensional assay, we next
conducted a chemical genetic screen to identify strong modu-
lators of branching, with the goal to use these compounds to
elucidate signaling pathways in epithelial cells critical for this
developmental process.Wewere specifically interested in com-
pounds that completely blocked FGF2-induced invasion yet
maintained the normal, bilayered morphology of the growing
aggregate. Thus, we were interested in compounds that
induced cyst morphology similar to EGF-treated aggregates.
We hypothesized that compounds causing cyst arrest in FGF2-
treated aggregates would more specifically target invasion
rather than growth-stimulating pathways.
587compounds fromtheUniversityofUtahChemistryDepart-
ment Collection were screened in the FGF2 branching assay. Six
dominant phenotypes were observed (Fig. 2, A and B): normal
branching, hyperbranching, reduced branching, cyst arrest, filled,
and cytotoxic. Additionally, 6% of compounds caused a mixed
phenotype consisting of two or more dominant characteristics
(Fig. 2B). The most potent compound that caused cyst arrest, a
diphenyl oxadiazole named 1023 (Fig. 2C), exhibited an EC50 of
1.2! 0.050!M in our branching assay (Fig. 2D) and had no signif-
icant toxicityoreffectongrowthcomparedwithDMSOtreatment
(vehiclecontrol) (Fig.2EandsupplementalMoviesS1andS2).The
effect of impairing branching while simultaneously maintaining
normal cyst growth (supplemental Fig. S1) suggested 1023 was a
specific modulator of FGF2-induced branching. Thus, we rea-
soned that elucidating the target of 1023 would lead to better
understanding of the molecular mechanisms downstream of
FGF2 duringmammary branchingmorphogenesis.
Activation of the Aryl Hydrocarbon Receptor Blocks Branch-
ing Morphogenesis—For insight into the biological mechanism
of action of 1023, we evaluated alterations in gene expression
FIGURE 2.Chemical library screen identifies 1023 as a potent inhibitor of in vitrobranchingmorphogenesis.A, six dominant phenotypeswere observed
in a chemical library screen for alterations on FGF2-induced branching. Representative DIC images of the phenotypes observed are shown. B, quantification of
the percentage of total compounds that induced each phenotype. C, structure of 1023, which was one of themost potent compounds to cause cyst arrest.D,
dose-response analysis for FGF2-induced branching in the presence of 1023 over 144 h. E, representative time course DIC images of MECs grown in the FGF2
branching assay with DMSO (vehicle control) (top) or 10 !M 1023 (bottom). A and E, scale bar, 40 !m. Error bars, S.D.
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following compound treatment. We conducted microarray
gene expression analysis on primary MECs grown in Matrigel
for 72 hwith FGF2 and eitherDMSOor 10!M1023. Compared
with DMSO, 1023 highly up-regulated Cyp1a1, Ahrr, Gsta3,
Aldh3a1, Nqo1, Cyp1b1, and Ugt-1a (Table 1, boldface type),
an expression profile known to be induced by activation of
AHR (18).
AHR is a ligand-activated transcription factor and member
of the Per-Arnt-Sim family of basic helix-loop-helix proteins.
Known for binding aromatic compounds (19, 20), AHR medi-
ates response to chemicals by up-regulating expression of met-
abolic enzymes (21). However, a growing number of studies
suggest that AHR has a wider physiologic role in regulating
critical cellular processes, including proliferation, differentia-
tion, and apoptosis (22, 23). To assess AHR as a potential target
of 1023, we used a homologymodel structure of humanAHR to
predict binding modes of 1023 (24). Using the lowest energy
conformer, 1023 was predicted to bind AHR with a free energy
of!20.83 kcal/mol (Fig. 3A), which suggested a strong interac-
tion between 1023 and AHR. In addition to van derWaals con-
tacts, our modeling predicted Phe-287, His-291, Phe-324, Cys-
300, His-337, and Gln-383 in the AHR binding cavity
significantly contributed to the binding mode of 1023 through
hydrogen bonding and other non-bonded contacts. Further-
more, themodeling data indicated that the addition of a trifluo-
romethyl group to the phenyl ring of 1023 would drastically
reduce its ability to bindAHRdue to steric clasheswithHis-291
and Phe-287. As a result, we synthesized the 1023-CF3 analog
(Fig. 3B, top), which had a predicted binding energy of!11.21
kcal/mol, to use as a negative control in our assays.
With AHR as the putative cellular target of 1023, we hypoth-
esized that TCDD (Fig. 3B, bottom), a widespread environmen-
tal pollutant and known activator of AHR (25, 26), would phe-
nocopy 1023. In our three-dimensional branching assay, TCDD
blocked branching of primary MECs (EC50 " 3.93 # 0.17 pM)
(Fig. 3C) and induced a strong cyst arrest phenotype (Fig. 3E,
top right), similar to 1023 (Fig. 3E, bottom left). In contrast,
1023-CF3 did not efficiently block branching (EC50 " 71.1 #
1.9 !M) compared with 1023 (EC50" 1.2# 0.05 !M) (Fig. 3, D
andE, bottompanels), as predicted by ourmodeling data. These
results suggested that activation of AHR is sufficient to block
mammary branching morphogenesis in vitro.
1023 Activates AHR to Disrupt Mammary Branching
Morphogenesis—We next probed the AHR pathway to verify
that 1023was a strong activator of AHR. Following ligand bind-
ing, AHR undergoes nuclear translocation, dimerizes with
ARNT, and activates transcription of downstream target genes
(19, 27, 28). Considering this mechanism, we wanted to deter-
minewhether 1023 treatment led to an increased accumulation
of AHR in the nucleus. To do so, we expressed an HA-tagged
AHR construct, pACTAG2-HA-AHR, in HEK-293T cells.
After 24 h of drug treatment, we performed immunofluores-
cence forHA and found that both 10 nMTCDDand 10!M1023
significantly increased the amount of nuclear AHR compared
with DMSO or 10 !M 1023-CF3 (Fig. 3F and supplemental Fig.
S2).
The increase in AHR nuclear translocation also correlated
with induction of AHR response genes. Cyp1a1 (cytochrome
P4501A1) is a direct AHR target and is used as a readout for
AHR activation (29). In primary MECs treated for 48 h, 10 nM
TCDD and 10 !M 1023 increased Cyp1a1 gene expression by
23.3- and 4.5-fold, respectively, compared with DMSO or 10
!M 1023-CF3 (Fig. 3G). Furthermore, we tested the specificity
ofCyp1a1 induction and asked whether AHR and its transcrip-
tional binding partner, ARNT, were required for 1023 to acti-
vateCyp1a1 expression.We generatedmousemammaryHC11
cell lines stably expressing either a nonspecific control shRNA,
shRNA against Ahr (shAHR-1), or shRNA against Arnt
(shARNT-1 or shARNT-2). In these cell lines, Ahr expression
was reduced by 61% (shAHR-1) (supplemental Fig. S3A) and
Arnt expression by 60% (shARNT-1) or 75% (shARNT-2) (sup-
plemental Fig. S3B). Cells withAhr orArnt knockdown showed
considerably reduced expression of Cyp1a1 than control cells
after treatment with 10 nM TCDD (supplemental Fig. S3C) or
10 !M 1023 (Fig. 4A). Together, these results confirmed that
1023 activated AHR, leading to its nuclear translocation and
induction of downstream gene targets.
Although 1023 activated AHR, it was still unclear whether
AHR was required for the observed branching defect. To
address this, we used lentiviral shRNA constructs to knock
down Ahr in primary MECs. Briefly, primary MECs were
infected in monolayer with a lentiviral control hairpin or
shRNA construct against Ahr (shAHR-1 or shAHR-2), and
knockdown of Ahr was confirmed by RT-PCR (supplemental
Fig. S3D). Following infection, primary MECs were embedded
as single cells in Matrigel and grown for 21 days with FGF2.
Within each well, single cells grew into clonal outgrowths that
were either untransduced or transduced, as distinguished by
GFP expression. As expected, control transduced outgrowths
(Fig. 4,B andC) branched in the presenceDMSObut generated
cysts in the presence of 10 nM TCDD or 10 !M 1023. Similar
results were observed with untransduced outgrowths that grew
in the same well as transduced outgrowths (supplemental Fig.
S3E). In contrast, transduction of MECs with lentiviruses con-
taining either of two different shRNA hairpins against Ahr sig-
TABLE 1
Genes of interest up-regulated bymicroarray inMECs treated for 72 h
with 1023





NM_009992 Cytochrome P450, family 1,






XM_484705 Desmoglein 1 " Dsg1 10.51
BY704100 Desmocollin 1 Dsc1 9.39
NM_010356 Glutathione S-transferase, !
3, transcript variant 2
Gsta3 7.13
NM_007436 Aldehyde dehydrogenase






NM_009994 Cytochrome P450, family 1,
subfamily b, polypeptide 1
Cyp1b1 3.49
NM_030596 Desmoglein 3 Dsg3 3.38
NM_201410 UDP glucuronosyltransferase
1 family, polypeptide A6B
Ugt-1a 2.91
a Log2 ratio for 1023-treated versus DMSO.
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nificantly rescued branching in the presence of 10 nMTCDD or
10 !M 1023 (Fig. 4, B and D and supplemental Fig. S3F). These
results demonstrated that AHR was required for TCDD and
1023 to block FGF2-induced branching morphogenesis.
Desmosomal Adhesion Is Regulated by the AHR Pathway—
After determining that 1023 targeted the AHR pathway, we
sought to mechanistically understand how activation of AHR
blocksmammary branching. Strikingly, ourmicroarray analysis
showed up-regulation of several genes involved in cellular
adhesion, including desmosomal cadherins (Table 1 and sup-
plemental Table S1). Because desmosomes are known to induce
very tight intercellular contacts (30, 31) and are one of the dom-
inant adhesion complexes found in the mammary gland (32),
we hypothesized that desmosomal adhesion would be critical
for maintenance of cysts caused by AHR activation.
First, we confirmed our microarray analysis by measuring
gene expression of desmosomal cadherins in primary MECs
treated for 96 h. RT-PCR results showed that both 10 nMTCDD
and 10 !M 1023 significantly up-regulated gene expression of
Dsc1 (desmocollin 1) (supplemental Fig. S4A), Dsg1 (desmog-
lein 1) (supplemental Fig. S4B), and Dsg3 (desmoglein 3) (Fig.
5A) compared with DMSO. Moreover, desmosomal cadherins
were up-regulated in primary MECs grown in the presence of
EGF compared with FGF2 (Fig. 5A and supplemental Fig. S4, A
FIGURE 3. 1023 activates the aryl hydrocarbon receptor. A, docking of 1023 (purple) with the homology model structure of human AHR (gray). Important
interacting residues are noted in green. The binding free energywas estimated at!20.83 kcal/mol, suggesting a favorable interaction between 1023 andAHR.
B, chemical structures of 1023-CF3 (top), a predicted inactive analog of 1023, and TCDD (bottom), a known activator of AHR. C, dose-response analysis for
FGF2-induced branching in primary MECs treated with TCDD for 144 h. D, 1023-CF3 was less effective at blocking branching than 1023, as shown by dose-
response analysis over 144 h for FGF2-induced branching. Error bars S.D. E, representative DIC images of the dominant phenotype observed in primary MECs
grown in the FGF2 branching assay with DMSO (top left), 10 nM TCDD (top right), 10 !M 1023 (bottom left), or 10 !M 1023-CF3 (bottom right). Scale bar, 40 !m.
F, in HEK-293T cells transiently expressing pACTAG2-HA-AHR, 10 nM TCDD and 10 !M 1023 increased nuclear localization of AHR compared with DMSO or 10
!M 1023-CF3 after 24 h of treatment. Quantification was based on immunofluorescence for HA. Results are shown as mean" S.D.; n# 7; ****, p$ 0.0001. G,
relative gene expression ofCyp1a1, a knownAHR response gene,was elevated in primaryMECs treated for 48 hwith 10nMTCDDor 10!M1023 comparedwith
DMSOor10!M1023-CF3.Cyp1a1geneexpressionwasmeasuredbyRT-PCRandnormalized to"-actinexpression. Results are shownasmean"S.E. (error bars);
n# 3; ***, p$ 0.001; **, p$ 0.01. F and G, statistical analysis was performed using Student’s t test.
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and B). To assess protein levels, we performed a Western blot
for DSG3 in primary MECs extracted from Matrigel after 96 h
of treatment. Consistent with our RT-PCR results, DSG3 pro-
tein levels were highly up-regulated in primary MECs grown
with EGF, 10 nM TCDD, or 10 !M 1023 compared with FGF2
alone (Fig. 5B). Finally, knockdown of Ahr or Arnt significantly
reduced induction of desmosomal cadherins (supplemental
Fig. S4,C andD). LikeCyp1a1,Dsg1 gene expression was lower
in HC11 cell lines with stable knockdown of Ahr or Arnt after
treatmentwith 10 nMTCDDor 10!M1023. These experiments
identifiedDsc1,Dsg1, andDsg3 as novel downstream targets of
the AHR signaling pathway.
Inhibition of Desmosomal Adhesion Promotes Branching of
the Mammary Epithelium—To assess the functional impor-
tance of desmosomal adhesion in AHR-mediated disruption of
branching morphogenesis, we sought to inhibit desmosome
formation. Desmocollin and desmoglein are members of the
cadherin family of proteins and require calcium to form func-
tional desmosomes in vitro (33–36). We predicted that if cad-
herin junctions were required to maintain the cyst phenotype,
then chelation of calcium would rescue the branching defect
elicited by 1023. Thus, we added 10 !M EGTA (pH 7.4) to che-
late calcium in our branching assay. After 144 h in culture, we
found a significant increase in branching with EGTA in the
presence 10 nM TCDD or 10 !M 1023 compared with vehicle
control (Fig. 5, C and D). Furthermore, calcium chelation sig-
nificantly increased branching in the presence of EGF, suggest-
ing that desmosomes play a central role in the transition to a
branched epithelial state.
Based on these results, we went on to selectively inhibit the
formation of desmosome complexes using blocking peptides.
These 10-mer peptides bind the cell adhesion recognition site
(37) of a specific desmosome cadherin and functionally inhibit
its ability to form adhesion complexes (38, 39). Accordingly, we
added 2 mM peptide against DSC3 or DSG3 to primary MECs
after 48 h in culture with 10!M 1023 and observed a significant
increase in branching at 144 h. In contrast, a nonspecific con-
trol peptide and a previously published peptide against E-cad-
herin (38) did not significantly affect branching in the presence
of 10 !M 1023 (Fig. 5, E and F), suggesting a specific role for
desmosomes. Together, these results demonstrate that desmo-
somes are a novel downstream target of ligand-induced AHR
signaling and critical to block branching morphogenesis of the
mammary gland.
FIGURE 4.AHR is the biological target of 1023. A, induction of Cyp1a1 by 1023 was lower in HC11 cells stably expressing an shRNA against Ahr (shAHR-1) or
Arnt (shARNT-1 or shARNT-2) than untransducedor control transduced cells.Cyp1a1gene expressionwasmeasured after 6 days of treatmentwithDMSOor 10
!M 1023 and normalized to "-actin expression. Results are shown as mean! S.E. (error bars). B, knockdown of Ahr in primary MECs rescued branching in the
presence of AHR agonists. Shown is a quantification of the percentage of branching in transduced outgrowths from primary MECs infected with a lentiviral
control shRNA (Control) or shRNA againstAhr (shAHR-1 or shAHR-2). Statistical analysiswas performedusing Student’s t test. Results are shown asmean! S.D.
(error bars);n"2; *,p#0.05; **,p#0.01.C, representative imagesof a clonal outgrowth fromprimaryMECs transducedwith a control shRNA.D, representative
images of a clonal outgrowth from primary MECs transduced with shAHR-2. B–D, following transduction, cells were embedded in Matrigel as single cells and
grown for 21 days in the presence of 2.5 nM FGF2 and DMSO, 10 nM TCDD, or 10 !M 1023. C and D, scale bar, 40 !m.
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Using a three-dimensional epithelial cell-based model of
branching, we demonstrate that FGF2, but not EGF, is suffi-
cient to drive morphogenesis of mammary epithelial cells,
which is in agreement with the role of growth factors in mam-
mary development (5, 40). In addition, we employed a novel
chemical genetic approach to identifymolecular pathways con-
trolling the dynamics of mammary branching morphogenesis.
The use of chemical genetics rather than a standard genetic
approach allowed us to specifically activate the AHR signaling
pathway and identify a new role for AHR in regulating adhesion
complexes in the mammary gland.
Environmental exposure to chemical pollutants, including
TCDD, is thought to contribute significantly to lactation defi-
ciencies inwomen (41). These findings are supported by studies
in rodents, which showed that TCDD exposure during gesta-
tion (42, 43) and pregnancy (44) decreased alveolar develop-
ment and milk production, respectively. It remains controver-
sial whether local or systemicmechanismsmediate the effect of
TCDDonmammary differentiation. AlthoughTCDD is known
to modulate estrogen receptor signaling (45), studies have
shown that it does not decrease circulating levels of prolactin,
estradiol, or progesterone in compound-treated mice (44).
Additionally, TCDD was shown to reduce alveolar develop-
ment in ex vivo cultures of whole mammary glands (46). In
agreement with these observations, our data show that AHR
activation has direct effects on mammary cells.
The keymediators of the effects of TCDD have been difficult
to study with in vitro organoid and in vivo transgenic models,
due to the complex interactions between epithelial and stromal
cells in these systems. Studies have shown that the DNA-bind-
ing domain of AHR is required for the deleterious effects of
TCDD on the mammary gland (46), implicating AHR tran-
scriptional regulation as a critical mechanism. Additionally,
reciprocal transplant experiments with AHR knock-out mice
suggest that both epithelial and stromal transcriptional targets
of AHR contribute to the block in branching (46). Here, we
demonstrate an epithelial mediatedmechanism, in which AHR
blocks alveolar development through desmosomal adhesion,
which is a novel target of the AHR pathway.
There is growing evidence to suggest that desmosomes con-
tribute significantly to mammary morphogenesis. In the 1970s,
electronmicroscopywas used to assess the ultrastructure of the
mousemammary gland (47). These studies showed that desmo-
somes were a major adhesion component in the mammary
gland, with large desmosome complexes connecting ductal epi-
thelial cells in the virgin gland. Interestingly, desmosomal com-
plexes were highly dynamic. At the onset of lactation, desmo-
somal adhesion was increased in major, nonsecretory ducts,
whereas milk-producing alveoli lost all desmosome contacts
during lactation. This stage-dependent shift in adhesion sug-
gested that desmosomes may have a critical role maintaining
ductal structure, and their down-regulation may functionally
contribute to productive lactation in lobuloalveoli.
Since these early studies, a functional role for desmosomal
adhesion in mammary epithelial cells has been slowly emerg-
ing. During branching morphogenesis, luminal epithelial cells
migrate collectively through the outer myoepithelial layer of a
cyst to form new branch points (16). EM studies on organoids
grown in Matrigel showed that despite an overall loss of adhe-
sion during this process, desmosomal adhesion is maintained
between luminal epithelial cells (32). In another study, desmo-
some-blocking peptides disrupted the ability of a clonal cell line
derived from mouse luminal epithelial cells to form clusters in
an in vitro assay (38). Taken together, these results suggest that
desmosomes are a critical form of adhesion between luminal
epithelial cells.
Although our results show that down-regulation of desmo-
somal adhesion facilitates branching morphogenesis, the spe-
cific role of these adhesion complexes in myoepithelial and
luminal cells is not clear. Our data suggest that the myoepithe-
lial-specific desmosome cadherins, Dsc3 and Dsg3 (38), must
be down-regulated for branching morphogenesis. Because
branch points are known to initiate from breaks in the myoep-
FIGURE 5.AHR signaling promotes desmosomal adhesion to blockmam-
mary branching morphogenesis. A, relative gene expression of Dsg3 (des-
moglein 3) in aggregatedprimaryMECsgrown for 96h inMatrigelwith 2.5 nM
EGF or 2.5 nM FGF2 andDMSOor 10 nM TCDDor 10!M1023. Gene expression
was measured by RT-PCR and normalized to "-actin expression. Results are
shown as mean! S.E. (error bars). B, Western blot analysis of DSG3 in aggre-
gatedprimaryMECs grown for 96 h inMatrigelwith 2.5 nM EGFor 2.5 nM FGF2
and DMSO or 10 nM TCDD or 10 !M 1023. C, the addition of 10 !M EGTA
significantly increased branching of primary MECs grown in the presence of
2.5 nM EGF or in the presence of 2.5 nM FGF2 and 10 nM TCDD or 10 !M 1023
compared with vehicle control. Representative DIC images are shown. D,
quantification of branching shown as mean! S.D. (error bars); n" 3; *, p#
0.05; **,p# 0.01; ***,p# 0.001.C andD, EGTAwas added after 48 h in culture,
and branching was scored at 144 h. E, the addition of 2 mM blocking peptide
against DSC3 or DSG3, but not E-cadherin or a nonspecific control peptide,
significantly increased branching of primary MECs grown in the presence of
FGF2 and10!M1023. RepresentativeDIC images are shown. F, quantification
of branching shown as mean ! S.D. (error bars); n " 3; *, p # 0.05. E and F,
peptidewas added after 48 h in culture, and branchingwas scored at 144 h. C
and E, scale bar, 40 !m. D and F, statistical analysis was performed using
Student’s t test.
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ithelial layer (16), the mechanical integrity of desmosomesmay
be selectively lost in myoepithelial cells to promote branching
and differentiation. Loss of robust adhesion between myoepi-
thelial cells would also facilitate contraction and milk delivery
required during lactation.
Our data demonstrate that desmosomes form a critical and
functional adhesion complex between mammary epithelial
cells. Because desmosome cadherins are commonlymutated or
silenced in human breast cancer (48, 49), desmosomesmay be a
critical adhesion complex that is lost in order to promote
tumorigenesis. These findings are supported by previous work,
which showed overexpression of desmosomal components
inhibited invasion of nonadhesive cells in collagen (39). In our
assay, desmosomal adhesionwas sufficient to block the invasive
mechanisms mediated by FGF2, consistent with an ability to
promote tight epithelial cell interactions. Similarly, AHR ago-
nists have been shown to inhibit invasion and increase differ-
entiation of breast cancer cells (50). Thus, dissecting the role
and regulation of desmosomes in vivowill be a critical next step
toward understanding morphogenesis and transformation of
the mammary gland.
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SUPPLEMENTAL FIGURE S1.  MECs treated with 1023 maintain an epithelial bilayer.  A.  
Representative DIC image of a primary MEC aggregate grown with 2.5 nM FGF2 and DMSO.  B.  
Representative DIC image of a primary MEC aggregate grown with 2.5 nM FGF2 and 10 µM 1023.  C-D.  
Immunofluorescence staining of a luminal epithelial marker, keratin-8 (K8, in green), and a myoepithelial 
marker, keratin-14 (K14, in red) in MEC aggregates grown in the FGF2 branching assay.  Nuclei were 
stained with DAPI (in blue).  C.  Representative staining of a primary MEC aggregate grown with 2.5 nM 
FGF2 and DMSO.  D.  Representative staining of a primary MEC aggregate grown with 2.5 nM FGF2 
and 10 µM 1023.  1023 maintained an epithelial bilayer, with luminal epithelial cells (in green) 
surrounded by myoepithelial cells (in red). A-D.  Aggregates were grown for 144 hours in Matrigel.  






































SUPPLEMENTAL FIGURE S2.  1023 and TCDD activate AHR to translocate to the nucleus.  
Representative images of HEK-293T cells transiently expressing pACTAG2-HA-AHR after 24 hours of 
treatment.  10 nM TCDD and 10 µM 1023 increased nuclear localization of AHR compared to DMSO or 








































SUPPLEMENTAL FIGURE S3.  AHR is the biological target of 1023.  A. AHR gene expression in 
HC11 cells stably expressing shAHR-1.  B.  ARNT gene expression in HC11 cells stably expressing 
either shARNT-1 or shARNT-2.  A-B.  Gene expression was measured by RT-PCR in stable cell lines 7 
days after lentiviral transduction and normalized to beta-actin.    Results are shown as mean ± s.e.m.  C.  
Cyp1a1 gene expression in untransduced HC11 cells or cells stably expressing a control shRNA, an 
shRNA against AHR (shAHR-1), or an shRNA against ARNT (shARNT-1 or shARNT-2).  Cyp1a1 gene 
expression was measured by RT-PCR after 6 days of treatment with DMSO or 10 nM TCDD and 
normalized to beta-actin expression.  Results are shown as mean ± s.e.m.  D.  AHR gene expression in   
primary MECs after transduction with lentiviral shRNA constructs against AHR.  Gene expression was 
measured by RT-PCR in primary MECs sorted by FACS for GFP expression and normalized to beta-
actin.  Results are shown as mean ± s.e.m.  E.  Quantification of percent branching in untransduced 
outgrowths from primary MECs infected with a lentiviral control shRNA (Control) or shRNA against 
AHR (shAHR-1 or shAHR-2).  Results are shown as mean ± s.d; n = 2.  F.  Representative images of a 
clonal outgrowth from primary MECs transduced with shAHR-1.  Scale bar = 40 µm.  E-F.  Following 
transduction, cells were embedded in Matrigel as single cells and grown for 21 days in the presence of 2.5 
































































SUPPLEMENTAL FIGURE S4.  AHR activation increases expression of desmosomal cadherins.  A.  
Relative gene expression of desmocollin 1 (Dsc1).  B.  Relative gene expression of desmoglein 1 (Dsg1).  
A-B.  Aggregated primary MECs were grown for 96 hours in Matrigel with 2.5 nM EGF or 2.5 nM FGF2 
and DMSO, 10 nM TCDD, or 10 µM 1023.  C.  Relative gene expression of Dsg1 in HC11 cells after 
treatment with 10 nM TCDD.  D.  Relative gene expression of Dsg1 in HC11 cells after treatment with 10 
µM 1023.  C-D.  Gene expression was measured in untransduced HC11 cells or cells stably expressing a 
control shRNA, an shRNA against AHR (shAHR-1), or an shRNA against ARNT (shARNT-1 or 
shARNT-2) after 6 days of compound treatment.  A-D.  Gene expression was measured by RT-PCR and 
















SUPPLEMENTAL MOVIE S1.  FGF2 induces branching in primary MECs.  Time-lapse imaging of a 
primary MEC aggregate embedded in Matrigel and grown in the presence of 2.5 nM FGF2 and 0.1% 
DMSO for 120 hours.  MECs initially reorganized to form a fluid-filled cyst, which collapsed near 72 
hours in culture and led to extensive branching through 120 hours in culture.  Images were captured every 
30 minutes. 
 
SUPPLEMENTAL MOVIE S2.  1023 blocks branching of primary MECs.  Time-lapse imaging of a 
primary MEC aggregate embedded in Matrigel and grown in the presence of 2.5 nM FGF2 and 10 µM 
1023 for 120 hours.  MECs initially reorganized to form a fluid-filled cyst, which continued to grow 
through 120 hours in culture.  Images were captured every 30 minutes.   
 
SUPPLEMENTAL TABLE S2.  Primer and shRNA sequences 
 
Primer sequences used for RT-PCR 
 
Target Forward  Reverse 
β-actin 5'-GGCTGTGCTGTCCCTGTATG-3' 5'-CAAGAAGGAAGGCTGGAAAA-3' 
Cyp1A1 5'-GGTTAACCATGACCGGGAACT-3' 5'-TGCCCAAACCAAAGAGAGTGA-3' 
AHR 5'-CTTTGCTGAACTCGGCTTGC-3' 5'-TTGCTGGGGGCACACCATCT-3' 
ARNT 5'-CTAAGAGACAGCTTTCAGCAGGT-3' 5'-AGGGTTTTGGAAGGTAAAGGAG-3' 
Dsc1 5'-CAGTAGTGGCGACAGATACA-3' 5'-CCTTCTCCTGCTGACAAATG-3' 
Dsg1 5'-GGGATAACCACCATCTGTGT-3' 5'-CCTCCCAGATCTTGCATTTC-3' 
Dsg3 5'-AGGTTCTGGCCATAGACGAA-3' 5'-TCACTGAGAGGGTCACAGAA-3' 
 
Oligo and shRNA sequences for shRNA lentiviral plasmids 
 
































































SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Mice–FVB/n mice were maintained following protocols reviewed and approved by the University of Utah 
Institutional Animal Care and Use Committee. 
Isolation of primary MECs–Organoids from the fourth inguinal mammary gland were isolated 
from 8-12 week-old female FVB/n mice as previously described (1).  All plasticware was pre-coated with 
sterile 3% bovine serum albumin (BSA) in phosphate buffered saline (PBS) in order to minimize cell loss 
during preparation.  Organoids were washed once in PBS without calcium or magnesium (Gibco), 
pelleted at 500 x g for 30 seconds, resuspended in 3 mL of PBS containing 750 µL 0.05% Trypsin/EDTA 
(Gibco), placed in a 6-well plate (Falcon) and incubated at 37 ºC.  Every 3 minutes, cells were pipetted to 
break up organoids and visualized under a light microscope.  This process was repeated until 
approximately 90% of the organoids dissociated into single cells or for a maximum of 20 minutes to 
minimize cell death.  Hanks’ balanced salt solution (HBSS) (Gibco) with 2% fetal bovine serum (FBS) 
(HyClone) was added to neutralize the trypsin and cells were pelleted (450 x g, 3 minutes).  The cell 
pellet was resuspended in 10 mL serum-free DMEM/F-12 (HyClone) containing 100 µg/mL DNase I 
(Sigma) and incubated at room temperature for 3 minutes with gentle mixing.  Cells were filtered through 
a 40 µm cell strainer (BD Falcon), counted, pelleted at 450 x g for 3 minutes, and used for branching 
assays.  Extra cells were pelleted and resuspended in DMEM/F-12 containing 20% FBS and 10% DMSO 
(Sigma) at a concentration of 4x106 cells/mL, and frozen in liquid nitrogen. 
Antibody staining–Staining for K8 (Developmental Studies Hybridoma Bank, Troma-1, 1:100) 
and K14 (Covance, PRB-155P-100, 1:400) was done on sections of mammary gland from virgin FVB/n 
mice and on primary MECs grown for 144 hours in 8-chamber culture slides (BD Falcon).  Staining on 
sections was done using standard microtome sectioning, deparaffinization and hydration, and antigen 
retrieval with boiling 10 mM sodium citrate buffer, pH 6.0.  For primary MECs, aggregates were 
embedded as described using 5 µL of Matrigel as the base layer and 200 aggregates suspended in 10 µL 
Matrigel on top.  Aggregates were fixed with 4% PFA for 30 minutes at room temperature (RT), washed 
three times with PBS, and permeablized with 0.5% triton X-100 (Omnipure) for 90 minutes at RT.  All 
samples were blocked in 5% BSA (Cell Signaling Technologies) + 1% normal goat serum for 1 hour at 
RT and incubated with primary antibody diluted in 1% BSA overnight at 4 ºC.  For HA (Covance, MMS-
101R, 1:500) staining, HEK-293T cells were fixed with 4% PFA for 15 minutes at RT, washed once with 
50 nM ammonium chloride (Sigma), and permeablized with 0.2% triton X-100 in PBS for 8 minutes at 
RT.  Cells were washed once in 1% BSA in PBS and blocked with fresh 1% BSA in PBS for 10 minutes.  
Following block, samples were incubated with primary antibody diluted in 1% BSA in PBS for 1 hour at 
RT.  After primary antibody incubations, samples were washed three times with PBS and incubated with 
secondary antibodies (Invitrogen, Alexa series, all 1:1000 in 1% BSA in PBS) for 1 hour at RT.  Nuclei 
were stained with 50 ng/mL DAPI (Molecular Probes) for 5 minutes at RT.  Coverslips were mounted 
with ProLong Gold anti-fade reagent (Invitrogen). 
Chemical compounds–TCDD (Cambridge Isotopes Laboratories, Inc., Andover, MA) was 
obtained as a DMSO stock solution.  1023 and 1023-CF3 were synthesized as described below and 
dissolved in DMSO at a stock concentration of 10 mM. 
Chemical synthesis–(5-(2,4-dichlorophenyl)-3-phenyl-1,2,4-oxadiazole [1023]: To a stirring 
solution of benzamidoxime (500 mg, 3.67 mmol) in dioxane (35 mL), was added 2,4 dichlorobenzoyl 
chloride (770 mg, 3.67 mmol) followed by BF3•OEt2 (114 µL, 0.80 mmol) at 0 °C.  The reaction mixture 
was stirred at room temperature for 30 minutes and heated to reflux for 12 hrs.  After completion of the 
reaction, the dioxane was removed by rotary evaporation and the residue was cooled in an ice bath and 
quenched with ice water.  The aqueous layer was then extracted with EtOAc (2 x 50 ml).  The combined 
organic layers were dried over Na2SO4, and concentrated under reduced pressure.  The resulting crude 
product was purified by flash column chromatography (10% EtOAc in hexanes) to yield 1023 (850 mg, 
80%) as a colorless solid.   
1H NMR (500 MHz, CDCl3) δ  8.18 (dd, J = 7.5, 1.4 Hz, 2H), 8.13 (d, J = 8.3 Hz, 1H), 7.61 (d, J = 1.9 
Hz, 1H), 7.56 – 7.70 (m, 3H), 7.43 (dd, J = 8.3, 1.9 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3): δ (ppm) 
137.7, 168.9, 139.2, 134.9, 132.9, 131.6, 131.6, 129.1, 127.8, 126.8, 122.3 ppm; IR (neat) 2152, 1595, 












1569, 1452, 1392, 1363, 1135, 1104, 748, 707, 691 cm-1; HRMS (ESI) calcd for C14H9Cl2N2O (M+H): 
291.0092, found: 291.0090.  Mp; 55-56 oC. 
(5-(2,4-dichlorophenyl)-3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole [1023-CF3]: To a 
stirring solution of 3-trifluorobenzamidoxime (346 mg, 1.69 mmol) in dioxane (17 mL), was added 
2,4 dichlorobenzoyl chloride (425 mg, 2.03 mmol) followed by BF3•OEt2 (52 µL, 0.42 mmol) at 0 °C.  
The reaction mixture was stirred at room temperature for 30 minutes and heated to reflux for 12 hrs.  
After completion of the reaction, the dioxane was removed by rotary evaporation and the residue was 
cooled in an ice bath and quenched with ice water.  The aqueous layer was then extracted with EtOAc (2 
x 50 ml).  The combined organic layers were dried over Na2SO4, and concentrated under reduced 
pressure.  The resulting crude product was purified by flash column chromatography (10 % EtOAc in 
hexanes) to yield 1023-CF3 (415 mg, 68%) as a colorless solid.    
1H NMR (CDCl3, 500 MHz) δ 8.45 (s, 1H), 8.36 (d, J= 7.8 Hz, 1H), 8.15 (d, J= 8.2 Hz, 1H), 7.80 (d, J= 
7.8 Hz, 1H), 7.68- 7.63 (m, 2H), 7.48- 7.44 (m, 1H) ppm; 13C NMR (400MHz, CDCl3) δ 174.5, 167.9, 
139.5, 135.0, 132.9, 131.9, 131.7, 131.6, 130.9, 129.7, 128.1, 128.1, 128.1, 127.9, 127.7, 125.3, 124.8, 
124.7, 124.7, 124.7, 122.5, 122.0 ppm; IR (neat) 1590, 1569, 1493, 1390, 1323, 1313, 1169, 1116, 1073, 
811, 707 cm-1; HRMS (ESI) calcd for C15H8Cl2N2OF3Cl2 (M+H): 358.9966, found: 358.9956.  Mp; 83-84 
oC. 
Microscopy–Live time-lapse imaging was performed using a Zeiss Axiovert S-100 microscope 
equipped with a digital CTI-Controller 3700 and Tempcontrol-37-2 to maintain cells at 37 oC with 5% 
CO2.  Images were captured using a 10x A-Plan objective lens every 30 minutes using OpenLab 4.0.2 
software (Improvision, Inc.).  All other imaging was performed using an Olympus IX81-ZDC microscope 
with an ORCAER CCD camera and Slidebook 5.0.0.24 software (Intelligent Imaging Innovations, Inc).  
DIC images were captured using a 10X Plan or 20X long working distance objective lens.  
Immunofluorescence imaging was performed using a 60X Plan oil objective lens (mammary sections) or 
40x U-Plan objective lens (Matrigel samples and AHR nuclear localization).  Imaging of single cell 
primary MEC outgrowths was done using a 20X U-Plan objective lens.  For immunofluorescence 
imaging of Matrigel samples, deconvolution was performed using Slidebook software and the nearest 
neighbor method.   
Microarray processing and analysis–Total RNA was isolated using the Qiagen RNeasy kit and 
assayed for quality on the Bioanalyzer RNA 6000 nano chip.  Samples were labeled with the Agilent 
Two-Color Low RNA Input Linear Amplification Kit and hybridized to the Agilent Whole Mouse Gene 
Expression array (Agilent microarray design ID 014868, GEO platform ID GPL7202) using standard 
Agilent two-color gene expression hybridization and wash protocols.  Microarray slides were scanned on 
an Agilent Technologies G2505B scanner at 5 micron resolution.  The slide images were processed using 
Agilent Feature Extraction software version 9.5.1.1, which performs linear Lowess normalization to 
correct for dye bias.  In this experiment DMSO controls were labeled with Cy3, and compound-treated 
samples were labeled with Cy5.  The Lowess normalized data from the arrays was filtered to remove 
control features and features flagged as nonuniform or feature population outliers.  Remaining features for 
any probe were averaged to yield a single value for each unique probe sequence.  The normalized data set 
was loaded into GeneSifter software (Geospiza Inc) for analysis.  The microarray data from this 
publication have been submitted to the Gene Expression Omnibus database 
(http://www.ncbi.nlm.nih.gov/geo/) and assigned the accession number GSE39249. 
Sequence alignment and homology modeling of the aryl hydrocarbon receptor (AHR)– Sequences 
of human AHR (hAHR) (NP_001612) and murine AHR (mAHR) (NP_038492) were extracted from the 
NCBI protein sequence database.  All sequences were imported into the ClustalW program (2) and the 
sequence alignment editor, BioEdit (3), for multiple pairwise alignments.  The resulting alignments were 
examined manually.  hAHR and mAHR had 27% and 50% sequence identity and similarity, respectively, 
to the solved crystal structure of the high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS 
domain (4) (PDB: 3F1O).  This crystal structure was used as a template for hAHR homology modeling in 
ICM.  Sequence similarity, 3D-PSSM threading, and ICM searches with hAHR provided the HIF2 alpha 
and ARNT C-terminal PAS domain as a template structure for homology modeling of hAHR.  In the 












HIF2 PAS-B Domain, an internal cavity was located using the Site Map with ICM, and electrostatic 
surfaces were generated using the identified binding sites with ICM force field.  A grid spacing of 0.5 Å 
and dielectric constant of 80 for the solvent were employed. 
 Molecular docking–1023 and 1023-CF3 were used for regular docking with the hAHR 
homology model.  Docking calculations were performed using the ICM (5) docking module with default 
setup.  The structure of each complex was energy minimized in the same environment and saved in PDB 
format.  These energy-minimized complexes were then reposed into ICM and converted into an ICM 
object, and MMFF charges were assigned for the select ligand.  The compounds were docked using the 
“interactive docking” menu of ICM.  A stack of different docked conformations were generated and 
visually checked.  100 conformers of each ligand docking were performed on a four AMD 64-bit 
processors Red Hat Linux server.  The best docking conformations were selected on the basis of docking 
energies and RMSD of the ligand from the initial ligand conformation.  The docking conformation 
validated as most realistic for each compound was used for calculation the ligand−hAHR binding energy 
(Cal. ΔG) using the ICM script for binding energy calculations. 
Plasmids–The HA-tagged mouse AHR expression plasmid (pACTAG-HA-mAHR) was kindly 
provided by Dr. Oliver Hankinson (University of California, Los Angeles, CA).  The pLentiLox5.0-GFP 
vector used for creating lentiviral shRNA constructs was a gift from Dr. James Bear (University of North 
Carolina, Chapel Hill, NC).  The following plasmids for generating lentivirus have been previously 
described: pMDLg/pRRE (6), pRSV-Rev (6), and pVSV-G (Clontech).  The identity of each plasmid was 
confirmed by sequencing. 
AHR nuclear localization assay–In 6-well tissue culture plates, 25,000 HEK-293T cells in 
DMEM (Gibco) with 10% charcoal-stripped FBS (CSFBS) (Dextran-coated charcoal: Sigma) were 
seeded onto lysine-coated glass coverslips.  The media was replaced 12 hours later with DMEM 
containing 2% CSFBS, and 2 µg pACTAG-HA-AHR was used for polyethyleneimine (PEI) 
(Polysciences) mediated transfection as follows.  For each well, 6 µg PEI was combined with 200 uL 
Opti-MEM (Invitrogen), inverted several times to mix, and incubated for 5 minutes at room temperature.  
Plasmid DNA was added dropwise to the PEI / Opti-MEM solution, mixed by inverting several times, 
and incubated at RT for 15-45 minutes.  Transfection mixtures were added dropwise to each well and 
mixed with gentle agitation.  Media was replaced 16 hours post-transfection and cells were dosed 48 
hours post-transfection with 0.1% DMSO (Sigma), 10 µM 1023, or 10 nM TCDD.  Samples were stained 
24 hours after dosing.  For each condition, a minimum of 100 cells per sample were scored.    
RNA extraction and real-time PCR–HC11 cells were washed twice with PBS and scraped into 1 
mL cold PBS.  Cells were pelleted at 1250 x g for 5 minutes at 4 ºC and resuspended in 600 uL RLT 
buffer (Qiagen).  For primary MECs, 1,000 aggregates were embedded per well and three wells were 
combined for each condition.  Cells were washed twice with PBS and suspended in 600 µL RLT buffer 
(Qiagen) containing beta-mercaptoethanol (BME) (1:100) in order to lyse cells and solubilize Matrigel.  
RNA was isolated and DNase I treated using the Qiagen RNeasy Mini Kit according to manufacturers 
instructions.  Total RNA was quantified using a Nanodrop (Thermo Scientific) and 1 µg of RNA was 
used to generate cDNA with the Superscript III Reverse Transcriptase Kit (Invitrogen) according to 
manufacturers instructions.  RNase H (Qiagen) was used to remove excess RNA and cDNA was diluted 
1:20 in TE buffer, pH 8.0.  For real-time detection, 5 uL reactions were performed with the LightCycler 
480 (Roche) in quadruplicate using 2x KAPA SYBR FAST qPCR Master Mix (Kapa Biosystems) and 
200 nM each of the forward and reverse PCR primers.  Beta-actin was used as an internal reference gene 
and relative gene expression was calculated by direct CT comparison (7).  Primer sequences are listed in 
supplemental Table S2.  
Molecular cloning–For shRNA constructs, oligonucleotides were diluted in TE Buffer pH 8.0 
(Ambion) to a final concentration of 60 µM.  Forward and reverse primers were combined at a final 
concentration of 1.2 µM each in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH pH 
7.4, 2 mM magnesium acetate) and incubated at 95 ºC for 5 minutes followed by stepwise 1 minute 
incubations at 0.5 ºC temperature decrements until 4 ºC was obtained.  The pLentiLox5.0-GFP vector (8) 
was digested for 1 hour with HpaI-XhoI and dephosphorylated.  Annealed oligos were diluted at 1:20 and 












ligated overnight at 16 ºC with 50 ng digested pLentiLox5.0-GFP vector.    Positive clones were 
identified using an XbaI restriction digest. 
Production and titration of lentivirus–HEK-293T cells were plated on 10-cm tissue culture dishes 
at 7x106 cells per plate in DMEM (Gibco) with 10% FBS (HyClone) 24 hours prior to transfection.  The 
culture medium was changed 2 hours prior to transfection and a total of 10.1 µg of DNA was used for PEI 
mediated transfection of each 10-cm dish.  For 1 mL transfection mixture per 10-cm plate, 30 µg of PEI 
was combined with Opti-MEM, inverted several times to mix, and incubated for 5-15 minutes at RT.  
Plasmids for transfection were combined at the following ratios per 10-cm plate: 5 µg transfer plasmid, 
1.7 µg pMDLg/pRRE packaging plasmid, 1.7 µg pRSV-Rev export plasmid, and 1.7 µg pVSVG 
envelope plasmid.  Plasmid DNA was added dropwise to the PEI / Opti-MEM solution, mixed by 
inverting several times, and incubated at RT for 15-45 minutes.  Transfection mixtures were added 
dropwise to each plate and mixed with gentle agitation.  The culture medium was replaced 12 hours after 
transfection and the viral supernatant was collected 24 and 48 hours later and kept at 4 ºC for all 
subsequent manipulations.  The viral supernatants were cleared of large cell debris by centrifugation at 
2450 x g for 10 minutes and filtered through a 0.45 µm cellulose acetate filter (Corning).  Viral 
supernatants were concentrated by ultracentrifugation at 100,000 x g for 1 h 45 min.  Viral pellets were 
resuspended in DMEM/F-12 by gentle pipetting and stored overnight at 4 ºC.  The following day, 
concentrated virus was aliquoted and stored at -80 ºC.  Viral titers were determined on HEK-293T cells as 
previously described with the following modifications (1). In six-well plates, 2x105 cells per well were 
plated and allowed to adhere for 12 hours.  The medium was replaced with 1 mL of either 1:200, 1:1,000, 
or 1:10,000 diluted viral concentrate.  The number of cells per well was counted at the time of virus 
addition and the average of three wells was used to calculate the viral titer.  Culture medium was replaced 
12 hours after infection and 60 hours later, cells were harvested and analyzed for fluorescent protein 
expression by FACS. Viral titers were calculated (TU/ml) according to the equation [cell number x (% 
fluorescent cells / 100)] x 1000/µl of viral concentrate (9).  Only transductions that resulted in fewer than 
15% fluorescent cells were used for titer calculations. 
HC11 cell culture and production of stable lines–HC11 cells were grown at 37 ºC with 5% CO2 
in RPMI (HyClone) supplemented with 10% FBS, ITS-X, Pen Strep Glutamine, and 10 ng/mL murine 
EGF.  For all compound treatments, FBS was reduced to 2% 12 hours after seeding cells.  For stable 
shRNA expression, 1.25x106 cells were seeded in a 10-cm tissue dish, cultured for 12 hours, and 
transduced at an MOI of 20.  The transduction efficiency was determined by FACS 72 hours after 
infection and lines with greater than 80% transduction were used for experiments as indicated.   
Lentiviral transduction of primary MECs–High efficiency lentiviral transduction of primary 
MECs was conducted as previously described (10) with the following modifications.  Primary MECs 
were seeded in a 6-well tissue culture plate at a concentration of 2x105 cells per well or a 10-cm tissue 
culture plate at a concentration of 1x106 cells per plate and incubated in PMEC growth media.  After 48 
hours, media was aspirated and replaced with 1 mL (6-well plate) or 8 mL (10-cm dish) of fresh PMEC 
growth media.  Lentiviral particles were layered onto primary MECs at a MOI of 40 and gently mixed.  
After 16 hours, virus-containing media was replaced with 2 mL (6-well plate) or 10 mL (10-cm dish) 
DMEM/F-12 containing ITS-X, Pen Strep, and 2.5 nM murine EGF or human FGF2.  48 hours later, 
primary MECs were trypsinized down to single cells, collected, and embedded in Matrigel as described. 
RNA isolation from transduced primary MECs–To measure knockdown of AHR in primary cells, 
MECs were seeded in 10-cm tissue culture plates and transduced as described above.  After 96 hours, 
cells were sorted by FACS based on GFP expression using a FACSAria-II SORP high-speed cell sorter.  
Untransduced (GFP negative) and transduced (GFP positive) cell populations were collected on ice in 
RLT buffer.  The ratio of sample:RLT was adjusted to 100 uL:350 uL for each sample and RNA was 
isolated and DNase I treated using the Qiagen RNeasy Mini Kit according to manufacturers instructions. 
Western blot–400 µL BD cell recovery solution (BD Biosciences#354253) per well was used to 
isolate primary MECs from Matrigel according to manufacturers instructions.  For each sample, 3 wells 
of a 24 well plate (1,000 aggregates per well) were combined.  Isolated primary MECs were lysed in 
RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton 












X-100, 1 mM DTT, 1X protease/phosphatase inhibitor cocktail) and sonicated at 4 ºC for 20 seconds.  30 
µg whole cell lysate was separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to 
PVDF membrane (Millipore) for detection of mDsg3 (1:200, MBL #D218-3) and α-tubulin (1:1000, 
Sigma-Aldrich #T6199).     
Peptides–The peptides used have been previously described (11): mouse Dsc3 (LIAYASTADG), 
mouse Dsg3 (ITCRALNALG), E-cadherin (LYSHAVSSNG), and control (YTGDAFPALT). Peptides 
were synthesized by the University of Utah DNA/Peptide Synthesis Facility (Salt Lake City, UT), 
purified (>96% purity) by high-performance liquid chromatography, and identified by laser desorption 
mass spectrometry.  Concentrations were determined using Ellman’s reagent (12) for mouse Dsg3, which 
does not contain tryptophan or tyrosine residues, and Edelhoch’s method (13) for all other peptides.  
Freeze-dried peptides were reconstituted in distilled water at a stock concentration of 40 mM.   
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a b s t r a c t
Bis-aryloxadiazoles are common scaffolds in medicinal chemistry due to their wide range of biological
activities. Previously, we identified a 1,2,4-bis-aryloxadiazole that blocks mammary branching morpho-
genesis through activation of the aryl hydrocarbon receptor (AHR). In addition to defects in mammary
differentiation, AHR stimulation induces toxicity in many other tissues. We performed a structure activity
relationship (SAR) study of 1,2,4-bis-aryloxadiazole to determine which moieties of the molecule are crit-
ical for AHR activation. We validated our results with a functional biological assay, using desmosome for-
mation during mammary morphogenesis to indicate AHR activity. These findings will aid the design of
oxadiazole derivative therapeutics with reduced off-target toxicity profiles.
! 2014 Elsevier Ltd. All rights reserved.
Small molecule libraries are widely used as a tool in chemical
biology,1 both to probe biological pathways and to develop new
therapeutics. However, the success of chemical library screening
efforts is limited by library composition and size. One strategy to
produce a large number of drug-like compounds is to use scaffolds
that have previously generated biologically active chemicals.2 In
particular, the oxadiazole nucleus has been used extensively as a
scaffold in drug development3 due to the range of activities
reported for its derivatives, including antimicrobial, anticancer,
anti-inflammatory, and antiviral effects.4–7
As a heteroaromatic ring, oxadiazoles can be prepared as sev-
eral constitutional isomers. The 1,2,4-oxadiazole isomer has been
used in numerous pharmacologic drugs, including metabotropic
glutamate subtype 5 receptor antagonists,8 sphingosine-1-phos-
phate-1 receptor agonists,9 and anticancer apoptosis inducers.10
Additionally, we previously identified a derivative of this isoform
as a potent compound that blocks mammary branching morpho-
genesis.11 In our assay, 1,2,4-bis-aryloxadiazole 1 (referred as
1023 in our previous communication) was the lead compound
identified in a chemical genetic screen for molecules that block
mammary branching morphogenesis. Further analysis showed 1
had an EC50 of 1.2 ± 0.050 lM and blocked branching through acti-
vation of the aryl hydrocarbon receptor (AHR).
In addition to influencing mammary branching, AHR agonists
also block differentiation and lactation in the mammary gland12–
14 and exhibit a wide range of toxic effects in other tissues.15,16
Our previous observations that compound 1 potently activated
AHR suggested that other 1,2,4-oxadiazole derivatives may display
unwanted drug effects due to AHR stimulation. Given the structural
relationship of these derivatives to 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), a known carcinogen and environmental toxin that
also activates AHR, we performed structure–activity relationship
(SAR) studies of 1 to identify key elements of themolecule that con-
tribute to AHR activation. A library of bis-aryloxadiazoles was pre-
pared by Lewis-acid mediated coupling of benzoyl chlorides with
benzamidoximes (Scheme 1). The activity of each analog was deter-
mined bymeasuring expression of the AHR target gene, Cyp1a1,17,18
in HC11 mammary epithelial cells (MECs) treated for 48 h with
10 lM compound.
We initially made systematic modifications on the C-ring of 1
(Table 1). Based on a previous homology model,11 this ring was
predicted to form charge/polar interactions with amino acid
residues His-291 and Gln-383 in the AHR binding pocket. Our
results indicated that replacing the o-Cl substituent with an amino
group (compound 2) increased AHR activity !5-fold, as shown by
http://dx.doi.org/10.1016/j.bmcl.2014.04.013
0960-894X/! 2014 Elsevier Ltd. All rights reserved.
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increased Cyp1a1 gene expression with compound 2. In contrast,
placement of an electron-withdrawing group (NO2) at the ortho
position of the C-ring dramatically decreased AHR activity (com-
pounds 3–7). These results suggested that the C-ring of bis-arylox-
adiazole is compatible with an electroneutral or protic-polar
substitution that can be stabilized by hydrogen bonding with
His-291 (Fig. 1). This was confirmed by replacing the nitro group
at the ortho position of compound 3 with an amino group (com-
pound 9), which partially restored Cyp1a1 gene expression.
In addition to the ortho position, the para group of the C-ring
also influenced AHR activity. Specifically, p-CF3 (compound 9)
showed significantly lower Cyp1a1 gene expression compared to
p-Cl (compound 2). This result is likely due to the electron with-
drawing and sterically bulky nature of CF3. Surprisingly, p-F (com-
pound 8) offset the decreased activity of o-NO2 observed in other
analogs. This may be explained by the small size of p-F, which
would decrease van der Waals repulsion and contribute to aro-
matic stabilization through charge interaction. Together, modifica-
tions on the C-ring suggested bis-aryloxadiazole requires subtle
electronic demand at the ortho and para positions and tight van
der Waals radii at the para position to elicit significant AHR
activation.
Next, we extended our SAR study to the A-ring of bis-arylox-
adiazole (Table 2). Previous modeling studies11,19 suggested this
portion of the molecule binds within a tight hydrophobic cavity
of AHR and is stabilized by aromatic p-stacking of Phe-324 and
Phe-287. As a result, we hypothesized that functional groups on
the A-ring of bis-aryloxadiazole able to distort this p-stacking
would also diminish AHR activation (Fig. 2). Supporting this
hypothesis, we previously showed that addition of m-CF3 to the
A-ring (compound 11) dramatically decreased AHR activity.11 Sim-
ilarly, polar carbomethoxy or carboxylate substituents at R4 (com-
pounds 12–14) showed low Cyp1a1 gene expression, irrespective
of identities at R1 and R2. Importantly, these substitution patterns
are seen in lead compounds for the treatment of nonsense muta-
tion disorders (e.g., Ataluren).20
In addition to meta substitutions, we altered other positions of
the A-ring and modified the A-ring itself. Substitution of CF3 with
Cl at different positions resulted in only subtle AHR activation,
with p-Cl showing the highest Cyp1a1 gene induction (compound
15–17). Similarly, larger para-substituents on the A-ring (com-





















Scheme 1. General strategy for synthesis of bis-aryloxadiazoles.
Table 2










Compound X R1 R2 R3 R4 Relative Cyp1a1
11 CH o-Cl p-Cl H m-CF3 1.84 ± 0.28
12 CH o-Cl p-Cl H m-CO2Me 0.18 ± 0.49
13 CH o-F H H m-CO2Me 0.29 ± 0.74
14 CH o-F H H m-CO2H 3.71 ± 0.22
15 CH o-Cl p-Cl H o-Cl 5.91 ± 0.18
16 CH o-Cl p-Cl H m-Cl 1.59 ± 0.30
17 CH o-Cl p-Cl H p-Cl 8.15 ± 0.14
18 CH o-Cl p-Cl H p-O-Propargyl 0.66 ± 0.26
19 CH o-NO2 p-Cl H p-O-Propargyl 0.29 ± 0.35
20 CH o-NH2 p-Cl H p-O-Allyl 0.62 ± 0.16
21 CH o-NH2 p-Cl H p-O-Propargyl 0.38 ± 0.42
22 N o-Cl m-Cl p-Cl H 0.53 ± 0.28
23 N o-Cl p-Cl H H 0.37 ± 0.13
24 N o-NO2 p-Cl H H 8.25 ± 0.13
25 N o-NO2 p-OAc H H 0.35 ± 0.41
Expression of an AHR response gene, Cyp1a1, was measured in HC11 MECs treated
with 10 lM compound for 48 h.
Figure 1. Homology model structure of human AHR (gray) and compound 2
(purple), with residues predicted to contribute to compound binding shown in
green. Hydrogen bonding between the amino group at the ortho position of the C-
ring and His-291 is predicted to stabilize binding.
Figure 2. Homology model structure of human AHR (gray) and compound 11
(purple). Residues predicted to contribute to compound binding are shown in green.
Steric interactions of the A-ring with Phe324 and Phe287 lead to decreased AHR
activation.
Table 1










Compound R1 R2 R3 Relative Cyp1a1
1 o-Cl p-Cl H 128.53 ± 0.17
2 o-NH2 p-Cl H 638.80 ± 0.14
3 o-NO2 p-CF3 H 0.36 ± 0.15
4 o-NO2 p-OMe H 0.42 ± 0.25
5 o-NO2 p-OH H 0.25 ± 0.14
6 o-NO2 p-OCO2Me H 0.39 ± 0.16
7 o-NO2 p-O-Propargyl H 2.43 ± 0.19
8 o-NO2 p-F H 122.64 ± 0.12
9 o-NH2 p-CF3 H 58.63 ± 0.15
10 o-Cl p-Cl m-Cl 25.79 ± 0.17
Expression of an AHR response gene, Cyp1a1, was measured in HC11 MECs treated
with 10 lM compound for 48 h.








(pyridine) nearly abolished AHR activity (compounds 22–25).
Taken together, these results show that any modification of the
A-ring of bis-aryloxadiazole has a profound effect on AHR binding
and activation.
From our SAR study, we identified 4 analogs of 1,2,
4-bis-aryloxadiazole that retained significant Cyp1a1 gene
expression (compounds 2, 8, 9, and 10). We next validated these
compounds as AHR agonists in a functional biological assay.
Previously, we showed 1 potently blocked mammary branching
morphogenesis of primary MECs.11 Using this same assay, we
observed that compounds 2, 8, and 9 recapitulated the
unbranched, cyst phenotype (Fig. 3a) and displayed an EC50 similar
to compound 1 (Fig. 3b). In contrast, compound 10, which induced
the lowest level of Cyp1a1 gene expression compared to the other
active analogs, did not inhibit branching and displayed a relatively
high EC50 (Fig. 3).
Finally, we assessed the level of desmosomal adhesion in pri-
mary MECs treated with compounds 2, 8, 9, and 10. We previously
identified desmosomes as a novel target of activated AHR, which
functionally disrupts mammary branching morphogenesis.11 Using
desmoglein 3 (DSG3) protein levels as an indicator of desmosome
complexes,21 we observed high levels of desmosomal proteins in
primary MECs treated with 10 nM TCDD, which is a known AHR
agonist, and 10 lM of compounds 1, 2, 8, and 9 (Fig. 4a and b).
Interestingly, compounds 10 and 11 showed the lowest levels of
DSG3, which correlated with their low Cyp1a1 gene expression lev-
els and poor EC50 values in our branching assay (Fig. 4b and c). The
shared patterns of Cyp1a1 gene expression and DSG3 protein levels
in these biological assays suggest DSG3 is a functional indicator of
AHR activity.
In summary, we performed SAR studies of 1,2,4-bis-arylox-
adiazole to identify components of the molecule critical for AHR
activation. Our results indicated the C-ring is agonistic when
substituted with electronically neutral or protic-polar moieties,
particularly when tight van der Waals radii at the para position
are maintained. In contrast, modification of the A-ring dramatically
reduced AHR activity in all cases, suggesting this portion of the
molecule significantly contributes to AHR binding and activation.
These findings indicate that chemical substitutions of the A-ring
that minimize AHR activation, but do not significantly alter thera-
peutic activity, should be considered for bis-aryloxadiazole com-
pounds. We validated our findings by assessing the biological
effects of these compounds on mammary branching morphogene-
sis. In agreement with our previous observations, there was a
Figure 3. Characterization of mammary branching morphogenesis in the presence
of 1,2,4-bis-aryloxadiazole analogs. (a) Representative images and (b) dose–
response analysis for branching in primary MECs. Scale bar = 40 lm. Calculated
EC50 values: compound 1 (1.2 ± 0.4 lM), compound 2 (1.4 ± 0.1 lM), compound 8
(2.2 ± 0.1 lM), compound 9 (3.2 ± 0.1 lM), compound 10 (>10 lM).
Figure 4. Effect of analog compounds on desmosomal adhesion and AHR readout genes in MECs. (a) Western blot analysis and (b) quantification of desmoglein 3 (DSG3) in
primary MECs. (c) Relative Cyp1a1 gene expression in HC11 MECs.
K. J. Basham et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2473–2476 2475
! 77!
 
strong correlation between Cyp1a1 induction, activation of desmo-
somal adhesion, and a block in mammary branching morphogene-
sis. Since loss of desmosomes is sufficient for mammary
branching,11 these results identified DSG3 as a functional readout
of AHR activation. These results will aid the design and use of
1,2,4-bis-aryloxadiazoles in order to maintain biological activity
of therapeutics while minimizing the activation of AHR.
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A. General experimental considerations: 
 All reactions requiring anhydrous conditions were conducted in flame-dried glassware under a positive 
pressure of either nitrogen or argon. Commercially available reagents were used as received; otherwise, materials 
were purified according to Purification of Laboratory Chemicals.1 Dichloromethane (CH2Cl2), acetonitrile 
(CH3CN) tetrahydrofuran (THF) diethyl ether (Et2O) were degassed with nitrogen and passed through a solvent 
purification system (Innovative Technologies Pure Solv). Triethylamine (Et3N) was distilled from CaH2 
immediately prior to use. Reactions were monitored by TLC and visualized by a dual short wave/long wave UV 
lamp and stained with aqueous solution of ceric ammonium molybdate.  Flash chromatography was performed 
on Merck silica gel Kieselgel 60 (230-400 mesh) from EM Science with the indicated HPLC grade solvent.
 Infrared spectra were obtained using a Nicolet 380-FT IR spectrometer fitted with a Smart Orbit sample 
system. Mass spectra were determined on a Micromass Quattro II (ESI/APCI-TOF) for HRMS at the University 
of Utah Mass Spectrometry Facility.  1H NMR and 13C NMR spectra were recorded at 500 MHz and 125 MHz, 
respectively. Proton resonances were reported relative to the deuterated solvent peak: 7.27 ppm for CDCl3 7.15 
ppm for C6D6, 3.31 ppm  (center line signal) for CD3OD and 4.80 ppm for D2O using the following format: 
chemical shift (G) (multiplicity (s  singlet, brs  broad singlet, d  doublet, dd  double of doublet, ddd  double of 
doublet of doublet, dddd  double of doublet of doublet of doublet, t  triplet, dtt  doublet of triplet of triplet, q  
quartet, m  multiplet), coupling constant(s) J in Hz, integration).2 Carbon resonances were reported as chemical 
shifts (G) in parts per million, relative to the center line signal of the respective solvent peak: 77.23 ppm for 
CDCl3, 128.0 ppm for C6D6 and 49.15 ppm for CD3OD and 164.2 ppm for TFA. 
 
1Purification of Laboratory Chemicals. 2003, 5th Ed. Armarego, W. L. F.; Chai, C. L. L. 
2 Hoye, T.R.; Hansen, P.R.; Vyvyan, J.R. J. Org. Chem. 1994; 59(15); 4096-4103. 
 
B. Experimental procedures 
General procedure for the preparation of the bis-aryloxadiazoles 
 
5-(2,4-dichlorophenyl)-3-phenyl-1,2,4-oxadiazole (1) 
 To a solution of benzamidoxime (500 mg, 3.67 Pmol) in dioxane (35 mL) at 0 °C 
was added 2, 4-dichlorobenzoyl chloride (770 mg, 3.67 mmol) and BF3•OEt2 (114 PL, 
0.80 mmol). The reaction mixture was stirred at rt for 30 min and heated to reflux for 12 
h. The volatiles were evaporated under reduced pressure and the residue was cooled in 
an ice bath and diluted with ice-water (25 mL). This solution was then transferred to a 
separatory funnel and the aqueous layer was extracted with EtOAc (2 u 50 ml). The combined organic layers 
were dried over Na2SO4 and concentrated under reduced pressure. The resulting crude product was purified by 
flash column chromatography (10% EtOAc in hexanes) to yield bis-aryl oxadiazole 1 (850 mg, 80%) as a 
colorless solid.  
 Mp   80 - 81 qC; 1H NMR (CDCl3, 500 MHz) G 8.18 (dd, J   7.5, 1.4 Hz, 2H), 8.13 (d, J   8.3 Hz, 1H), 
7.61 (d, J   1.9 Hz, 1H), 7.56 - 7.70 (m, 3H), 7.43 (dd, J   8.3, 1.9 Hz, 1H) ppm; 13C NMR (CDCl3, 100 MHz) G 
137.7, 168.9, 139.2, 134.9, 132.9, 131.6, 131.6, 129.1, 127.8, 126.8, 122.3 ppm; IR (neat) 2152, 1595, 1569, 
1452, 1392, 1363, 1135, 1104, 748, 707, 691 cm-1; HRMS (ESI) calcd for C14H9Cl2N2O (M+H): 291.0092, 




Mp  104 - 105 qC; 1H NMR (DMSO-d6, 300 MHz) G 8.16 - 8.12 (m, 2H), 8.03- 7.99 
(m, 2H), 7.78 (dd, J   8.3, 2.0 Hz, 1H), 7.58 - 7.48 (m, 3H) ppm; 13C NMR (CDCl3, 125 
MHz) G 171.6, 169.3, 149.4, 139.6, 133.1, 132.4, 131.8, 129.1, 127.8, 126.3, 125.1, 















1; ESI-MS m/z 302.0 [M+H]+. 
 
 To a solution of nitro-oxadiazole 2SM (455 mg, 1.51 mmol) obtained above in 
EtOH (25 mL) was added SnCl2x2H2O (858 mg, 4.48 mmol) and the resultant solution 
was heated to reflux for 3h. The volatiles were evaporated under reduced pressure and 
the residue obtained was diluted with water (20 mL) and basified (pH | 12) with 
saturated aq. NaHCO3 (10 mL). This solution was transferred to a separatory funnel and 
extracted with CH2Cl2 (4 u 25 mL). The combined organic layers were dried over Na2SO4 and concentrated 
under reduced pressure to afford the amino-oxadiazole 2 (275 mg, 88%) as an off-white solid. 
 Mp  165 - 166 qC; 1H NMR (CDCl3, 300 MHz) G8.17 - 8.12 (m, 2H), 8.94 (d, J   8.5, 1H), 7.58 - 7.48 (m, 
3H), 6.84 (d, J   1.9 Hz, 1H), 6.78 (dd, J   8.5, 1.9 Hz, 1H), 6.09 (bs, 2H) ppm; 13C NMR (CDCl3, 125 MHz) G 
174.4, 168.1, 148.5, 140.1, 131.4, 130.6, 129.0, 127.7, 126.9, 117.8, 116.1, 104.7 ppm; IR (neat) 3422, 3329, 
1628, 1613, 1604, 1566, 1546, 1375, 1251 cm-1; ESI-MS m/z 272.0 [M+H]+. 
 
5-(2-nitro-4-(trifluoromethyl)phenyl)-3-phenyl-1,2,4-oxadiazole (3) 
 Mp  102 -104 qC; 1H NMR (CDCl3, 500 MHz) G 8.72 (d, J   1.5Hz, 1H), 8.56 
- 8.53 (m, 1H), 8.18- 8.16 (m, 1H), 8.17 (dd, J   8.0, 1.5Hz, 1H), 8.06 (d, J   8.0Hz, 
1H), 7.59 - 7.52 (m, 3H) ppm; 13C NMR (CDCl3, 125 MHz) G 172.3, 169.7, 129.4 (q, J 
  7.2 Hz), 129.3 (q, J   19.8 Hz), 129.2, 127.7, 127.0, 126.8, 126.1, 124.6, 121.6 (q, J 




 Mp  102 - 104 qC; 1H NMR (CDCl3, 300 MHz) G 8.16 - 8.11 (m, 2H), 7.99 (d, 
J   8.7 Hz, 1H), 7.55- 7.47 (m, 2H), 7.45 (d, J   4.5 Hz, 2H), 7.27 (s, 1H), 7.26 (dd, J 
  8.7, 2.7 Hz, 1H), 3.98 (s, 3H) ppm; 13C NMR (CDCl3, 125 MHz) G 172.4, 169.1, 
163.1, 150.4, 132.7, 131.6, 129.1, 127.8, 126.7, 118.2, 110.8, 110.3, 56.5 ppm; IR 
(neat) 3079, 3019, 2844, 2359, 2341, 1617, 1538, 1497, 1443, 1360, 1290, 1245, 
1135, 1030, 751 cm-1. 
 
3-nitro-4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenol (5) 
  To a solution of methyl carbonate 6 (250 mg, 0.76 mmol) in EtOH: H2O (3:2, 10 
mL) was added crushed NaOH (91 mg, 2.28 mmol) at rt and the resultant solution was 
stirred for 2h. The volatiles were evaporated under reduced pressure and the residue 
obtained was diluted with water (10 mL) and extracted with CH2Cl2 (2 u 25 mL). The 
combined organic layers were dried over Na2SO4 and concentrated under reduced 
pressure to afford the nitro-phenol 5 (175 mg, 82%) as a yellow solid.  
 Mp  260 - 262 qC; 1H NMR (DMSO-d6, 300 MHz) G8.62 (d, J   1.5 Hz, 1H), 8.45 (dd, J   8.0, 1.5, 1H), 
8.32 (d, J   7.9 Hz, 1H), 8.10 - 8.05 (m, 2H), 7.69- 7.59 (m, 3H) ppm; 13C NMR (CDCl3, 125 MHz) G 171.9, 
168.3, 164.7, 135.9, 135.9, 133.8, 132.2, 129.4, 127.1, 125.4, 125.2, 120.7 ppm; IR (neat) 3057, 1703, 1548, 
1445, 1426, 1357, 1288 cm-1. 
 
methyl (3-nitro-4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl) carbonate (6) 
 Mp  116 - 118 qC; 1H NMR (CDCl3, 500 MHz) G8.64 (d, J   1.5 Hz, 1H), 
8.63 (dd, J   8.1, 1.8 Hz, 1H), 8.16 - 8.13 (m, 3H), 7.58 - 7.49 (m, 3H), 4.03 (s, 
3H) ppm; 13C NMR (CDCl3, 125 MHz) G 171.7, 169.4, 164.1, 149.0, 134.9, 
133.5, 131.8, 131.8, 129.2, 127.8, 126.2, 125.7, 122.5, 53.4 ppm; IR (neat) 3087, 














 Mp  111 - 113 qC; 1H NMR (CDCl3, 300 MHz) G8.66 (d, J   1.6 Hz, 1H), 8.47 
(dd, J   8.1, 1.6 Hz, 1H), 8.19 - 8.12 (m, 3H), 7.59 - 7.49 (m, 3H) 5.03 (d, J   2.4 Hz, 
2H), 2.62 (t, J   2.4 Hz, 1H) ppm; 13C NMR (CDCl3, 125 MHz) G171.5, 169.4, 162.9, 
149.1, 134.2, 133.7, 131.9, 129.2, 127.8, 126.1, 125.8, 122.8,76.8, 76.3, 53.9 ppm; IR 
(neat) 3293, 3091, 1732, 1542, 1357, 1279, 1246, 1113 cm-1. 
 
5-(4-fluoro-2-nitrophenyl)-3-phenyl-1,2,4-oxadiazole (8) 
 Mp  94 - 95 qC; 1H NMR (CDCl3, 500 MHz) G8.14 (dd, J   6.5, 1.5 Hz, 2H), 
8.08 (dd, J   9.0, 5.5 Hz, 1H), 7.76 (dd, J   7.2, 4.5 Hz, 1H), 7.56- 7.50 (m, 4H) ppm; 
13C NMR (CDCl3, 125 MHz) G 171.6, 169.2, 165.4, 163.3, 133.6, 133.5, 131.8, 128.4 (d, 
J   170.4 Hz), 126.3, 120.4 (d, J   21.3 Hz), 115.4, 113.1 (d, J   26.7 Hz) ppm; IR 
(neat) 3079, 2359, 2341, 1625, 1569, 1541, 1506, 1362, 1267, 1216, 668 cm-1; ESI-MS 
m/z 286.4 [M+H]+. 
 
2-(3-phenyl-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)aniline (9) 
 To a solution of nitro-oxadiazole 3 in EtOH (210 mg, 0.62 mmol) was added 
SnCl2x2H2O (356 mg, 1.88 mmol) and the resultant solution was heated to reflux for 
3h. The volatiles were evaporated under reduced pressure and the residue obtained 
was diluted with water (20 mL) and basified (pH | 12) with saturated aqueous 
NaHCO3 (10 mL). This solution was transferred to a separatory funnel and extracted 
with CH2Cl2 (4 u 25 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced 
pressure to afford the amino-oxadiazole 9 (116 mg, 61%) as a yellow solid. 
 Mp  146 - 147 qC; 1H NMR (CDCl3, 500 MHz) G8.19 - 8.15 (m, 2H), 7.61 (bs, 3H), 
7.56 - 7.50 (m, 3H), 4.41 (bs, 2H) ppm; 13C NMR (CDCl3, 125 MHz) G 128.1, 
26 (q, J   8.0 Hz)126.6, 124.3 (q, J   272.3 Hz), 117.0, 116.3, 2 ppm;,R (neat) 3369, 3257, 
1655, 1581, 1567, 1528, 1509, 1370, 1327, 1092 cm-1; ESI-MS m/z 306 [M+H]+. 
 
3-phenyl-5-(2,4,6-trichlorophenyl)-1,2,4-oxadiazole (10)  
 Mp  95 - 96 qC; 1H NMR (CDCl3, 500 MHz) G8.24 (d, J  6.8Hz, 2H), 8.19 (m, 
2H), 7.63- 7.49 (m, 3H) ppm; 13C NMR (CDCl3, 125 MHz) G 132.9, 131.7, 131.4, 
129.3, 129.2, 129.0, 128.4, 128.3, 127.8, 127.7 ppm; IR (neat) 3366, 3221, 3078, 2360, 
2340, 1743, 1634, 1578, 1548, 1410, 1369, 1258, 1114, 1055, cm-1. 
 
5-(2,4-dichlorophenyl)-3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole (11). 
 Mp  107 - 109 qC;  1H NMR (CDCl3, 500 MHz) G 8.45 (s, 1H), 8.36 (d, J   
7.8 Hz, 1H), 8.15 (d, J   8.2 Hz, 1H), 7.80 (d, J   7.8 Hz, 1H), 7.68 - 7.63 (m, 2H), 
7.48 - 7.44 (m, 1H) ppm; 13C NMR (CDCl3, 100 MHz) G174.2, 167.9, 139.5, 
135.0, 132.9, 131.9, 131.8 (q, J   16.5 Hz), 130.9, 129.7, 128.1 (q, J   5.7 Hz), 
127.9, 127.7, 124.7 (q, J   5.7 Hz), 123.9 (q, J   273.1 Hz), 122.0 ppm; IR (neat) 
1590, 1569, 1493, 1390, 1323, 1313, 1169, 1116, 1073, 811, 707 cm-1; HRMS (ESI) calcd for C15H8Cl2N2OF3Cl2 
(M+H): 358.9966, found: 358.9956. 
 
methyl 3-(5-(2,4-dichlorophenyl)-1,2,4-oxadiazol-3-yl)benzoate (12) 
 Mp  132 - 133 qC; 1H NMR (CDCl3, 500 MHz) G8.84 (d, J   2.0 Hz, 
1H), 8.38 (d, J   8.0 Hz, 1H), 8.23 (d, J   8.0 Hz, 1H), 8.17 (d, J   9.0 Hz, 1H), 
7.64 - 7.60 (m, 2H), 7.47 (dd, J   8.0, 2.0 Hz, 1H), 4.0 (s, 3H) ppm; 13C NMR 
(CDCl3, 125 MHz) G 173.2, 166.4, 162.9, 156.8, 138.8, 133.4, 132.5, 131.7, 
131.4, 131.2, 129.3, 127.9, 127.6, 52.62 ppm; IR (neat) 3477, 3352, 2360, 
























methyl 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)benzoate (13) 
 Mp  124 - 126 qC; 1H NMR (CDCl3, 500 MHz) G8.81 (s, 1H), 8.33 (d, J 
 5.2 Hz, 1H), 8.23 - 8.17 (m, 2H), 7.62 - 7.56 (m, 
2H), 7.34 - 7.25 (m, 2H), 3.98 (s, 3H) ppm; 13C NMR (CDCl3, 125 MHz) G
 (d, J   8.3 Hz)0.2 (d, J 
  240.3 Hz).4, 124.9, 124.9, 117.4 (d, J   20.6), 112.8 (d, J   11.4 Hz), 52.5 ppm; IR (neat) 1725, 
1621, 1472, 1436, 1372, 1293, 1264, 1229 cm-1.  
 
3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)benzoic acid (14) 
 To a solution of methyl ester 13 (228 mg, 0.76 mmol) in EtOH: H2O (3:2, 10 
mL) was added crushed NaOH (91 mg, 2.27 mmol) and the solution was stirred at rt 
for 3h. The volatiles were evaporated under reduced pressure and the residue 
obtained was acidified with 1N aqueous HCl  (pH | 4). This solution was then 
transferred to a separatory funnel and extracted with EtOAc (3 u 20 mL). The combined organic layers were 
dried Na2SO4 and concentrated under reduced pressure to afford the title acid 14 (123 mg, 54%) as a white solid. 
 Mp  239 - 240 qC; 1H NMR (DMSO-d6, 500 MHz) G64J 1.4 Hz, 1H), 8.33 (ddd, J   7.8, 2.9, 1.4 Hz, 
1H), 8.27 (dt, J   7.8, 1.9 Hz, 1H), 8.18 (ddd, J   7.8, 2.9, 1.4 Hz, 1H), 7.83- 7.79 (m, 1H), 7.75 (t, J   7.8 Hz, 
1H), 7.57 (dd, J   10.7, 8.7 Hz, 1H), 7.51 (dd, J   7.3, 0.9 Hz, 1H) ppm; 13C NMR (DMSO-d6, 125 MHz) 
G 172.7, 167.4, 166.5, 161.0, 158.9, 135.8 (d, J   9.1 Hz), 132.3, 131.8, 131.0 (d, J   22.8 Hz), 127.8, (d, J   
263.9 Hz) 126.3, 125.5, 125.5, 117.5 (d, J   20.6 Hz), 111.7 (d, J   10.6 Hz) ppm; IR (neat) 3145, 2359, 2342, 
1733, 1699, 1646, 1575, 1472, 1305, 744, 668 cm-1; ESI-MS m/z 285.1 [M+H]+ 
 
5-(2-chlorophenyl)-3-(2,4-dichlorophenyl)-1,2,4-oxadiazole (15) 
 Mp  99 - 101 qC; 1H NMR (CDCl3, 500 MHz) G 8.16 (d, J 8.3 Hz, 1H), 8.04 (d, 
J 7.3 Hz, 1H), 7.64 (s, 1H), 7.59 (brd, J  8.3 Hz, 1H), 7.50- 7.42 (m, 3H) ppm; 13C 
NMR (CDCl3, 125 MHz) G 173.25, 167.80, 139.38, 135.07, 133.83, 132.98, 132.10, 
132.05, 131.70, 131.25, 127.92, 127.18, 126.08, 122.13 ppm; IR (neat) 3076, 2360, 




 Mp  133 - 134 qC; 1H NMR (500 MHz, CDCl3) G 8.14 (t, J 1.8 Hz, 1H), 
8.10 (d, J 8.4 Hz, 1H), 8.03 (J 7.6, 1.34Hz, 1H), 7.59 (d, J 2.1 Hz, 1H), 7.49 
(ddd J 7.9, 2.1, 1.1, 1H), 7.44 - 7.41 (m, 2H); 13C NMR (125 MHz, CDCl3) G 
173.9, 167.9, 139.4, 135.2, 135.0, 132.9, 131.7, 131.6, 130.4, 128.5, 127.9, 127.8, 
125.8, 122.0 ppm; IR (neat) 3086, 1592, 1566, 1536, 1522, 1477, 1457, 1437, 1388, 1363, 1298, 1145, 1105, 
1086, 1051, 892, 872, 839, 816, 792, 771, 757, 719, 674 cm-1; ESI-MS m/z 325.2 [M+H]+. 
 
5-(4-chlorophenyl)-3-(2,4-dichlorophenyl)-1,2,4-oxadiazole (17) 
 Mp 143 - 144 qC; 1H NMR (CDCl3, 500 MHz) G 8.13- 8.10 (m, 3H), 7.62 (d, J 
 1.95 Hz, 1H), 7.54- 7.49 (m, 3H) ppm; 13C NMR (CDCl3, 125 MHz) G 139.5, 
132.9, 131.6, 129.4, 129.0, 127.9, 125.3, 122.1, 95.2 ppm; IR (neat) 3079, 2359, 
1703, 1592, 1410, 759 cm-1; ESI-MS m/z 325.3 [M+H]+. 
 
5-(2,4-dichlorophenyl)-3-(4-(prop-2-ynyloxy)phenyl)-1,2,4-oxadiazole (18) 
 Mp  139 - 141 qC; 1H NMR (CDCl3, 300 MHz) G 8.13 (d, J   8.9 Hz, 2H), 







































7.11 (d, J   8.9 Hz, 2H), 4.78 (d, J   2.3 Hz, 2H), 2.57 (t, J   2.3 Hz, 1H) ppm; 13C NMR (DMSO-d6, 125 MHz) 
G 173.5, 168.5, 160.1, 139.1, 134.9, 132.8, 131.6, 129.4, 127.8, 122.4, 120.1, 115.4, 78.1, 76.2, 56.0 ppm; IR 
(neat): 3302, 3090, 1614, 1587, 1570, 1388, 1251 cm-1; ESI-MS m/z 345 [M+H]+. 
 
5-(4-chloro-2-nitrophenyl)-3-(4-(prop-2-ynyloxy)phenyl)-1,2,4-oxadiazole (19) 
 Mp  133 - 134 qC; 1H NMR (CDCl3, 500 MHz) G8.08 (d, J   9.5 Hz, 2H), 
8.00 (d, J   8.5 Hz, 1H), 7.98 (d, J   2.5 Hz, 1H), 7.78 (dd, J   8.5, 2.0 Hz, 1H), 
7.10 (d, J   9.5 Hz, 2H), 4.78 (d, J   2.5 Hz, 2H), 2.57 (t, J   2.5 Hz, 1H) ppm; 
13C NMR (125 MHz, CDCl3) G 171.3, 168.9, 160.3, 139.5, 134.1, 133.0, 132.4, 
129.4, 125.1, 119.6, 117.4, 115.5, 78.1, 76.2, 56.0 ppm; IR (neat) 3293, 3265, 




 Mp  160 - 163 qC; 1H NMR (CDCl3, 300 MHz) G8.05 (d, J   9.0 Hz, 2H), 
7.99 (d, J   8.3 Hz, 2H), 7.76  (dd, J   8.3, 2.0 Hz, 1H), 7.02 (d, J   9.0 Hz, 2H), 
6.07 (ddt, J   17.1, 10.4, 5.2 Hz, 1H), 5.44 (ddt, J   17.3, 3.1, 1.6 Hz, 1H), 5.33 
(ddt, J   10.4, 2.7, 1.3 Hz, 1H), 4.61 (ddd, J   5.3, 1.5, 1.5 Hz, 2H) ppm; 13C NMR 
(CDCl3, 125 MHz) G 171.2, 169.0, 161.4, 139.5, 133.0, 132.8, 132.4, 129.4, 125.1, 
122.3, 118.8, 118.3, 117.4, 115.3, 69.0 ppm; IR (neat) 3093, 2874, 2359, 2340, 1699, 1610, 1589, 1534, 1352, 
1249, 835, 770 cm-1; ESI-MS m/z 357.5 [M+H]+.  
 To a solution of nitro-oxadiazole 20SM (225 mg, 0.63 mmol) obtained above 
in EtOH (25 mL) was added SnCl2x2H2O (358 mg, 1.89 mmol) and the resultant 
solution was heated to reflux for 3h. The volatiles were evaporated under reduced 
pressure and the residue obtained was diluted with water (20 mL) and basified (pH 
| 12) with saturated aqueous NaHCO3 (10 mL). This solution was transferred to a 
separatory funnel and extracted with CH2Cl2 (4 u 25 mL). The combined organic layers were dried over Na2SO4 
and concentrated under reduced pressure to afford the amino-oxadiazole 20 (118 mg, 57%) as a light yellow 
solid. 
 Mp  160 - 162 qC; 1H NMR (DMSO-d6, 300 MHz) G9.58 (brs, 1H), 9.35 (d, J   1.2 Hz, 1H), 8.09 (d, J   
8.7 Hz, 2H), 7.96 (d, J   8.3 Hz, 1H), 7.34(d, J   2.0 Hz, 1H), 7.15 (d, J   8.9 Hz, 2H), 6.95 (dd, J   8.5, 2.0 Hz, 
1H), 6.06 (ddt, J   17.1, 10.4, 5.2 Hz, 1H), 5.44 (ddt, J   17.3, 3.4, 1.6 Hz, 1H), 5.30 (ddt, J   10.5, 3.0, 1.3 Hz, 
1H), 4.67 (ddd, J   5.2, 1.5, 1.5 Hz, 2H) ppm; 13C NMR (DMSO-d6, 125 MHz) G 172.8, 167.2, 160.7, 151.1, 
139.2, 133.2, 130.6, 129.0, 118.2, 118.0, 117.8, 115.3, 112.3, 103.2, 68.3 ppm; IR (neat) 3276, 2360, 2341, 1652, 
1610, 1540, 1473, 1256, 836 cm-1; ESI-MS m/z 328.1 [M+H]+ 
 
5-chloro-2-(3-(4-(prop-2-ynyloxy)phenyl)-1,2,4-oxadiazol-5-yl)aniline (21) 
 To a solution of propargyloxadiazole 19 in EtOH (410 mg, 1.15 mmol) was 
added SnCl2x2H2O (656 mg, 3.46 mmol) and the resultant solution was heated to 
reflux for 3h. The volatiles were evaporated under reduced pressure and the 
residue obtained was diluted with water (20 mL) and basified (pH | 12) with 
saturated aqueous NaHCO3 (10 mL). This solution was then transferred to a 
separatory funnel and extracted with CH2Cl2 (4 u 25 mL). The combined organic layers were dried over Na2SO4 
and concentrated under reduced pressure to afford the amino-oxadiazole 21 (256 mg, 68%) as a yellow solid. 
 Mp  178 - 179 qC; 1H NMR (DMSO-d6, 500 MHz) G 8.12 (d, J   8.9 Hz, 2H), 7.84 (d, J   8.6 Hz, 1H), 
7.21 (bs, 2H), 7.18 (d, J   8.9 Hz, 2H), 7.03 (d, J   1.9 Hz, 1H), 6.71 (dd, J   8.5, 2.0 Hz, 1H), 4.92 (d, J   2.3 
Hz, 2H), 3.65 (t, J   2.4 Hz, 1H) ppm; 13C NMR (DMSO-d6, 125 MHz) G 173.7, 166.9, 59.6, 149.6, 138.5, 130.4, 
128.9, 119.0, 115.6, 115.4, 115.3, 102.6, 78.8, 78.6, 55.6 ppm; IR (neat) 3472, 3350, 2359, 2341, 1734, 1717, 













 Mp  173 - 174 qC; 1H NMR (DMSO-d6, 300 MHz) G8.73 (d, J   4.8 Hz, 2H), 
7.88 (s, 1H), 7.79 (s, 1H), 7.73 (d, J   5.5 Hz, 2H) ppm; 13C NMR (DMSO-d6, 125 
MHz) G164.8, 155.1, 149.2, 139.5, 135.6, 134.8, 130.8, 128.1, 121.4 ppm; IR (neat) 
3332, 3176, 3077, 1744, 1641, 1603, 1577, 1546, 1409, 1370, 1255, 1111, 1054 cm-1. 
ESI-MS m/z 348.3 [M+K]+. 
 
5-(2,4-dichlorophenyl)-3-(pyridin-4-yl)-1,2,4-oxadiazole (23) 
 Mp  136 - 137 qC; 1H NMR (CDCl3, 500 MHz) G 8.83 (d, J   4.4 Hz, 2H), 8.14 
(d, J   8.7 Hz, 1H), 8.04 (d, J   5.8 Hz, 2H), 7.64  (d, J   1.9 Hz, 1H), 7.47 (dd, J   
8.7, 1.9 Hz, 1H) ppm; 13C NMR (CDCl3, 125 MHz)G 174.5, 167.4, 150.9, 139.6, 135.0, 
134.2, 132.9, 131.7, 127.9, 121.8, 121.5 ppm; IR (neat) 3750, 3743, 3670, 2359, 2341, 
1699, 1576 cm-1; ESI-MS m/z 292.0 [M+H]+ 
 
5-(4-chloro-2-nitrophenyl)-3-(pyridin-4-yl)-1,2,4-oxadiazole (24) 
 Mp  172 - 174 qC; 1H NMR (CDCl3, 500 MHz) G 8.83 (dd, J   7.5, 2.5 Hz, 2H), 
8.04 (d, J   3.5 Hz, 1H), 8.02 (d, J   14.0 Hz, 1H), 8.01 (dd, J   7.5, 2.5 Hz, 2H), 7.81 
(dd, J   14.0, 3.5 Hz, 1H) ppm; 13C NMR (CDCl3, 125 MHz) G 172.5, 167.8, 150.8, 
140.1, 133.8, 133.2, 132.4, 131.8, 125.3, 121.6, 116.9 ppm; IR (neat) 3076, 2923, 1681, 
1534, 1415, 1365, 1250, cm-1; ESI-MS m/z 303.0 [M+H]+ 
 
methyl 3-nitro-4-(3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)benzoate (25) 
 Mp  138 - 140 qC; 1H NMR (DMSO-d6, 300 MHz) G8.95 (d, J   6.5 Hz, 
2H), 8.57 (d, J   1.5 Hz, 1H), 8.40 (dd, J   7.9, 1.6 Hz, 1H), 8.13- 7.56 (m, 3H), 
3.95 (s, 3H) ppm; 13C NMR (DMSO-d6, 125 MHz) G163.9, 153.9, 147.0, 144.8, 
134.2, 133.6, 132.9, 130.8, 130.3, 124.4, 124.2, 123.4, 53.1 ppm; IR (neat) 3099, 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2. Biological Experiments: 
 
A. Chemical compounds for screening–TCDD (Cambridge Isotopes Laboratories, Inc., Andover, 
MA) was obtained as a DMSO stock solution.  1,2,4-bis-aryloxadiazole and all associated analogs 
were synthesized as described above and dissolved in DMSO at a stock concentration of 10 mM. 
 
B. HC11 cell culture–HC11 cells were grown at 37 ºC with 5% CO2 in RPMI (HyClone) 
supplemented with 10% FBS (HyClone), 1x ITS-X (Invitrogen), 1X 
penicillin/streptomycin/glutamine (Invitrogen), and 10 ng/mL murine EGF (BD Biosciences).  
For all compound treatments, FBS was reduced to 2% 12 hours after seeding cells and cells were 
treated as indicated. 
 
C. RNA extraction and real-time PCR–HC11 cells were treated for 48 hours with vehicle (0.1% 
DMSO), TCDD (10 nM), or an analog of 1,2,4-bis-aryloxadiazole (10 PM).  RNA isolation and 
RT-PCR was performed as previously described1 with the following primer sequences: E-actin 
forward 5’-GGCTGTGCTGTCCCTGTATG-3’, E-actin reverse 5’-
CAAGAAGGAAGGCTGGAAAA-3’, Cyp1a1 forward 5’-GGTTAACCATGACCGGGAACT-
3’, Cyp1a1 reverse 5’-TGCCCAAACCAAAGAGAGTGA-3’.  Relative gene expression was 
calculated by direct CT comparison2 using E-actin as an internal reference gene.  Results are 
shown as mean ± s.e.m.  
 
D. Isolation, aggregation, and culture of primary MECs–Organoids from the fourth inguinal 
mammary gland were isolated from 8-12 week-old female FVB/n mice3 (FVB/n mice were 
maintained following protocols reviewed and approved by the University of Utah Institutional 
Animal Care and Use Committee).  Single cells were aggregated and grown in Matrigel as 






(Invitrogen) for 144 hours with vehicle (0.1% DMSO) or an analog of 1,2,4-bis-aryloxadiazole 
(10 PM).  Results are shown as mean ± s.d.; n = 3.   
 
E. Microscopy–Imaging was performed using an Olympus IX81-ZDC microscope with an 
ORCAER CCD camera and Slidebook 5.0.0.24 software (Intelligent Imaging Innovations, Inc).  
DIC images were captured using a 20X long working distance objective lens.  
 
F. Western blot protocol– Cell lysates were harvested and processed as previously described1.  
For each sample, MEC aggregates were grown for 144 hours in Matrigel with 2.5 nM FGF2 and 
vehicle (0.1% DMSO), TCDD (10 nM) or an analog of 1,2,4-bis-aryloxadiazole (10 PM).  Three 
wells of a 24 well plate (1,000 aggregates per well) were combined.  Whole cell (10 µg) lysate 
was separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to PVDF 
membrane (Millipore) for detection of mouse DSG3 (1:200, MBL #D218-3) and D-tubulin 
(1:1000, Sigma-Aldrich #T6199).  Integrated intensity values were measured on a LI-COR 
Odyssey Scanner with mean background subtraction.  For each sample, DSG3 levels were 
normalized to D-tubulin levels.         
1Basham, K. J.; Kieffer, C.; Shelton, D. N.; Leonard, C. J.; Bhonde, V. R.; Vankayalapati, H.;  
Milash, B.; Bearss, D. J.; Looper, R. E.; Welm, B. E. J. Biol. Chem. 2013, 288, 2261. 
2Schefe, J. H.; Lehmann, K. E.; Buschmann, I. R.; Unger, T.; Funke-Kaiser, H. J Mol Med (Berl)  
2006, 84, 901. 
























DIOXIN EXPOSURE BLOCKS LACTATION THROUGH A DIRECT  
EFFECT ON MAMMARY EPITHELIAL CELLS MEDIATED  









This research is under review for publication in Toxicological Sciences.  Kaitlin J. 
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In mammals, lactation is a rich source of nutrients and antibodies for newborn 
animals.  However, millions of mothers each year experience an inability to breastfeed.  
Exposure to several environmental toxins, including 2,3,7,8-Tetrachlorodibenzo-p-dioxin 
(TCDD), has been strongly implicated in impaired mammary differentiation and 
lactation.  TCDD and related polyhalogenated aromatic hydrocarbons are widespread 
industrial pollutants that activate the aryl hydrocarbon receptor (AHR).  Despite many 
epidemiological and animal studies, the molecular mechanism through which AHR 
signaling blocks lactation remains unclear.  We employed in vitro models of mammary 
differentiation to recapitulate lactogenesis in the presence of toxins.  We demonstrate 
AHR agonists directly block milk production in isolated mammary epithelial cells.  
Moreover, we define a novel role for the aryl hydrocarbon receptor repressor (AHRR) in 
mediating this response.  Our mechanistic studies suggest AHRR is sufficient to block 
transcription of important milk genes and requires recruitment of a corepressor complex 
for this function.  Since TCDD is a prevalent environmental toxin that affects women 
worldwide, our results have important public health implications for newborn nutrition. 
 
Introduction 
Lactation is a critical biological process in mammals that provides both nutritional 
and immune support for offspring.  However, an estimated 3-6 million human mothers 
worldwide suffer from impaired lactation each year (1).  Several factors contribute to 
milk production and secretion, but a growing number of studies suggest certain 
environmental toxins negatively impact the ability of women to initiate and sustain 
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breastfeeding (2).  For example, maternal exposure to pesticides has been associated with 
shortened duration of lactation in both the United States (3) and Mexico (4).   
One specific xenobiotic known to affect lactation is 2,3,7,8-Tetrachlorodibenzo-p-
dioxin (TCDD).  TCDD is a byproduct of natural processes, such as volcanic eruptions 
and forest fires, and industrial processes, including smelting, waste incineration, pesticide 
production, and combustion (5).  Once produced, TCDD persists in the environment and 
contaminates air, soil, and food sources (6,7).  Although inhalation and skin exposure 
occur, ingestion of contaminated food sources is the primary route of exposure for 
humans (8).  With an average half-life between 7 and 8 years in humans (9), TCDD is a 
highly stable chemical that bioaccumulates in fat tissue.  Thus, TCDD exposure amasses 
and persists (10). 
Previous studies have demonstrated TCDD exerts its toxicity through activation 
of the aryl hydrocarbon receptor (AHR) (11).  As a ligand activated transcription factor, 
AHR is restricted to the cytoplasm in its unbound state.  Once activated, AHR 
translocates to the nucleus and forms a transcriptionally active complex with the AHR 
nuclear translocator (ARNT) to alter expression of specific target genes (12).  Although 
the identity of endogenous AHR activators remains controversial, several exogenous 
chemicals have been shown to target AHR (13).  In particular, we previously identified a 
1,2,4-bis-aryloxadiazole, referred to as 1023, as a novel AHR agonist (14,15). 
 An association between AHR activation and changes in milk production has been 
observed in animal studies.  Specifically, pregnant mice exposed to TCDD in vivo 
produced lower levels of the milk proteins β-casein (16) and whey acidic protein (WAP) 
(17), and were unable to nutritionally support their offspring (17).  Moreover, exposure of 
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pregnant rats to TCDD led to severe defects in mammary gland differentiation and 
decreased pup size following lactation (18,19), suggesting TCDD exposure impaired 
functional development of the mammary gland.  Together with epidemiological studies in 
humans, these observations support a strong link between AHR activation and diminished 
milk production.   
Despite these studies, the molecular mechanism through which AHR signaling 
blocks milk production remains unclear.  Moreover, reciprocal transplant studies with 
AHR null mammary glands implicate both indirect, systemic effects and direct, cellular 
consequences of AHR signaling on alveolar differentiation! (20).  Indirectly, TCDD 
disrupts endocrine function by altering estrogen-mediated signaling (21,22).  However, 
changes in circulating estradiol, progesterone, or prolactin levels were not observed in 
pregnant mice after in vivo TCDD exposure (17), which suggests mammary tissue may 
respond directly to AHR agonists.  Moreover, explant studies, where mammary glands 
were cultured ex vivo under hormonal stimulation with TCDD, showed decreased 
lobuloalveolar structures (23).  Together, these studies suggest AHR signaling contributes 
to impaired lactogenesis by directly targeting mammary tissue.   
 We aimed to identify direct epithelial mechanisms through which AHR activation 
blocks milk production.  Using in vitro models of mammary morphogenesis and 
differentiation, we show that both environmental toxins (TCDD) and novel AHR agonists 
(1023) block lactogenesis directly in mammary epithelial cells.  Furthermore, we identify 
a new role for the aryl hydrocarbon receptor repressor (AHRR) in mediating this 
response.  Our results support a model in which AHRR induction promotes formation of 
AHRR/ARNT heterodimers, which transcriptionally inhibit milk production.  
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Results 
AHR agonists inhibit milk production in mammary epithelial cells   
To study the effect of AHR activation on lactation, we sought to recapitulate this 
process in vitro.  Initially, we grew primary mammary epithelial cells (MECs) in the 
presence of AHR agonists in our three-dimensional branching assay (14) and performed 
microarray analysis to determine differentially expressed genes.  Compared to vehicle 
treatment (DMSO), cells grown with 10 µM 1023 showed downregulation of several 
genes important for milk production, including whey acidic protein and multiple casein 
genes (Table 4.1).  Given the lack of stromal components in this system (14,24), these 
results suggested AHR activation blocked milk production through a direct mechanism in 
mammary epithelial cells. 
To validate these results, we next utilized the HC11 mammary epithelial cell line.  
HC11 cells were clonally derived from immortalized COMMA-1D epithelial cells (25), 
which were isolated from the mammary gland of midpregnant BALB/c mice (26).  
Importantly, these cells can be induced to differentiate with lactogenic hormones and 
produce milk proteins in culture (25,27).  Using this assay, cells grown in the presence of 
10 µM 1023 or 10 nM TCDD failed to produce the milk protein, β-casein, compared to 
vehicle treated cells (DMSO) (Figure 4.1A).  In agreement with our microarray data from 
primary MECs, a block in β-casein production was also observed by RT-PCR (Figure 
4.1B), suggesting a transcriptional mechanism of gene regulation.  
Previously, we identified and validated AHR as the biological target of 1023 (14).  
To confirm the observed inhibition of milk protein production was dependent on the 
AHR pathway, we used lentiviral constructs to generate stable HC11 cell lines expressing  
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Table 4.1  Genes involved in milk production down regulated in MECs treated for 72 
hours with 10 µM 1023 
 
Gene identifier Gene name Gene symbol Ratio* 
NM_007784 Casein alpha s1 Csn1 +10.97 
NM_007786 Casein kappa Csn3 +8.24 
NM_011709 Whey acidic protein Wap +7.88 
NM_009972 Casein beta Csn2 +6.84 
*Log2 ratio for 1023-treated versus DMSO 
   
 
 
either a nonspecific shRNA (Control) or an shRNA against AHR (shAHR #1 and shAHR 
#2).  In cells with ~50% AHR knockdown (Figure 4.1C), we observed a partial rescue in 
β-casein expression in the presence of AHR agonists (Figure 4.1D).  These results 
suggested TCDD and 1023 inhibited milk production in mammary epithelial cells 
through AHR pathway activation.  
 
The aryl hydrocarbon receptor repressor is sufficient to inhibit lactation   
Given our data in both primary MECs and mammary HC11 cells, we 
hypothesized AHR activation blocked milk production through a transcriptional 
mechanism.  Moreover, we became interested in a potential role for AHRR in mediating 
this process.  As a direct target of activated AHR (28), AHRR is highly upregulated in 
primary MECs treated with 1023 (14) and has a known role as a transcriptional repressor.  
Specifically, AHRR forms a heterodimer with ARNT and binds to xenobiotic-responsive 
elements (XREs) in the promoter region of AHR target genes.  Subsequent recruitment of 
a corepressor complex, which includes ANKRA2, HDAC4, and HDAC5, inhibits 












Figure 4.1.  AHR activation blocks milk production in MECs.  Mammary HC11 cells 
were treated with vehicle control (DMSO), 10 µM 1023, or 10 nM TCDD and induced 
with lactogenic hormones (LH) to produce milk proteins.  A, HC11 cell lysates were 
probed for β-casein and α-tubulin (control).  B, β-casein mRNA levels were measured in 
the same assay by RT-PCR and normalized to β-actin expression.  Results are shown as 
normalized mean β-casein expression (± SEM).  An **** indicates a statistically 
significant difference compared to vehicle treated cells (p ≤0.0001).  C, Lentiviral 
shRNA constructs (shAHR#1 and shAHR#2) were used to stably knockdown AHR 
expression HC11 cells.  AHR expression was measured by RT-PCR, normalized to β-
actin expression, and compared to HC11 cells stably expressing a control shRNA 
(Control).  D, Stable HC11 cell lines were treated, induced, and probed for β-casein and 
β-actin (control) as described above.  Abbreviations: TCDD, 2,3,7,8-Tetrachlorodibenzo-
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To test the effect of AHRR on milk production, we first stably expressed a 
lentiviral hemagglutinin (HA)-tagged AHRR construct in HC11 cells.  We confirmed 
overexpression (Figure 4.2A) and validated the construct by measuring a well- 
characterized AHR response gene, Cyp1A1.  Compared to control transduced cells, 
overexpression of AHRR decreased induction of Cyp1A1 after 48 hours of treatment with 
10 µM 1023 (Figure 4.2B).  These results verified our tagged AHRR construct interacted 
with ARNT to functionally repress known target genes. 
Next, to examine a potential role for AHRR in repressing milk production, we 
tested whether AHRR expression was sufficient to block β-casein production in the 
absence of AHR agonists.  In HC11 cells induced with lactogenic hormones, and without 
exposure to AHR agonists, β-casein production was repressed at both the mRNA (Figure 
4.2C) and protein level (Figure 4.2D) in cells expressing HA-AHRR compared to control 
cells.  These results demonstrated the presence of AHRR was sufficient to block 
lactation. 
  AHRR contains a transcriptional repression domain within its C-terminal region, 
which consists of three conserved small ubiquitin-like modifier (SUMO)ylation sites at 
Lys-542, Lys-583, and Lys-660.  Previous studies demonstrated these lysine residues are 
modified by SUMO-1 to facilitate interaction between AHRR and its corepressor 
complex (30).  To genetically test the requirement of this interaction for AHRR to inhibit 
milk production, we mutated all three lysine residues to arginine (HA-AHRRmutant).  
Previously, these mutations in AHRR have been shown to allow interaction between 
AHRR and ARNT, but prevent interaction between AHRR and its corepressor complex 










Figure 4.2.  AHRR is sufficient to block milk production in MECs.  HC11 cells were 
transduced with lentivirus to generate cell lines stably expressing hemagglutinin (HA)-
tagged AHRR (pEiZ-HA-AHRR) or a control (pEiZ).  A, Western blot of lysates from 
stable cell lines probed for HA and α-tubulin (control).  B, Stable HC11 cell lines were 
treated for 48 hours with vehicle control (DMSO) or 10 µM 1023.  Cyp1A1 mRNA levels 
were measured by RT-PCR and normalized to β-actin expression.  Results are shown as 
normalized mean Cyp1A1 expression (± SEM).  An **** indicates a statistically 
significant difference compared to control cells (p ≤0.0001).  Stable HC11 cell lines 
were induced with lactogenic hormones (LH) to produce milk proteins.  C, β-casein 
mRNA levels were measured by RT-PCR and normalized to β-actin expression.  Results 
are shown as normalized mean β-casein expression (± SEM).  An **** indicates a 
statistically significant difference compared to control cells (p ≤0.0001).  D, Cell lysates 
were probed for β-casein and α-tubulin (control).  E, An HC11 cell line was generated to 
express AHRR mutated to prevent SUMOylation in the C-terminal region (HA-
AHRRmutant).  All stable cell lines were induced with LH and probed for β-casein and 
α-tubulin (control) as before.  Abbreviations: HA, hemagglutinin; AHRR, aryl 
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SUMOylation mutant fully rescued β-casein production (Figure 4.2E), indicating AHRR 
requires interaction with its corepressor complex to inhibit lactogenesis. 
 
ARNT is required for milk production in mammary epithelial cells   
To elucidate the mechanism through which AHRR inhibits milk production, we 
examined the role of its major binding partner, ARNT, during normal lactation.  Stable 
HC11 cell lines expressing a nonspecific lentiviral shRNA (Control) or a lentiviral 
shRNA against ARNT (shARNT #1 or shARNT #2) were generated (Figure 4.3A-B).  
Following induction with lactogenic hormones, knockdown of ARNT inhibited β-casein 
expression at both the mRNA (Figure 4.3C) and protein level (Figure 4.3D).  As loss of 
AHR had no effect on milk production in HC11 cells (Figure 4.1D), these results 
implicated an independent role for ARNT during milk production. 
 
Overexpression of ARNT rescues milk production in the presence  
of AHR agonists   
Based on our results, we hypothesized ARNT participated in a transcriptionally 
active complex to promote expression of milk genes, such as β-casein, during 
lactogenesis.  Furthermore, since ARNT was required for lactogenesis, we speculated 
AHRR might inhibit milk production through competitive interactions with ARNT.  To 
test this hypothesis, we overexpressed ARNT prior to treatment with AHR agonists and 
assessed milk production.  We reasoned overexpression of ARNT would promote 












Figure 4.3.  ARNT is required for milk production in MECs.  Lentiviral shRNA 
constructs (shARNT#1 and shARNT#2) were used to stably knockdown ARNT 
expression in HC11 cells.  A, ARNT expression was measured by RT-PCR, normalized to 
β-actin expression, and compared to HC11 cells stably expressing a control shRNA 
(Control).  Results are shown as normalized mean ARNT expression (± SEM).  An * 
indicates a statistically significant difference compared to control cells (p ≤0.05).  B, 
ARNT protein levels were measured in cell lysates from stable lines.  Western blot of 
lysates probed for ARNT and α-tubulin (control).  Stable HC11 cell lines were induced 
with lactogenic hormones (LH) to produce milk proteins.  C, β-casein mRNA levels were 
measured by RT-PCR and normalized to β-actin expression.  Results are shown as 
normalized mean β-casein expression (± SEM).  An **** indicates a statistically 
significant difference compared with control cells (p ≤0.0001).  D, Western blot of 
lysates probed for β-casein and α-tubulin (control).  Abbreviations: ARNT, aryl 











































































































































agonists.  In HC11 cells stably overexpressing a lentiviral HA-ARNT construct (Figure 
4.4A), we found milk production partially restored in the presence of both 10 µM 1023 
and 10 nM TCDD compared to control cells (Figure 4.4B).  These results support a 
model in which AHRR blocks milk production by acting as a transcriptional repressor to 
inhibit ARNT signaling.   
 
Discussion 
Using an epithelial-based model of mammary lactation, we demonstrate AHR 
agonists directly block milk production.  Specifically, we showed AHRR, a robust 
downstream target of AHR signaling, was sufficient to inhibit lactogenesis.  Although 
well studied in the context of AHR activation, AHRR is also induced by other toxic 
insults.  In particular, recent studies showed cigarette smoking, including secondhand 
exposure, caused significant demethylation and increased expression of AHRR (31,32).  
As women who smoke have consistently been shown to produce significantly less milk 
volume (33,34) and breastfeed for a shorter duration (33,35-38), our results provide a 
potential molecular mechanism through which this toxicity occurs. 
 Following induction, AHRR forms a heterodimer complex with ARNT (39).  As 
loss of ARNT completely blocked milk protein production in mammary epithelial cells, 
our results implicate an important role for ARNT during lactation.  These observations 
are consistent with the phenotype observed in conditional ARNT knockout mice, where 
ARNT deletion using the MMTV-Cre transgene resulted in impaired mammary function 
(40).  Specifically, loss of ARNT led to incomplete alveolar development, smaller litter 


















Figure 4.4.  ARNT overexpression rescues milk production in the presence of AHR 
agonists.  A hemagglutinin (HA) tagged ARNT construct (pEiZ-HA-ARNT) was stably 
expressed in mammary HC11 cells using lentiviral transduction.  An empty expression 
vector (pEiZ) was used to create a stable control HC11 cell line.  A, Western blot of 
lysates probed for HA and α-tubulin (control).  B, Stable HC11 cell lines were treated 
with vehicle control (DMSO), 10 µM 1023, or 10 nM TCDD and induced with lactogenic 
hormones (LH) to produce milk proteins.  Western blot of lysates probed for β-casein and 
α-tubulin (control).  Abbreviations: HA, hemagglutinin; ARNT, aryl hydrocarbon 











































































































However, inactivation of ARNT using WAP-Cre resulted in normal mammary 
differentiation during pregnancy (40).  Furthermore, transplantation of ARNT null 
mammary epithelium generated using MMTV-Cre into wild type recipients normalized 
alveolar development (40).  Although inconsistent with initial studies and our current 
findings, these incongruent results may be explained by differences in methodology.  
Specifically, WAP-Cre reduced ARNT levels in 80% of the mammary epithelium 
(40,41), resulting in residual ARNT expression that may facilitate normal development.  
In reciprocal transplant studies, the high selective pressure of transplantation may have 
induced compensation from other ARNT family members, including ARNT2.  Expressed 
in the mammary gland (42), ARNT2 is known to form functional complexes with AHR 
(43) and may be capable of contributing to mammary development.  Further in vivo 
studies will be required to explain these differences.  
 Our experiments with AHRR and ARNT suggest a model in which ARNT 
promotes milk production under lactogenic conditions (Figure 4.5).  As a basic helix-
loop-helix (bHLH) PER-ARNT-SIM (PAS) family member, ARNT requires dimerization 
to form a functional transcription complex.  Although ARNT is known to interact with 
multiple proteins, we hypothesize that hypoxia inducible factor-1α (HIF1α) or single-
minded 2 (SIM2) interact with ARNT to promote lactation.  In previous studies, 
conditional knockout of ARNT prevented induction of known HIF1α target genes (44), 
suggesting ARNT is critical for HIF1α signal transduction.  Additionally, deletion of 
HIF1α in the mammary epithelium resulted in severe differentiation defects and failed 
lactation (45).  Previous studies with SIM2 also support its potential role in cooperating 










Figure 4.5.  Working model for the mechanism through which AHR activation blocks 
milk production in mammary epithelial cells.  (Right)  In the absence of AHR agonists, 
we propose ARNT signaling promotes milk production during lactogenic stimulation.  
(Left)  In the presence of AHR agonists, AHR translocates to the nucleus and forms a 
heterodimer with ARNT.  AHR/ARNT heterodimers bind XRE sequences to increase 
transcription of AHR target genes, including AHRR.  Once induced, AHRR competes 
with AHR for interaction with ARNT and forms a transcriptionally repressive complex, 






































β-casein and WAP occurred in vitro and in vivo, and chromatin immunoprecipitation 
(ChIP) experiments showed SIM2 associated with the β-casein promoter.    Conversely, 
loss of SIM2 inhibited milk production (46).  Taken together, these experiments strongly 
implicate a role for HIF1α or SIM2 in promoting ARNT-mediated lactogenesis.  
 In response to toxic stimuli, AHRR/ARNT heterodimers form and are sufficient 
to block lactation.  One potential mechanism of AHRR repression under these conditions 
is ARNT sequestration.  Competition for a limited pool of ARNT has been observed 
previously, where ARNT availability regulated AHR signaling through HIF1α (47) and 
SIM1 (48,49).  However, our experiments using an AHRR repression mutant that could 
bind ARNT, but not recruit a corepressor complex, suggested this is not the dominant 
mechanism.  Rather, our results indicate AHRR requires SUMOylation and subsequent 
recruitment of ANKRA2, HDAC4, and HDCA5 to block milk production.  Further 
experiments will be needed to determine whether activating ARNT complexes and 
repressive AHRR/ARNT heterodimers bind the same DNA response elements.  
Additionally, these studies will help determine whether ARNT-mediated complexes bind 
directly in the promoter region of milk target genes or whether they control activity of an 
intermediate factor(s).  
 Our data demonstrate that AHR signaling directly disrupts milk protein 
production in isolated mammary epithelial cells.  Since industrial waste is one of the 
main sources of TCDD and other related polyhalogenated aromatic hydrocarbons, human 
exposure to these toxins is highest in industrialized countries (50).  However, acute 
exposure has occurred in several distinct populations worldwide, including exposure to 
Agent Orange herbicide in Vietnam (51), indigenous Canadian Inuit populations who 
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consume contaminated marine species (52), and people living in Seveso, Italy during the 
1976 industrial explosion (53), among others.  Given the prevalence of these 
environmental toxins and their ability to bioaccumulate over time, our study has 
substantial implications on public health, particularly with regard to the ability of women 
to breastfeed.  Thus, future efforts to monitor TCDD exposure levels, analyze 
epidemiological data, and elucidate the molecular mechanism downstream of AHRR are 
needed to address this problem.  
 
Materials and Methods 
Microarray data 
Data previously generated (14) were analyzed using GeneSifter software 
(Geospiza Inc).  Microarray data analyzed for this publication can be obtained from the 




TCDD (Cambridge Isotopes Laboratories, Inc., Andover, MA) was obtained as a 
DMSO stock solution.  1023 was synthesized as previously described (14) and dissolved 
in DMSO at a stock concentration of 10 mM. 
 
HC11 cell culture and induction with lactogenic hormones 
HC11 cells were maintained at 37 oC with 5% CO2 in HC11 culture media (RPMI 
(HyClone), 10% FBS (HyClone), ITS-X (Invitrogen), 1X 
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penicillin/streptomycin/glutamine (Invitrogen), and 10 ng/mL murine epidermal growth 
factor (EGF) (BD Biosciences)).  For induction with lactogenic hormones, 1x106 cells per 
well were seeded in 6-well tissue culture plates.  Two-day confluent cultures were 
washed twice with EGF-free HC11 culture media and grown for 96 additional hours in 
EGF-free HC11 culture media containing 5 µg/mL ovine prolactin (Sigma) and 1 µM 
dexamethasone (Sigma).  For compound treatments, FBS was reduced to 2% 12 hours 
after seeding and cells were grown with 0.1% DMSO, 10 µM 1023, or 10 nM TCDD as 
indicated.  Throughout each assay, media were replaced every 48 hours.    
 
Western blot   
HC11 cells were washed twice and scraped in 1 mL cold PBS.  Cells were 
pelleted at 1250 x g for 5 minutes, lysed in RIPA buffer (50 mM Tris-HCL pH 8.0, 150 
mM NaCL, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 1 mM DTT, 1X 
protease/phosphatase inhibitor cocktail), and sonicated for 20 seconds.  All processing 
steps occurred at 4oC or on ice.  Whole cell lysate (50 µg) was separated by 10% SDS-
polyacrylamide gel electrophoresis and transferred to PVDF membrane (Millipore) for 
detection of β-casein (1:100, Santa Cruz #sc-17969), α-tubulin (1:1000, Sigma-Aldrich 
#T6199), HA (1:500, Covance #MMS-101R), or ARNT (1:500, BD Biosciences 
#611078).  Integrated intensity values were measured on a LI-COR Odyssey Scanner 





RNA extraction, cDNA synthesis, and real-time PCR 
RNA was isolated, converted to cDNA, and used for real-time PCR as previously 
described (14).  Primer sequences were as follows: β-actin forward (5'-GGCTGTGCTGT 
CCCTGTATG-3'), β-actin reverse (5'-CAAGAAGGAAGGCTGGAAAA-3'), β-casein 
forward (5’-CAATCCCGTCCCACAAAA-3’), β-casein reverse (5’-TCCAGTTTCAGT 
CAGTTCAAAAA-3’), AHR forward (5'-CTTTGCTGAACTCGGCTTGC-3'), AHR 
reverse (5'-TTGCTGGGGGCACACCATCT-3'), Cyp1A1 forward (5'-GGTTAACCATG 
ACCGGGAACT-3'), Cyp1A1 reverse (5'-TGCCCAAACCAAAGAGAGTGA-3'), ARNT 
forward (5'-CTAAGAGACAGCTTTCAGCAGGT-3'), ARNT reverse (5'-AGGGTTTTG 
GAAGGTAAAGG AG-3'). 
 
Plasmids and molecular cloning  
Constructs expressing an shRNA against AHR or ARNT were previously 
generated (14) using the pLentiLox5.0-GFP vector (54) provided by Dr. James Bear 
(University of North Carolina, Chapel Hill, NC).  Lentiviral expression constructs were 
generated using the pEiZ plasmid (pHIV-Zsgreen, plasmid 18121, Addgene, Cambridge, 
MA) previously described (24).  For generation of pEiZ-HA-AHRR, a mouse AHRR 
expression plasmid (pcDNA-mAhRR) (55) provided by Dr. Mark Hahn (Woods Hole 
Oceanographic Institution, Woods Hole, MA) was used to PCR amplify AHRR with 
addition of an N-terminal HA tag and EcoRI restriction sites.  The following primers 
were used for amplification:  forward (5’-CTAGAATTCCCACCATGAGCGTAGTCTG 
GGACGTCGTATGGGTAATGATGATTCCGTCTGGAGAGTGTACA-3’), reverse 
(5’-GACGAATTCACTCTAGGGTAGGAAAATTCCATCAGAGCC-3’).  The resulting 
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PCR product was subcloned into the pCR®2.1-TOPO® TA vector to create Topo-HA-
AHRR, which was then digested with EcoRI, and ligated into the same site in pEiZ.  For 
generation of pEiZ-HA-AHRRmutant, site-directed mutagenesis was performed using the 
Strategene QuikChange Site-Directed Mutagenesis Kit (Strategene, La Jolla, CA) and the 
Topo-HA-AHRR plasmid according to manufactures instructions.  Lys-542, Lys-583, 
and Lys-660 were each mutated to an arginine residue in separate reactions using the 
following primer sequences:  Lys-542-Arg sense (5’-CACTGGATGTGCCAATCAGGA 
TGGAGAATGAATCTGG-3’), Lys-542-Arg antisense (5’-CCAGATTCATTCTCCATC 
CTGATTGGCACATCCAGTG-3’), Lys-583-Arg sense (5’-CCAGGATGCACCTGAG 
AACAGAGCCCGACTA-3’), Lys-583-Arg antisense (5’-TAGTCGGGCTCTGTTCTCA 
GGTGCATCCTGG-3’), Lys-660-Arg sense (5’-ACTGCAGAGCTCCTATTGTTAGGC 
GTGAGCCTC-3’), Lys-660-Arg antisense (5’-GAGGCTCACGCCTAACAATAGGAG 
CTCTGCAGT-3’).  Following site-directed mutagenesis, Topo-HA-AHRRmutant was 
digested with EcoRI and the resulting fragment was ligated into pEiZ using the same site.  
For generation of pEiZ-HA-ARNT, an HA-tagged mouse ARNT expression plasmid 
(pACTAG-HA-ARNT) (56) provided by Dr. Oliver Hankinson (University of California, 
Los Angeles, CA) was used to PCR amplify the HA-ARNT fragment with additional 
EcoRI restriction sites.  The resulting PCR product was subcloned into the pCR®2.1-
TOPO® TA vector to create Topo-HA-ARNT, which was digested with EcoRI and 
ligated into the same site in pEiZ.  The following plasmids for generating lentivirus have 
been previously described: pMDLg/pRRE (57), pRSV-Rev (57), and pVSV-G 
(Clontech).  The identity of each plasmid was confirmed by sequencing.  
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Production and titration of lentivirus  
High titer lentivirus was produced, concentrated, and titrated as previously 
described (14). 
 
Generation of stable HC11 cell lines 
For stable HC11 cell lines expressing an shRNA or expression construct, 
1.25x106 cells were seeded in a 10-cm dish, cultured for 12 hours, and transduced at an 
MOI of 20.  Transduced cells were sorted 72 hours later based on GFP expression to 
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Desmosomes are specialized adhesion complexes that provide tight contacts 
between epithelial cells.  Previously, we identified a role for desmosomes during 
mammary morphogenesis.  Using a 3D model of in vitro mammary branching, we found 
loss of desmosomes was sufficient to induce branching morphogenesis in primary 
mammary epithelial cells (MECs).  Furthermore, activation of the aryl hydrocarbon 
receptor (AHR) blocked mammary branching by upregulating desmosomes.  In the 
present study, we investigated desmosome dynamics during in vivo mammary branching.  
In agreement with our previous data, desmosomes were lost in wild type mice during 
pregnancy.  However, we observed differential regulation of desmosomal adhesion 
during pregnancy, with only myoepithelial specific desmosomes downregulated.  These 
results suggest myoepithelial desmosomes significantly contribute to ductal integrity and 
regulate initiation of mammary branching morphogenesis.  We also investigated 
desmosomes in the context of AHR activation and found loss of the aryl hydrocarbon 
receptor repressor (AHRR) increased desmosomes and blocked branching.  Since AHRR 
negatively regulates AHR activity, these results implicate a direct link between activated 
AHR and desmosomal adhesion.   
   
Introduction 
Desmosomes are specialized intercellular junctions expressed in epithelial cells.  
These highly organized complexes contain proteins from the cadherin, armadillo, and 
plakin families (1).  Cell-cell adhesion is mediated by desmosomal cadherins, which are a 
family of transmembrane proteins further divided into desmocollin (Dsc1-3) and 
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desmoglein (Dsg1-4) proteins (2).  Armadillo proteins, including plakoglobin and 
plakophilin, bridge the cytoplasmic domains of the cadherins to desmoplakin (3), which 
attaches to intermediate filaments (1).  By connecting the plasma membrane to the 
intermediate filament cytoskeleton, desmosomes stabilize tissues during mechanical 
stress (4).  However, desmosomes are dynamic structures that also function in cell and 
tissue morphogenesis.     
Previously, we identified a role for desmosomes during mammary morphogenesis 
(5).  Unlike other organs, the mammary gland undergoes differential development after 
birth.  A rudimentary ductal tree is formed during embryogenesis, but significant 
mammary growth does not begin until puberty, when hormonal cues stimulate ductal 
elongation.  This process creates an elaborate ductal network that fills the surrounding 
adipose tissue (6).  Mammary ducts maintain a bilayered morphology, with luminal 
epithelial cells surrounded by myoepithelial cells.  During pregnancy, tertiary branching 
continues to expand the epithelial network and lobuloalveolar development occurs to 
form alveolar buds.  These structures are critical to the function of the mammary gland, 
as they contain both differentiated luminal cells capable of producing milk proteins and 
contractile myoepithelial cells that aid milk delivery (7).  Ultimately, mammary 
branching morphogenesis establishes an extensive ductal network capable of producing 
and delivering milk to newborn animals.   
As a highly secretory epithelial tissue, the mammary gland must maintain both 
barrier integrity and cell permeability.  The distinct phases and cyclical nature of 
mammary gland development requires a highly dynamic relationship between these two 
functions.  Transmission electron microscopy (EM) performed in the 1970s suggests 
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cellular adhesion helps regulate this balance (8).  In the virgin mouse mammary gland, 
EM analysis shows close interaction between ductal cells.  Tight junctions, intermediate 
junctions, gap junctions, and desmosomes mediate luminal cell interactions.  Dispersed 
desmosomes and gap junctions connect luminal and myoepithelial cells, and 
hemidesmosomes attach myoepithelial cells to the basal lamina.  Alveoli resemble 
mammary ducts in early pregnancy, but once they gain secretory capacity, desmosomes 
appear to be lost.  As tight and gap junctions remained, these observations suggested loss 
of desmosomes facilitates mammary morphogenesis and increases cell permeability.  
Supporting these early observations, our previous work determined that increased 
desmosomal adhesion in primary mammary epithelial cells (MECs) blocks mammary 
branching (5).  These results were obtained using an in vitro three-dimensional (3D) 
model of branching morphogenesis in which primary MECs were stimulated with 
fibroblast growth factor-2 (FGF2).  In the first step of this assay, MECs reorganize to 
form duct-like structures before they initiate branching morphogenesis.  Using a forward 
chemical genetic screen, we found activation of the aryl hydrocarbon receptor (AHR) 
blocked branching and maintained cells as apparently normal duct-like structures.  
Functionally, we showed AHR stimulation blocked the transition of MECs from duct-like 
to branched structures by promoting desmosomal adhesion.  Likewise, loss of 
desmosomes was sufficient to induce mammary branching in MECs grown with 
epidermal growth factor (EGF), which normally promotes duct-like formation.  Together, 
these results implicated desmosomes as a critical regulator of mammary morphogenesis.   
Here, we investigated the temporal and spatial regulation of desmosomes during 
in vivo mammary branching.  In support of our previous studies, we observed loss of 
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desmosomes during pregnancy in wild type mice.  However, desmosomal cadherins were 
differentially regulated, with Dsc3 and Dsg3 exclusively expressed in myoepithelial cells 
and dramatically downregulated during pregnancy, while Dsc2 and Dsg2 were uniformly 
expressed and maintained during pregnancy.  Our results support loss of myoepithelial 
specific desmosomes as a driving force during mammary branching.  In addition to 
differences in expression and regulation during pregnancy, desmosomal cadherins also 
showed differential response to AHR stimulation.  To further elucidate the molecular link 
between AHR activation and desmosomes, we studied primary MECs from aryl 
hydrocarbon receptor repressor (AHRR) deficient mice.  Surprisingly, loss of AHRR 
alone blocked mammary branching and significantly increased desmosomes.  These 




Specific desmosomal cadherins are lost during pregnancy   
Based on our previous studies, we hypothesized desmosomes were lost in vivo 
during pregnancy to facilitate branching.  To test this, we harvested mammary epithelial 
tissue from virgin and 15-day pregnant FVB/n female mice (Figure 5.1A) and performed 
qRT-PCR to measure mRNA levels of desmosomal cadherins.  We found desmocollin 1 
(Dsc1), desmoglein 1 (Dsg1), desmocollin 3 (Dsc3), and desmoglein 3 (Dsg3) 
dramatically downregulated in late pregnancy, compared to the virgin control (Figure 













Figure 5.1.  Desmosomal cadherins are lost during pregnancy.  (A.)  Representative 
whole mount analysis of mammary glands from (left) virgin and (right) 15 day pregnant 
FVB/n female mice.  Glands were collected and stained with carmine alum.  Scale bar, 
250 µm.  (B-E.)  Desmocollin 1 (Dsc1), desmoglein 1 (Dsg1), desmocollin 3 (Dsc3), and 
desmoglein 3 (Dsg3) mRNAs were significantly down regulated at 15 days pregnancy 
compared to the virgin control.  Dsc1, Dsg1, Dsc3, and Dsg3 gene expression was 
measured in primary mammary epithelial cells (MECs) by qRT-PCR and normalized to 
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maintained during pregnancy (Figure 5.2A-B).  Unlike the other desmosomal cadherins, 
Dsc2 and Dsg2 were not upregulated by AHR activation in our 3D culture system (Figure 
5.2C-D).  Only cadherin isoforms regulated by AHR signaling were altered in vivo during 
branching morphogenesis.  These results demonstrate the differential in vivo regulation of 
desmosome components during pregnancy.  
   
Desmosomal cadherins have distinct expression patterns  
in the mammary gland   
To better characterize these complexes, we next determined the expression pattern 
of desmosomal cadherins in the normal mammary gland.  With a bilayered morphology, 
the mammary gland consists of cytokeratin-8 (K8) positive luminal epithelial cells 
surrounded by cytokeratin-14 (K14) positive myoepithelial cells (Figure 5.3A).  Since 
Dsc1 and Dsg1 are not expressed in the human mammary gland (9), we focused our 
studies on Dsc2, Dsg2, Dsc3, and Dsg3.  Primary MECs from virgin FVB/n female mice 
were FACS sorted using CD49f expression to enrich for mammary stem and 
myoepithelial cells (10).  Using gene expression analysis, we found Dsc3 and Dsg3 were 
exclusively expressed in K14-positive, CD49f-high MECs, and Dsc2 and Dsg2 were 
expressed in both CD49f-low and CD49f-high populations (Figure 5.3B).  These results 
were consistent with previous studies analyzing human (9) and bovine (11) mammary 













Figure 5.2.  Dsc2 and Dsg2 are maintained during pregnancy.  (A-B.) Expression of 
desmocollin 2 (Dsc2) and desmoglein 2 (Dsg2) mRNAs were not significantly changed 
between the virgin and pregnant state.  Gene expression was measured in primary 
mammary epithelial cells (MECs) from FVB/n female mice.  (C-D.) Similarly, epidermal 
growth factor (EGF) or aryl hydrocarbon receptor (AHR) agonists did not induce 
expression of Dsc2 or Dsg2 mRNA.  Gene expression was measured in aggregated 
primary MECs grown in Matrigel for 96 hours with 2.5 nM EGF or 2.5 nM fibroblast 
growth factor-2 (FGF2) and 0.1% DMSO or 10 nM TCDD or 10 µM 1023.  Gene 
expression was measured by qRT-PCR and normalized to β-actin expression.  Results are 
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Figure 5.3.  Desmosomes are differentially expressed in mammary epithelial cells 
(MECs). (A.) (Left) The virgin mammary gland contains a lymph node (LN) and large 
surrounding ductal network. Whole mount analysis from a virgin FVB/n female mouse is 
shown.  Scale bar, 250 µm.  (Right) Mammary ducts are composed of an epithelial 
bilayer, with cytokeratin-14 (K14, red) positive myoepithelial cells surrounding 
cytokeratin-8 (K8, green) positive luminal epithelial cells.  Immunofluorescence was 
performed on a cross section of a duct from a virgin FVB/n female mouse and nuclei 
were stained with DAPI (blue).  Scale bar, 40 µm.  (B.) Desmocollin 3 (Dsc3) and 
desmoglein 3 (Dsg3) mRNA expression were highly enriched in myoepithelial cells, 
which also express high levels of K14.  In contrast, desmocollin 2 (Dsc2) and desmoglein 
2 (Dsg2) mRNA expression was similar in both myoepithelial cells and luminal epithelial 
cells.  Luminal epithelial cells were enriched for milk fat globule-EGF factor 8 (Mfge8) 
and lactotransferrin (Ltf), as expected.  Gene expression was measured by qRT-PCR in 
CD49f sorted primary MECs isolated from virgin FVB/n female mice.  Gene expression 
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Expression of EMT factors correlates with desmosome dynamics   
Next, we sought to determine how desmosomes were differentially regulated in 
the mammary gland.  Although desmosome turnover can be controlled by endocytosis 
(12,13), our data implicated a transcriptional mechanism.  As a result, we focused our 
studies on Snai1 and Snai2, which are two critical epithelial-to-mesenchymal transition 
(EMT) factors that act as transcriptional repressors.  Snai1 and Snai2 are necessary and 
sufficient for branching morphogenesis in organotypic culture of MECs (14).  
Furthermore, Snai1 was shown to induce cell scattering in MDCK cells by disrupting 
cellular adhesion (15) and Snai2 dissociated desmosomes in NBT-II cells (16), a rat 
bladder carcinoma cell line.  Based on these studies, we hypothesized Snai1 or Snai2 
differentially regulated desmosomal cadherins in the mammary gland to induce branching 
morphogenesis. 
To begin assessing these EMT factors as potential negative regulators of 
desmosomes, we first looked at their expression in response to AHR stimulation.  We 
hypothesized Snai1 or Snai2 would be downregulated in TCDD-treated primary MECs, 
thus allowing for upregulation of desmosomes.  Based on time-lapse imaging, 48 hours in 
culture represented a critical decision point in primary MEC cultures between cyst 
formation and branching morphogenesis (Figure 5.4A), and was also when robust 
upregulation of desmosomal cadherins began (Figure 5.4B-C).  We observed ~50% 
reduction in Snai1 expression (Figure 5.4D) and no significant change in Snai2 
expression (Figure 5.4E) after 48 hours of TCDD treatment.  These results implicated a 












Figure 5.4.  AHR activation downregulates Snai1 expression.  (A.) Time-course imaging 
of primary MECs grown in Matrigel with 2.5 nM fibroblast growth factor-2 (FGF2).  
Early initiation of branching is observed between 48 and 72 hours in culture.  (B.) 
Primary MECs treated for 48 hours with 10 nM TCDD showed upregulation of 
desmocollin 3 (Dsc3) and (C.) desmoglein 3 (Dsg3) mRNAs.  At this same time point, 
(D.) Snai1 mRNA expression was reduced, but (E.) Snai2 showed no change.  Gene 
expression was measured by qRT-PCR and normalized to β-actin expression.  Results are 
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After identifying Snai1 as a strong candidate, we next measured its expression in 
the virgin gland.  We isolated primary MECs from virgin FVB/n female mice and FACS 
sorted based on CD49f expression.  Since we previously observed high expression of 
Dsc3 and Dsg3 in virgin myoepithelial cells, we hypothesized that Snai1 expression 
would be relatively low in this cellular compartment.  Consistent with our previous 
observations, Snai1 displayed higher expression in luminal epithelial cells from virgin 
MECs compared to myoepithelial cells (Figure 5.5A).   
Next, we assessed Snai1 expression during pregnancy.  Our data demonstrated 
myoepithelial desmosomes were dramatically downregulated at day 15 of pregnancy.  As 
a result, we hypothesized Snai1 expression would be increased in pregnant primary 
MECs.  In agreement with this prediction, Snai1 expression was induced in primary 
MECs from 15-day pregnant FVB/n mice compared to the virgin control (Figure 5.5B).  
Taken together, these results show an inverse relationship in the mammary gland between 
Snai1 and myoepithelial desmosomes.  
 
Loss of the aryl hydrocarbon receptor repressor blocks  
mammary branching morphogenesis   
Our next goal was to determine the intersection of normal FGF2-mediated 
branching and AHR signaling.  Once activated, AHR translocates to the nucleus and 
forms a dimer with the AHR nuclear translocator (ARNT).  As a heterodimer, 
AHR/ARNT binds xenobiotic-responsive elements (XREs) in the promoter region of 
AHR target genes, including the aryl hydrocarbon receptor repressor (AHRR) (17).  We 










Figure 5.5. Snai1 expression increases during pregnancy.  (A.) In mammary epithelial 
cells (MECs) isolated from virgin FVB/n female mice, Snai1 mRNA expression was 
enriched in the luminal cell population. Luminal and myoepithelial cell populations were 
isolated based on CD49f expression.  (B.) Compared to MECs isolated from virgin mice, 
MECs from 15-day pregnant FVB/n female mice showed higher levels of Snai1 mRNA 
expression.  Gene expression was measured by qRT-PCR and normalized to cytokeratin-
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was shown to regulate Snai1 through CK2α (18,19), a serine/threonine kinase that 
contains multiple XREs in its promoter region (20).  Based on these observations, we 
hypothesized that AHRR was a critical downstream mediator of AHR signaling required 
for activation of desmosomes and blocked branching morphogenesis.  To test our 
hypothesis, we generated an AHRR knockout (KO) mouse using targeted sperm obtained 
from the Knockout Mouse Project (KOMP) Repository.   
First, we isolated primary MECs from wild type (WT) and AHRR KO mice and 
treated them with 10 nM TCDD.  Since AHRR drives a repressive feedback loop that 
inhibits AHR activity (21), we expected AHRR KO cells to display heightened AHR 
activation.  In our assay, AHRR KO MECs showed significantly higher induction of the 
AHR readout gene, Cyp1A1, than WT MECs (Figure 5.6A).  These results confirmed 
AHRR was properly targeted.  
Next, we isolated primary MECs from WT and KO female mice and performed 
an in vitro 3D branching assay.  We reasoned if AHRR was critical for activation of 
desmosomal cadherins, loss of AHRR would rescue branching in the presence of TCDD.  
Unexpectedly, primary MECs from AHRR KO mice failed to undergo FGF2-induced 
branching morphogenesis, even in the absence of AHR ligands.  Rather, we observed 
large, fluid-filled cysts in KO MECs grown with 2.5 nM FGF2.  In the presence of 10 nM 
TCDD, we observed cyst arrest with both WT and KO MECs (Figure 5.6B).  
 
Loss of AHRR highly upregulates desmosomes   
We previously demonstrated AHR activation blocked branching morphogenesis 

















Figure 5.6.  Loss of AHRR blocks mammary branching.  (A.) Primary mammary 
epithelial cells (MECs) isolated from aryl hydrocarbon receptor repressor (AHRR) 
knockout (KO) mice showed increased Cyp1A1 mRNA induction in the absence of AHR 
agonists.  AHRR KO cells treated with 10 nM TCDD also showed elevated Cyp1A1 
induction compared to primary MECs isolated from wild type (WT) mice.  Gene 
expression was measured by qRT-PCR and normalized to β-actin expression.  Results are 
shown as mean ± S.E. (error bars); ****, p < 0.0001.  (B.) Primary MECs isolated from 
AHRR KO mice failed to branch in 3D.  Aggregated MECs were grown in Matrigel for 
144 hours with 2.5 nM fibroblast growth factor-2 (FGF2) and 0.1% DMSO or 10 nM 






























































































KO MECs failed to branch due to increased desmosomal adhesion.  To test this, we 
measured expression of the desmosome cadherins previously induced by AHR signaling 
(5) in WT and AHRR KO MECs.  Compared to WT MECs grown with 10 nM TCDD, 
AHRR KO MECs grown in the absence of TCDD showed higher levels of Dsc1 and 
Dsg1 and comparable levels of Dsg3.  In the presence of 10 nM TCDD, AHRR KO 
MECs showed exceptionally high levels of these isoforms (Figure 5.7).  Contrary to our 
original hypothesis, these results demonstrated AHRR was not required for AHR agonists 
to activate desmosomes.  Rather, loss of AHRR alone was sufficient to induce levels of 
desmosomal adhesion capable of functionally blocking mammary branching.     
 
Discussion 
 Using a 3D model of mammary morphogenesis, we previously demonstrated loss 
of desmosomal adhesion is sufficient to induce mammary branching (5).  In the present 
study, we further investigated the dynamic regulation of desmosomes in the mammary 
gland.  In the virgin gland, we observed differential expression of desmosomal cadherins.  
Specifically, we found Dsc2 and Dsg2 expressed in both luminal and myoepithelial cells, 
while Dsc3 and Dsg3 were restricted to the myoepithelial cell population.   
The differential expression pattern we observed in the mammary gland parallels 
the tissue- and cell-type specific expression of desmosomes.  In particular, Dsc2 and 
Dsg2 are uniformly expressed in all tissues that form desmosomes while Dsc1, Dsg1, 
Dsc3 and Dsg3 are restricted to stratified epithelia (22,23).  Additionally, expression of 
desmosomal cadherins shows cell-type specificity.  In the epidermis for example, Dsg1 













Figure 5.7.  Loss of AHRR activates desmosomal adhesion.  (A.) Primary mammary 
epithelial cells (MECs) isolated from aryl hydrocarbon receptor repressor (AHRR) 
knockout (KO) mice showed increased desmocollin 1 (Dsc1), (B.) desmoglein 1 (Dsg1), 
and (D.) desmoglein 3 (Dsg3) mRNA induction in the absence of aryl hydrocarbon 
receptor (AHR) stimulation.  These levels were comparable or higher than wild type 
(WT) MECs grown with 10 nM TCDD.  (C.) Increased desmocollin 3 (Dsc3) mRNA 
expression was not observed in AHRR KO MECs.   Aggregated MECs were grown in 
Matrigel for 144 hours with 2.5 nM fibroblast growth factor-2 (FGF2) and 0.1% DMSO 
or 10 nM TCDD.  Gene expression was measured by qRT-PCR and normalized to β-


























































































































































































function is observed.  Dsc3 and Dsg3 are concentrated in the spinosum layer, and Dsc2 
and Dsg2 are dominant in the basal layer, where proliferation is highest (24).  These 
observations suggest desmosomes have differentiation-dependent expression patterns in 
epidermal tissue.   
In addition to the expression pattern, we also observed differences in the temporal 
regulation of mammary desmosomes.  Dsc2 and Dsg2 were unaffected by AHR 
stimulation and were maintained during pregnancy.  Conversely, Dsc1, Dsg1, Dsc3, and 
Dsg3 were induced during AHR-mediated cyst formation in 3D culture and lost during 
pregnancy.  Given our data, we hypothesize myoepithelial specific desmosomal cadherins 
are preferentially lost during both in vitro and in vivo branching (Figure 5.8).  The 
restricted loss of Dsc3 and Dsg3 would facilitate breaks in myoepithelial cell coverage, 
where luminal branch points have been previously shown to arise in organotypic 
mammary cultures (25).  Additionally, maintenance of Dsc2 and Dsg2 during branching 
would support collective migration of luminal epithelial cells, where desmosomes are 
thought to be maintained (26).  
To fully test this model, selective inhibition of desmosomal cadherins is required.  
We predict loss of Dsc3 and Dsg3 in the virgin gland, but not Dsc2 or Dsg2, will induce 
precocious branching.  Previously, distinct desmosomes have been indirectly targeted in 
the mammary gland.  In particular, Perp (p53 apoptosis effector related to PMP-22) 
deficiency led to loss of Dsg1/2 and Dsc2 in the mammary epithelium.  Although Perp 
null mammary glands had increased immune infiltration, normal ductal development was 
observed (27).  In addition to Perp, conditional deletion of the tumor suppressor gene 













Figure 5.8.  Working cellular model for how desmosomes regulate mammary branching 
morphogenesis in vitro and in vivo.  (Left) In the virgin mammary gland or during AHR 
activation, desmosomal adhesion is induced in all cell types, allowing ductal architecture 
to be maintained.  (Middle) As branching morphogenesis initiates, we propose 
myoepithelial specific desmosomes are downregulated, which allows branch points to 
form.  (Right) Luminal epithelial cells maintain desmosomes and migrate collectively 
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deletion induced in vitro and in vivo hyperbranching (28).  Since desmosome defects 
were visualized by transmission electron microscopy, it is unclear which cadherin 
isoforms were inhibited by Lkb1.  Direct in vivo targeting of individual desmosomal 
cadherins will be needed to fully understand how desmosomes regulate the dynamics of 
mammary branching morphogenesis. 
Our studies of desmosomes and mammary morphogenesis have focused on 
postnatal stages of development, namely puberty and pregnancy.  However, remodeling 
of cellular adhesion is also thought to drive early mammary morphogenesis.  At E15, 
desmosomes are absent in the mammary bud.  However, desmosomes are restored at E17  
as the mammary bud elongates and begins cavity formation.  Importantly, desmosomes 
remain absent in the distal region of the elongating bud, where branches create the 
mammary sprout (29).  Similar to our current observations, these studies of embryonic 
mammary gland development suggest increases in desmosomes are linked to lumen 
formation while decreases in desmosomes coincide with branch point formation. 
Supporting our model in the mammary gland, differential desmosomal adhesion is 
thought to drive morphogenesis of other ectoderm-derived tissues.  In early hair follicle 
morphogenesis, placode formation is accompanied by downregulation of desmosomes.  
As cell masses form in epithelial buds, desmosomes are almost completely lost and do 
not reform again until hair follicle elongation begins (30).  Similar to the high expression 
of mammary desmosomes during ductal morphogenesis, re-expression of desmosomes in 
the elongating hair follicle coincides with cavity formation.  In addition to the hair 
follicle, remodeling of cellular adhesion is also associated with tissue morphogenesis in 
the submandibular gland.  Desmosomes are absent in the early cell mass, but 
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strengthened during lumen formation.  Interestingly, desmosomes are strongest in cells 
near the lumen and weaker in the terminal lobules (31), thus paralleling the distribution 
of desmosomes during mammary morphogenesis.  Taken together, these studies strongly 
implicate desmosomes as a critical force driving tissue morphogenesis.     
Aside from normal mammary development, we previously demonstrated AHR 
agonists upregulated desmosomes to functionally block mammary branching.  Here, we 
hypothesized AHRR was a key downstream mediator of AHR activation required for 
desmosome regulation.  Surprisingly, loss of AHRR alone upregulated desmosomes and 
inhibited mammary branching.  These results were inconsistent with a role for AHRR 
promoting desmosomes downstream of AHR activation.  Rather, our results implicated a 
more direct role for activated AHR in regulating desmosomes.   
Loss of AHRR results in hyperactivation of AHR/ARNT heterodimers (17).  
Since desmosomes were upregulated under these conditions, our data suggest 
AHR/ARNT complexes regulate desmosomes.  Directly, AHR/ARNT may bind the 
promoter region of desmosomal cadherins, which are organized in a tandem array on 
chromosome 18 (32).  Alternatively, AHR/ARNT may indirectly regulate desmosomal 
cadherins through other transcription factor(s), such as Snai1.  ChIP-sequencing 
experiments will be required to parse out direct and indirect effects of AHR/ARNT on 
desmosomal cadherins.  
Overall, our data demonstrate desmosomal adhesion helps regulate invasion and 
migration of normal primary MECs.  Desmosomes promote ductal integrity in the virgin 
gland and undergo dynamic remodeling to drive mammary morphogenesis during 
pregnancy.  In the context of tumorigenesis, these results predict deterioration of 
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desmosomal adhesion would enhance cellular motility and facilitate a more aggressive 
tumor phenotype.  Interestingly, estrogens are known to increase desmosome formation 
in normal and malignant breast cells (33), which may contribute to the less invasive 
phenotype observed in estrogen receptor-positive tumors (34).  Additionally, 
desmosomes are disrupted in several types of breast cancer cells.  Shedding of Dsg2 was 
observed in A431 cells due to stabilization of ADAM17 through EGF signaling (35).  
Furthermore, Dsc3 expression was downregulated in breast cancer cell lines and primary 
breast tumors (36,37) primarily due to methylation-mediated epigenetic silencing (37).  
Thus, understanding the molecular mechanisms that regulate mammary desmosomes will 
help identify new strategies to inhibit tumor growth and invasion.  
 
Materials and Methods 
Mice  
Mice were maintained following protocols reviewed and approved by the 
University of Utah Institutional Animal Care and Use Committee. 
 
Whole mount analysis  
Mammary glands were prepared for whole mount analysis as previously described 
(38).  Briefly, the fourth inguinal mammary gland was removed, spread on a slide, and 
fixed in Carnoy’s fixative (60% ethanol, 30% chloroform, 10% glacial acetic acid) for 2 
hours at room temperature.  Fixed mammary glands were rehydrated, stained in carmine 
alum overnight, dehydrated, and cleared in xylene overnight. Stained glands were imaged 
between two slides and mounted with permount for long-term storage. 
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Isolation of primary MECs 
Organoids from the fourth inguinal mammary gland were isolated from virgin (8-
12-week-old) and 15-day pregnant female mice and processed to single epithelial cells as 
previously described (5).  
 
RNA isolation and real-time PCR 
RNA was isolated from primary MECs, converted to cDNA, and used for real-
time PCR as previously described (5).  Primer sequences are shown in Table 5.1.  
 
Chemical compounds 
TCDD (Cambridge Isotopes Laboratories, Inc., Andover, MA) was obtained as a 
DMSO stock solution.  1023 was synthesized as previously described (5) and dissolved in  
 
Table 5.1  Primer sequences used for RT-PCR 
Target Forward (5’->3’) Reverse (5’->3’) 
β-actin GGCTGTGCTGTCCCTGTATG CAAGAAGGAAGGCTGGAAA
A Dsc1 CAGTAGTGGCGACAGATACA CCTTCTCCTGCTGACAAATG 
Dsg1 GGGATAACCACCATCTGTGT CCTCCCAGATCTTGCATTTC 








Dsc2  CATTTTGAAGGGCAATG ATGATTCCCAGAGTTCC 
 















DMSO at a stock concentration of 10 mM.   
 
Aggregation and culture of primary MECs in 3D  
Primary MECs were aggregated overnight, embedded, and grown in Matrigel as 
previously described (5).  For branching studies and imaging, 250 aggregates per well 
were plated in 48-well tissue culture plates.  To calculate percent branching, samples 
were fixed in 4% paraformaldehyde and quantified using bright field microscopy at low 
magnification.  Branching was defined as three ducts or more, as previously established 
(39).  Three independent samples were averaged for each experiment.  For RNA 
extraction, 1,000 aggregates per well were plated in 24-well tissue culture plates and 
three wells were combined for each sample.          
 
Immunofluorescence 
Staining for cytokeratin-8 (Developmental Studies Hybridoma Bank, Troma-I, 
1:100) and cytokeratin-14 (Covance, PRB-155P-100, 1:400) was performed on sections 
of mammary gland from virgin FVB/n mice as previously described (5).  
 
Microscopy 
Mammary whole mounts were imaged using an Olympus MVX10 dissecting 
microscope with a SPOT Insight FireWire 4 CCD camera and Spot Alias 4.6.1.38 
software (Diagnostic Instruments, Inc).  Immunofluorescence and DIC imaging were 
performed using an Olympus IX81-ZDC microscope with an ORCAER CCD camera and 
Slidebook 5.0.0.24 software (Intelligent Imaging Innovations, Inc.).  
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Immunofluorescence imaging was performed using a 40X U-Plan objective lens and DIC 
images were captured using a 20X long working distance objective lens.  For 
immunofluorescence imaging, deconvolution was performed using Slidebook software 
and the nearest neighbor method. 
 
FACS sorting 
Primary MECs were aggregated overnight as described.  After 16 hours, 
aggregates were collected into a 15 mL conical tube (450 x g for 2 minutes) and washed 
twice with 10 mL DMEM/F-12 base media (HyClone).  Pelleted aggregates were 
trypsinized (0.05% trypsin/EDTA, Gibco) for 10 minutes at 37 oC with gentle pipetting 
every 5 minutes.  Single cells were washed with Hanks’ balanced salt solution (HBSS) 
(Gibco) containing 2% fetal bovine serum (FBS) (Gibco) to inactivate trypsin.  Pelleted 
cells were resuspended in HBSS/2% FBS at a concentration of 5 x 10^6 cells per mL.  
The following aliquoted samples were kept on ice and in the dark: 1) 200 µL unstained 
control, 2) 200 µL 7AAD control, 3) 200 µL CD49f-FITC control, 4) experimental 
sample.  Cells were incubated with primary antibody (1:100, BD Pharmingen) for 15 
minutes, washed (1 mL HBSS/2% FBS, 1000 x g for 2 minutes), and resuspended in 400 
µL HBSS/2%FBS.  7AAD (10 µL per 1 x 10^6 cells) was added as indicated and cells 
were filtered through a 40 µm sterile filter (BD Biosciences).  Samples were sorted 





AHRR knockout mice 
Targeted sperm used to rederive Ahrrtm1a(KOMP)Wtsi mice was generated by the 
trans-NIH Knock-Out Mouse Project (KOMP) and obtained from the KOMP Repository 
(www.komp.org).  NIH grants to Velocigene at Regeneron Inc (U01HG004085) and the 
CSD Consortium (U01HG004080) funded the generation of gene-targeted ES cells for 
8500 genes in the KOMP Program and archived and distributed by the KOMP Repository 
at UC David and CHORI (U42RR024244).  Oocytes from C57Bl6/CBA F1 female mice 
were used for in vitro fertilization (IVF).  After heterozygous Ahrrtm1a(KOMP)Wtsi mice were 
backcrossed to FVB/n mice for 9 generations, heterozygous matings were used to 
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Mammary Branching Morphogenesis 
 
Mammary gland development is a highly coordinated process that ultimately 
establishes an elaborate network of epithelial ducts poised for differentiation and milk 
production (1).  Over the course of several distinct stages, the gland undergoes robust 
proliferation and branching.  Many hormonal and local signals have long been recognized 
as important factors regulating this process (2).  These include estrogen and progesterone, 
as well as epidermal growth factor (EGF) and fibroblast growth factor (FGF).  Despite 
identification of these major factors, the downstream mediators of these pathways that 
more directly drive morphogenesis have remained unclear.   
We established an in vitro, three-dimensional (3D) model of mammary 
development using primary mammary epithelial cells (MECs) stimulated with fibroblast 
growth factor-2 (FGF2) (3).  Using this system, primary MECs underwent considerable 
reorganization and established proper cellular polarity, thus recapitulating key aspects of 
in vivo development.  We then coupled this assay with a library of small molecules to 
identify compounds that block FGF2-mediated mammary branching.  Follow-up studies 
with our lead compound elucidated a new role for desmosomal adhesion during 
mammary branching morphogenesis.  Specifically, our results suggested loss of 
desmosomes facilitated mammary branching.   
To fully understand the implications of this work, we next need to determine 
which type(s) of mammary branching desmosomes participate in.  Bifurcation of terminal 
end buds (TEBs), side branching, and lobuloalveolar formation are distinct branching 
processes that all occur during mammary development.  TEBs are club shaped structures 
that form at the tips of elongating ducts during puberty (4).  Composed of a multilayered 
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inner core of body cells and an outer layer of cap cells, TEBs bifurcate to create new 
primary ducts (4).  In contrast, side branching occurs to create new secondary and tertiary 
branches during puberty and early pregnancy (5).  These branch points form in the main 
portion of ducts, which contain an inner layer of luminal epithelial cells surrounded by an 
outer layer of myoepithelial cells.  As a result, new branch points must invade through 
both the myoepithelial layer and the basement membrane.  Finally, lobuloalveolar 
development occurs during pregnancy.  This process is characterized by formation of 
sphere-shaped alveolar structures (6), which each contain a single layer of milk-
producing luminal epithelial cells surrounded by a discontinuous myoepithelial layer.  
This cellular arrangement promotes contact between luminal epithelial cells and the 
basement membrane, which is required for full differentiation (7,8).  
Based on cellular composition and architecture, our 3D branching model appears 
to most closely resemble side branching.  Primary MECs in our assay consist of luminal 
epithelial cells and myoepithelial cells, which reorganize to form bilayered cysts prior to 
branching (3).  Moreover, the specific growth signals present in our system are more 
consistent with TEBs or side branching than lobuloalveolar development.  Rather than 
progesterone and prolactin, which are required for alveolar formation, our system 
includes insulin and FGF2.  These signals are known to be important in vivo during 
puberty (2,5,9) and bypass the need for upstream factors like estrogen and EGF.  
Together, the cellular composition, branching mode, and regulatory growth signals 
present in our assay implicate side branching as the primary branching mode.  
These observations suggest loss of desmosomes specifically facilitates side 
branching.  One way to test this hypothesis is to extend our original findings to an in vivo 
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system.  We anticipate that loss of desmosomes in vivo would induce precocious side 
branching.  However, desmosomes may also play a role in other branching mechanisms, 
which could result in increased TEBs and/or alveoli formation.   
 In addition to these studies, investigating the role of desmosomes during breast 
cancer progression is an important next phase of the project.  Our data suggest 
desmosomes limit FGF2-induced cellular invasion.  Although desmosomes are not as 
well studied as related adhesion complexes, they are beginning to be appreciated as 
important players in breast cancer.  Mechanisms that destabilize and downregulate 
desmosomal cadherins, including Dsg2 and Dsc3, have been observed in breast cancer 
cell lines and primary breast tumors (10-12).  Conversely, signals that increase 
desmosome formation in breast cells, such as estrogen (13), are associated with less 
invasive tumor phenotypes (14).  Together, these studies support our findings in primary 
MECs and underlie the importance of further characterizing desmosomes in the context 
of malignant breast growth. 
In studying the relationship between desmosomes and breast cancer, it will be 
important to look specifically at myoepithelial cells.  Our work demonstrates that 
desmosomes expressed exclusively in myoepithelial cells have the most significant 
impact on mammary branching (3).  As a result, we hypothesize desmosomal adhesion 
creates a myoepithelial barrier to prevent invasion.  These observations are consistent 
with the known capacity of myoepithelial cells to function as tumor suppressors in the 
context of breast cancer (15,16).  Although rarely transformed (16,17), myoepithelial 
cells are significantly lost during cancer progression (18).  These cells preferentially 
contain many tumor suppressor proteins (19) and have a higher capacity for DNA repair 
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than neighboring luminal epithelial cells (20).  Additionally, our work suggests that 
myoepithelial cells restrain tumor growth through expression of specific desmosome 
complexes that are able to robustly block cellular invasion.  By inhibiting myoepithelial 
desmosomes in vivo and assessing the invasive and metastatic behavior of transformed 
primary MECs, we can functionally validate this idea. 
 
AHR Signaling and Mammary Differentiation 
The lead compound from our chemical screen was a bis-aryloxadiazole, referred 
to as 1023, which increased desmosomes by activating the aryl hydrocarbon receptor 
(AHR) (3).  Discovered nearly 40 years ago, AHR is a ligand-activated transcription 
factor and important mediator of vertebrate toxicity (21).  Specifically, a wide range of 
synthetic and naturally occurring compounds activates AHR and subsequently induces 
expression of metabolic enzymes to help eliminate these harmful substances (22).   
Consistent with its role remediating toxins, AHR is thought to significantly affect 
normal physiological processes, including mammary gland development and function.  
Epidemiological studies in humans suggest exposure to the environmental toxin and 
AHR agonist, 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), impairs mammary 
development and negatively impacts the ability of women to breastfeed (23-25).  Studies 
in rodents support these observations and demonstrate TCDD severely blocks mammary 
branching and milk production (26-31).  Despite these findings, the molecular 
mechanism through which AHR signaling alters mammary function has remained 
unclear. 
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In terms of mammary development, our work identified desmosomes as a novel 
downstream target critical for AHR-mediated inhibition of mammary branching (3).  We 
observed a strong correlation between AHR activation, desmosome levels, and a block in 
mammary branching morphogenesis (32), suggesting desmosomes are a robust indicator 
of AHR activity in the mammary gland.  Beyond branching, we also assessed the effect 
of AHR stimulation on lactogenesis.  Using an in vitro model of mammary 
differentiation, we found AHR activation inhibited milk production through a direct 
effect on MECs.  Moreover, we defined downstream targets of activated AHR that block 
transcription of critical milk genes (Figure 6.1). 
Interestingly, different cellular compartments appear to mediate the different 
effects of AHR activation on the mammary gland.  The desmosomal cadherin isoforms 
upregulated by the AHR pathway, which functionally block branching, are exclusively 
expressed in myoepithelial cells.  Conversely, milk production occurs in luminal 
epithelial cells, which are negatively impacted by AHR signaling during lactation.  We 
would like to more elegantly demonstrate this differential effect of AHR activation by 
reconstituting the mammary gland in vivo with MECs from wild type and AHR knockout 
mice.  Following treatment with TCDD, glands containing wild type luminal epithelial 
cells and knockout myoepithleial cells should display normal mammary branching, but 
impaired milk production.  
 To further elucidate the mechanism through which AHR signaling blocks 
mammary development and differentiation, we have focused on the aryl hydrocarbon 
receptor repressor (AHRR).  AHRR is a key component of the AHR pathway and 










Figure 6.1.  Working molecular model for how AHR activation disrupts mammary 
function.  Stimulation of the aryl hydrocarbon receptor (AHR) by both novel small 
molecules (1023) and environmental pollutants (TCDD) blocks mammary branching and 
lactation.  (Left) Activated AHR upregulates desmosomal adhesion to functionally block 
branching.  This phenotype appears to be mediated by myoepithelial cells, as the 
desmosomal cadherin isoforms targeted by AHR are exclusively expressed in this 
compartment.  Overall, these results suggest loss of desmosomes facilitates mammary 
branching morphogenesis.  (Right) The aryl hydrocarbon receptor repressor (AHRR), 
which is upregulated by the AHR pathway, is sufficient to block milk production.  Since 
milk production occurs in luminal epithelial cells, the luminal epithelial cell compartment 




























of AHRR alone upregulated desmosomes and inhibited mammary branching in our 3D 
assay.  Since AHR signaling is promoted under these conditions, these results suggest 
AHR and its binding partner, ARNT, regulate desmosomes.  Additionally, 
overexpression of AHRR was sufficient to block milk production, implicating AHRR as 
a critical factor inhibiting lactogenesis.     
In the broader context, our results suggest the AHR pathway may be active and 
dynamically regulated during normal mammary gland development.  If AHR signaling 
were completely inactive during mammary development, loss of AHRR would have little 
impact.  Thus, the block in mammary branching observed in AHRR deficient MECs 
suggests the AHR pathway may have a basal level of activity.  This is consistent with 
expression studies in developing mice, where indicators of AHR activity, including both 
nuclear AHR and Cyp1A1 expression, were observed in a portion of mammary epithelial 
cells (34).   
However, given the robust ability of the AHR pathway to inhibit mammary 
branching and lactation, any basal activity is likely restricted to earlier stages of 
development.  This is supported by the dynamic expression of AHR (34) and ARNT (35) 
in the mammary gland, which is very high during puberty.  AHR activity during ductal 
elongation would support epithelial integrity and prevent hyperbranching.  Moreover, the 
induction of AHRR would inhibit premature mammary differentiation and milk 
production.  With the onset of pregnancy, we expect the AHR pathway to be dramatically 
downregulated.  However, we anticipate ARNT remains active throughout this period 
since our mechanistic studies with AHRR show this protein likely blocks milk production 
by disrupting a normal function of ARNT.  Supporting this idea, AHR expression 
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declines rapidly in pregnancy (34) while ARNT does not decrease significantly until 
involution (35).  The sustained expression of ARNT during lactation is consistent with a 
critical role for ARNT during normal milk production. 
Overall, our study of the AHR pathway in the mammary gland has revealed new 
aspects of both mammary gland biology and AHR signaling.  In particular, we have 
discovered a novel role for AHRR in regulating mammary branching and differentiation.  
Through the characterization of AHRR knockout mice, we hope further define the 
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